"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_PARMA",2000,37,7.83783783783784,2.37837837837838,0.675675675675676,0.189189189189189,0.675675675675676,1.44262295081967,1.19047619047619,1.4,1.19047619047619,0.27027027027027,1,14,8,1,12,0.38,0.22,0.03,0.32,45.92,1.012969967317,NA,0.135135135135135,0.594594594594595,0.394,0.283,0.321,0.283,"ANNAMARIA GUAZZI;VINCENZO CATALANO;STEFANO CASCINU;P. CORTELLINI;G RESTORI;GIORGIO COCCONI;RITA NIZZOLI;NADIA NALDI;N SEBASTIO;S MELI;SANDRO BARNI;INCARBONE GP;CECILIA BOZZETTI;ANNA MARIA BALDELLI;PELLEGRINO CRAFA;ICILIO DODI;CARLA VERROTTI;MARIA PIA STACCIOLI;PAOLO CARBOGNANI;G. MAGNANI","4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","G RESTORI;M MERGONI;DÉSIRÉE COEN HERAK;P. CORTELLINI;DI NINNO G;N SEBASTIO;S MELI;ANNAMARIA GUAZZI;GIORGIO COCCONI;RITA NIZZOLI;INCARBONE GP;CECILIA BOZZETTI;VINCENZO CATALANO;STEFANO CASCINU;ENRICO SESENNA;BERNARDO BIANCHI;NADIA NALDI;ERMANNO ROSSI;E. ROSSI;E. FERRI","1.92;0.67;0.67;0.63;0.5;0.49;0.49;0.46;0.46;0.46;0.46;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","ANNAMARIA GUAZZI;VINCENZO CATALANO;STEFANO CASCINU;G RESTORI;GIORGIO COCCONI;RITA NIZZOLI;NADIA NALDI;N SEBASTIO;S MELI;INCARBONE GP;CECILIA BOZZETTI;MARIA PIA STACCIOLI;PAOLO CARBOGNANI;G. MAGNANI;MICHAEL A. MANFREDI;ALESSANDRO BARILLI;PIETRO MURETTO;MARIA MICHIARA;M MERGONI;DÉSIRÉE COEN HERAK","4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","G RESTORI;M MERGONI;DÉSIRÉE COEN HERAK;N SEBASTIO;S MELI;ANNAMARIA GUAZZI;GIORGIO COCCONI;RITA NIZZOLI;INCARBONE GP;CECILIA BOZZETTI;VINCENZO CATALANO;STEFANO CASCINU;NADIA NALDI;A TULLIO;P CORTELLINI;LAURA CATTANI;ENRICO BIGLIARDI;ENRICO PARMIGIANI;F. DE RENSIS;E. BAZZANI","1.92;0.67;0.67;0.49;0.49;0.46;0.46;0.46;0.46;0.35;0.33;0.33;0.33;0.33;0.27;0.25;0.25;0.25;0.25;0.25","CARLO FERRARI;ABIGAIL SELZER KING;ANTONIO BERTOLETTI;CAROLINA BONI;GRAHAM S. OGG;MALA K. MAINI;STEPHANIE REIGNAT;AKEEM ALISA;CHUN KYON LEE;DIEGO VERGANI;J.R. LARRUBIA;JETHRO HERBERG;NIKOLAI V. NAOUMOV;RICHARD GILSON;ROGER WILLIAMS;ANDREAS CERNY;ANDREAS R. KAMMER;FRANZISKA LECHNER;GERD R. PAPE;JACOPO UGGERI","1105;842;842;842;842;842;842;792;792;792;792;792;792;792;792;313;313;313;313;313","CARLO FERRARI;CAROLINA BONI;JACOPO UGGERI;SIMONA URBANI;DANIELA GHISI;G IZZI;STEFANO CASCINU;ANNAMARIA GUAZZI;CECILIA BOZZETTI;GIORGIO COCCONI;NADIA NALDI;RITA NIZZOLI;ALESSANDRO BARILLI;MARIA MICHIARA;ROBERTA CAMISA;G. MAGNANI;ANDREA CIMARELLI;CLAUDIO CASOLI;E. CATTANEO;ELISA VICENZI","1105;842;313;313;114;84;82;73;73;73;73;73;55;55;55;43;42;42;42;42","ANNAMARIA GUAZZI;CECILIA BOZZETTI;GIORGIO COCCONI;RITA NIZZOLI;NADIA NALDI;STEFANO CASCINU;ALESSANDRO BARILLI;CARLO FERRARI;CAROLINA BONI;G. MAGNANI;M MERGONI;MARIA MICHIARA;ROBERTA CAMISA;VITTORIO FRANCIOSI;A TULLIO;ANDREA CIMARELLI;C COSCELLI;C. ASCHELE;C. BRICCHI;CLAUDIO CASOLI","4;4;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;BUSINESS;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY","33;11;6;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;CARDIOLOGY;ONCOLOGY;OPTICS;VIROLOGY;BIOCHEMISTRY;RADIOLOGY;ENDOCRINOLOGY;GYNECOLOGY;OBSTETRICS;UROLOGY;ANESTHESIA;ELECTRICAL ENGINEERING;ENVIRONMENTAL HEALTH;GENERAL SURGERY;PEDIATRICS;PSYCHIATRY","23;12;9;8;7;7;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2","CANCER;IMMUNOHISTOCHEMISTRY;CHEMOTHERAPY;VIRUS;CONCORDANCE;IMMUNE SYSTEM;IN VITRO;INCIDENCE (GEOMETRY);BIOPSY;BLOOD PRESSURE;BOLUS (DIGESTION);CARCINOMA;HISTOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);PREGNANCY;AMBULATORY;CHOLESTEROL;CYTOLOGY;DISEASE;DUODENUM;ENDOSCOPY;ESOPHAGUS;GENE;LUNG;LUNG CANCER;POPULATION;TRANSMISSION (TELECOMMUNICATIONS);TRANSPLANTATION","8;7;6;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CD8;COLORECTAL CANCER;CYTOTOXIC T CELL;DIASTOLE;FINE-NEEDLE ASPIRATION;FLUOROURACIL;HEPATITIS C VIRUS;AMBULATORY BLOOD PRESSURE;BREAST CANCER;HEART RATE;HEPATITIS B VIRUS;T CELL;VAGINAL DELIVERY;VIRAL DISEASE;VIRAL LOAD;VIRAL REPLICATION;AMBULATORY CARE;ANDROGEN;ANTIMETABOLITE;AORTIC ARCH;ARTIFICIAL INSEMINATION;AZATHIOPRINE;BISPECTRAL INDEX;BLOOD LIPIDS;BONE MARROW TRANSPLANTATION;BRONCHOALVEOLAR LAVAGE;CAESAREAN SECTION;CD34;CHEMOKINE;COINFECTION;CORONARY ANGIOGRAPHY;DIABETIC FOOT;DIRECT COST;DYSLIPIDEMIA;EPITOPE;ESSENTIAL HYPERTENSION;EX VIVO;FLUORESCEIN ANGIOGRAPHY;FUNGEMIA;GEMCITABINE;GERM CELL;GERM CELL TUMORS;GLANS;GLANS PENIS;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;HISTOGENESIS;INSEMINATION;INTERSTITIAL LUNG DISEASE;INTRAVENOUS SEDATION;LASER THERAPY;LEFT VENTRICULAR HYPERTROPHY;LEUKOPENIA;LIPOPROTEIN;LUNG FUNCTION;LUNG VOLUMES;METASTASIS;MICROBICIDE;NECK DISSECTION;NEURORADIOLOGY;NEUTROPENIA;PANCREATIC CANCER;PEDIATRIC GASTROENTEROLOGY;PERIPHERAL BLOOD MONONUCLEAR CELL;POLYCLONAL ANTIBODIES;POSITIVE END-EXPIRATORY PRESSURE;PREHYPERTENSION;PROSTATE;PULMONARY COMPLIANCE;RENIN–ANGIOTENSIN SYSTEM;RESPIRATORY PHYSIOLOGY;RETROPERITONEAL FIBROSIS;RETROPHARYNGEAL SPACE;SPONDYLITIS;SUBCLAVIAN STEAL SYNDROME;TACROLIMUS;THERAPEUTIC ENDOSCOPY;TRICHOSPORON;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRULENCE;WAIST","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CARCINOMA;ESTROGEN RECEPTOR;MAMMARY GLAND;ANTIRETROVIRAL THERAPY;BRANCH RETINAL ARTERY OCCLUSION;CD38;DIFFUSING CAPACITY;DIHYDROTESTOSTERONE;FINASTERIDE;FOLINIC ACID;OPPORTUNISTIC INFECTION;OPPORTUNISTIC PATHOGEN;OXALIPLATIN;PLASMA RENIN ACTIVITY;RIGHT CORONARY ARTERY;SEX HORMONE-BINDING GLOBULIN;SEXUAL TRANSMISSION;SIDA;THYMIDYLATE SYNTHASE;URETEROLYSIS;WAIST–HIP RATIO;ZIDOVUDINE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;COLONIC NEOPLASMS;FLUOROURACIL;TUMOR SUPPRESSOR PROTEIN P53;CD8-POSITIVE T-LYMPHOCYTES;GASTROINTESTINAL DISEASES;HEPATITIS C;PROSTATIC HYPERPLASIA;ABDOMINAL NEOPLASMS;ARTERIAL OCCLUSIVE DISEASES;BIOMARKERS, TUMOR;BREAST NEOPLASMS;DEOXYCYTIDINE","27;18;15;14;11;10;9;8;7;7;6;5;5;5;5;4;4;4;4;4","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;BREAST PATHOLOGY AND IMAGING TECHNIQUES;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANESTHESIA AND SEDATION MANAGEMENT;ASSESSMENT OF ANIMAL WELFARE IN VARIOUS SPECIES;BODY COMPOSITION ASSESSMENT AND ANALYSIS;CANCER OF UNKNOWN PRIMARY SITE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;ESOPHAGEAL INTERVENTION TECHNIQUES;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CONCORDANCE;BLOOD PRESSURE;BOLUS (DIGESTION);HISTOLOGY;HYPERTENSION;BIOMARKER ANALYSIS;BREAST CANCER;BREAST CARCINOMA;HEART RATE VARIABILITY;METASTATIC GASTRIC CANCER;PROGESTERONE RECEPTOR;ANTIFUNGAL RESISTANCE;BIOFEEDBACK;BISPECTRAL INDEX;BODY FAT PERCENTAGE;CANCER CELL METABOLISM;CANCER THERAPY;CHEMOPROPHYLAXIS;CIRCUMFERENCE;COMPLICATIONS","4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","SURGICAL SPECIMENS;VIRUS INFECTION;BENIGN PROSTATIC;BIOLOGIC VARIABLES;BLOOD FILTERABILITY;BOLUS -FLUOROURACIL;BREAST CARCINOMAS;CD CELLS;CELL LUNG;COLORECTAL CANCER;DIGESTIVE ENDOSCOPY;DIGESTIVE TRACT;ESSENTIAL HYPERTENSION;HEART RATE;IMMUNOCYTOCHEMICAL ASSAYS;IMMUNOHISTOCHEMICAL DETERMINATION;LUNG CANCER;NON-SMALL CELL;PERSISTENT HEPATITIS;PRIMARY BREAST;PROSTATIC HYPERPLASIA;RATE HOURS;TRACT CANCER;VIRUS-SPECIFIC CD;ABDOMINAL METASTASES;ABPM LEVELS;ACUTE HEPATITIS;ADVANCED COLORECTAL;ADVANCED PANCREATIC;ADVANCED STAGE","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","BLOOD PRESSURE;BREAST CARCINOMA;CD CELLS;ER PGR;HBV-SPECIFIC CD;STANDARD DEVIATION;ASBPM HOURS;HOURS STANDARD;ADBP MMHG;ASBP MMHG;BIOLOGIC CHARACTERIZATION;CD RESPONSE;HBV INFECTION;IMMUNOCYTOCHEMICAL EVALUATION;-SPECIFIC CD;ADBPM HOURS;CORE --SPECIFIC;DIASTOLIC BLOOD;HBV REPLICATION;LEFT VENTRICULAR;LIVER INFLAMMATION;MALE SEX;MALES AGE;SYSTOLIC BLOOD;TRIPLE THERAPY;ABPM HOURS;AGE LENGTH;AGE LH;AMBULATORY DIASTOLIC;AMBULATORY SYSTOLIC","8;8;6;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2",3,0.08,8.41,4.5,1,1,0,0,2.5,0,0,4.5,0,0,2,0,0,0,0,2,0,0,0,100.5,100.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,13.75,579.25,9.26,1,0.2,115.2,0,0,1,0,4,0,0,0,0,5,0,0,0,0,0,0,0,3,1,1,5,0,0,0,0,0,0,0,0,0,"United States;Belgium;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","5;4;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;ORPHAN DRUG;PATIENT SAFETY;AGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;LUNG;LUNG CANCER;PREVENTION;PROSTATE CANCER;UROLOGIC DISEASES;UTERINE CANCER","5;5;4;4;3;3;1;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","5;4","ENDOMETRIAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LUNG CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;3;1;1",2,1635488.5,103151.74,5.5,42.5,11,1,9.5,40730.7287469288,0.908405057760965,"ERASMUS MC;OSPEDALE DI PARMA;ANDALUSIAN HEALTH SERVICE;ARISTOTLE UNIVERSITY OF THESSALONIKI;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERA DI PADOVA;BAMBINO GESÙ CHILDREN'S HOSPITAL;BAR-ILAN UNIVERSITY;CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT-PIERRE;CHILDREN'S HEALTH IRELAND AT CRUMLIN;DÉLÉGATION PARIS 11;EALING HOSPITAL NHS TRUST;ERASMUS UNIVERSITY ROTTERDAM;GOETHE UNIVERSITY FRANKFURT;GUY'S AND ST THOMAS' NHS FOUNDATION TRUST;HEINRICH HEINE UNIVERSITY DÜSSELDORF;HOSPICES CIVILS DE LYON;HOSPITAL DE BASURTO","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","2;1;1;1","INFECTIOUS DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;HIV/AIDS;LIVER DISEASE;PEDIATRIC","2;1;1;1;1;1;1;1;1;1;1","INFECTION","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1;1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","2",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2001,31,6.35483870967742,1.61290322580645,0.516129032258065,0.193548387096774,0.516129032258065,1.13636363636364,1.06666666666667,1,1.06666666666667,0.387096774193548,1,14,6,2,9,0.45,0.19,0.06,0.29,38.16,0.835177536833033,NA,0.225806451612903,0.741935483870968,0.349,0.207,0.16,0.207,"P MANGANELLI;FABIO PARAZZINI;ENRICO SESENNA;AMALIA PENNA;C COSCELLI;STEFANO CASCINU;M MERGONI;CAROLINA BONI;CARLO FERRARI;ROBERTO LABIANCA;F FERROZZI;SIMONA URBANI;PIERANNA FIETTA;ALESSANDRA GAVARINI;GIOVANNA TAGLIABUE;CARLO MARCHESI;M. LANDONI;LUIGI FABRIZIO RODELLA;GUALTIERO PALARETI;A BRIGANTI","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","GIORGIO COCCONI;P MANGANELLI;M MERGONI;PIERANNA FIETTA;ENRICO SESENNA;ANTÔNIO ROSSI;F FERROZZI;BERNARDO BIANCHI;I. FILICE;L PAVÍA;A TULLIO;A. CARBONI;STEFANO CASCINU;ROBERTO LABIANCA;FABIO PARAZZINI;C COSCELLI;MARINA CAROTTI;LEOPOLDO SARLI;C. BRICCHI;GIULIO ZUCCOLI","1;0.95;0.75;0.7;0.53;0.5;0.36;0.33;0.33;0.33;0.33;0.33;0.3;0.3;0.28;0.28;0.25;0.25;0.25;0.25","P MANGANELLI;ENRICO SESENNA;AMALIA PENNA;C COSCELLI;STEFANO CASCINU;M MERGONI;CAROLINA BONI;CARLO FERRARI;F FERROZZI;SIMONA URBANI;PIERANNA FIETTA;ALESSANDRA GAVARINI;B. BLANCHI;SERGE FERRARI;GIOVANNI DELSANTE;FRANCESCO TADDEI;LEOPOLDO SARLI;C. BRICCHI;CORRADO PATTACINI;G. BIANCHI","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GIORGIO COCCONI;P MANGANELLI;M MERGONI;PIERANNA FIETTA;ENRICO SESENNA;F FERROZZI;A TULLIO;A. CARBONI;STEFANO CASCINU;C COSCELLI;LEOPOLDO SARLI;C. BRICCHI;G TOGNINI;G. NERVI;ANNALISA VOLPI;AMALIA PENNA;CAROLINA BONI;CARLO FERRARI;SIMONA URBANI;B. BLANCHI","1;0.95;0.75;0.7;0.53;0.36;0.33;0.33;0.3;0.28;0.25;0.25;0.25;0.25;0.25;0.23;0.23;0.23;0.23;0.2","AMALIA PENNA;CARLO FERRARI;CAROLINA BONI;SIMONA URBANI;A. CAVALLI;ANTONIO BERTOLETTI;CRISTINA CAVALLO;F FIACCADORI;GRAHAM S. OGG;MASSIMO PILLI;RICHARD BOEHME;RUGGERO PANEBIANCO;P MANGANELLI;A G DETTORI;CESARE MANOTTI;GUALTIERO PALARETI;LUIGI RIA;MARCO MOIA;VITTORIO PENGO;C COSCELLI","381;381;381;381;334;334;334;334;334;334;334;334;111;105;105;105;105;105;105;100","CARLO FERRARI;P MANGANELLI;CESARE MANOTTI;C COSCELLI;LEOPOLDO SARLI;M MERGONI;ALESSANDRA GAVARINI;E UGGERI;FRANCESCO TADDEI;MARCO VITALE;DARIO OLIVIERI;STEFANO CASCINU;RODOLFO PASSALACQUA;ANNALISA VOLPI;C. BRICCHI;AMALIA PENNA;CAROLINA BONI;JACOPO UGGERI;SIMONA URBANI;DIEGO ARDISSINO","381;111;105;100;71;65;64;64;64;57;54;53;50;49;49;47;47;47;47;35","P MANGANELLI;C COSCELLI;CARLO FERRARI;DIEGO ARDISSINO;M MERGONI;STEFANO CASCINU;A GIANNINI;A TULLIO;ALESSANDRA GAVARINI;AMALIA PENNA;ANNALISA VOLPI;ANNARITA TAGLIAFERRI;C. BRICCHI;CAROLINA BONI;CESARE MANOTTI;CORRADO PATTACINI;CRISTINA QUARANTELLI;DARIO OLIVIERI;E UGGERI;F FERROZZI","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;ECONOMICS;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;PSYCHOLOGY","29;4;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NURSING;PHYSICAL THERAPY;ANATOMY;ANESTHESIA;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;PEDIATRICS;VIROLOGY;CANCER RESEARCH;EMERGENCY MEDICINE;MACROECONOMICS;ONCOLOGY;PSYCHIATRY;UROLOGY","22;12;8;8;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;DIABETES MELLITUS;IN VITRO;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;RHEUMATOLOGY;VIRUS;ALTERNATIVE MEDICINE;ANXIETY;CLINICAL TRIAL;CONFIDENCE INTERVAL;COPD;CYTOKINE;DEPRESSION (ECONOMICS);IMMUNE SYSTEM;LUNG;MEDICAL RECORD;MITRAL VALVE;MYOCARDIAL INFARCTION;RESPIRATORY SYSTEM;TONGUE","5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CYTOTOXIC T CELL;ACUTE CORONARY SYNDROME;CD8;COLORECTAL CANCER;HEPATITIS C VIRUS;LUNG VOLUMES;PROGRESSIVE DISEASE;RESPIRATORY PHYSIOLOGY;T CELL;ACUTE CARE;ACUTE RESPIRATORY FAILURE;AFTERLOAD;ANORECTAL MANOMETRY;ANTITHROMBIN;BACK PAIN;BLADDER CANCER;CHEMOTHERAPY REGIMEN;CHRONIC CONSTIPATION;CHRONIC FATIGUE;DEFECOGRAPHY;DOCETAXEL;ECHOGENICITY;EJECTION FRACTION;ELASTIC RECOIL;EPITOPE;EXPIRATION;FUNCTIONAL CONSTIPATION;GENERAL HEALTH QUESTIONNAIRE;GLOSSECTOMY;GLYCEMIC;HEPATITIS A VIRUS;HEPATITIS B VIRUS;HERNIA REPAIR;HODGKIN LYMPHOMA;HUMAN LEUKOCYTE ANTIGEN;HYPERINFLATION;HYPOGLYCEMIA;IMMUNOTHERAPY;INGUINAL HERNIA;INTERLEUKIN;INTERLEUKIN 2;K562 CELLS;MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;MINNESOTA MULTIPHASIC PERSONALITY INVENTORY;MITRAL VALVE PROLAPSE;MITRAL VALVE REPAIR;MUCOSAL MELANOMA;MYELODYSPLASTIC SYNDROMES;NECK DISSECTION;NEPHRECTOMY;NEUROFIBROMA;NEUTROPENIA;PANCREATIC CANCER;PAROTIDECTOMY;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;PLACEBO;POSITIVE END-EXPIRATORY PRESSURE;PREVALENCE OF MENTAL DISORDERS;SALBUTAMOL;ST SEGMENT;SYNOVITIS;THROMBIN;TYPE 1 DIABETES;TYPE 2 DIABETES;UPPER URINARY TRACT;VIRAL LOAD;WARFARIN","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CTL*;DYNAMIC HYPERINFLATION;FILGRASTIM;FUNCTIONAL RESIDUAL CAPACITY;GASTROINTESTINAL CANCER;HIRUDIN;IMMUNODOMINANCE;INTERLEUKIN 12;INTERLEUKIN 15;INTERLEUKIN 21;KILLIP CLASS;LAMIVUDINE;NATURAL KILLER T CELL;NS3;ORAL ANTICOAGULANT;PLEXIFORM NEUROFIBROMA;TRANSITIONAL CELL CARCINOMA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;MYOCARDIAL INFARCTION;STOMACH NEOPLASMS;DIABETES MELLITUS, TYPE 1;DIABETES MELLITUS, TYPE 2;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;ADOLESCENT;ANGINA, UNSTABLE;HEPATITIS B, CHRONIC;INTERLEUKIN-2;T-LYMPHOCYTES, CYTOTOXIC;;BLOOD GLUCOSE;CARCINOMA, HEPATOCELLULAR;CARCINOMA, SQUAMOUS CELL","27;21;17;17;14;12;9;7;6;6;6;5;5;5;5;5;4;4;4;4","HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;STANDARDISATION AND MANAGEMENT OF COPD;ATRIAL FIBRILLATION;CANCER OF UNKNOWN PRIMARY SITE;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;HEPATITIS B INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;HERNIA REPAIR TECHNIQUES AND MATERIALS;IMPACT OF HYPERGLYCEMIA ON HEALTH OUTCOMES;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COPD;CTL*;DEPRESSION (ECONOMICS);DIABETES;MEDICAL RECORD;PULMONARY DISEASE;RESPIRATORY PHYSIOLOGY;T CELL;ACUTE CARE;ACUTE RESPIRATORY FAILURE;AFTERLOAD;ANKYLOSING SPONDYLITIS;ANORECTAL MANOMETRY;ANTIBODIES;ANTICOAGULANT THERAPY;BACK PAIN;CANCER INCIDENCE;CANCER REGISTRY DATA;CANCER SURVIVORSHIP;CARDIAC ELECTROPHYSIOLOGY","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE CORONARY;ACUTE RESPIRATORY;CORONARY SYNDROMES;CYTOTOXIC T-CELL;RESPIRATORY FAILURE;ADVANCED GASTRIC;ADVANCED RENAL;AFFINITY PULSE;ANKYLOSING SPONDYLITIS;ANTICOAGULANT TREATMENT;ANTICOAGULATED PATIENTS;APOPTOSIS MEDIATED;APROAT AUTOMATED;AUTOCAPTURE FUNCTION;AUTOMATED PROGRAM;BILATERAL INGUINAL;BIOCHEMICAL DATA;BLOOD GLUCOSE;BRONCHITIS RANDOMIZED;BRONCUS HYPOTHESIS;CELL CARCINOMA;CHRONIC HEPATITIS;CHRONIC IDIOPATHIC;CIGARETTE SMOKING;CLINICAL ELECTROCARDIOGRAPHIC;CLINICAL EXPERIENCE;COEXISTENT MARFANS;COLORECTAL CANCER;COLOUR DOPPLER;COMPUTER-AIDED MANAGEMENT","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NK CELLS;PARTIAL RESPONSE;TYPE II;STABLE DISEASE;BIOCHEMICAL MARKERS;CHRONIC HEPATITIS;COMPLETE RESPONSE;CTL RESPONSE;CTL RESPONSES;GASTRIC CANCER;II DIABETES;RESPONSE RATE;ACHIEVED COMPLETE;AIDS DIAGNOSIS;CD POSITIVE;CHRONIC HBV;CHRONIC OBSTRUCTIVE;CLINICAL BENEFIT;CONFIDENCE INTERVAL;EXOGENOUS STIMULATION;GASTROINTESTINAL TUMORS;HBV INFECTION;HCV GENES;HCV INFECTION;ILPRIMED NK;IMMUNE THERAPIES;ITALIAN POPULATION;LAMIVUDINE THERAPY;LAMIVUDINE TREATMENT;LOW DOSES","8;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",4,0.13,6,3,0,0,0,0,4.75,0,1,3,0,0,0,0,1,0,0,0,0,0,0,43.25,43.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,7,2028.67,10.53,1,0.25,114.25,0,0,0,0,4,0,0,0,0,4,0,0,0,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,"Belgium;United States;Canada;Italy","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","4;4;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;LUNG;LUNG CANCER;ORPHAN DRUG;BRAIN CANCER;BRAIN DISORDERS;BREAST CANCER;PREVENTION;UROLOGIC DISEASES","4;4;4;4;3;2;2;2;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1","LUNG CANCER;BLADDER CANCER;BRAIN TUMOR;BREAST CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;2",2,2050000,410000,3.5,5,4,1,2,279064.062080262,0.111085604391023,"OSPEDALE DI PARMA;FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS;HERZLIYA MEDICAL CENTER;IDS SCHEER (CZECHIA);KING'S COLLEGE LONDON;LETO MATERNITY HOSPITAL;NATIONAL UNIVERSITY OF TUCUMÁN;UNIVERSITAT POLITÈCNICA DE VALÈNCIA;UNIVERSITY OF PARMA","2;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-IST - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON A ""USER-FRIENDLY INFORMATION SOCIETY, 1998-2002"" (PROGRAMME)","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES","1;1;1;1;1;1","NUTRITION","1","METABOLIC AND ENDOCRINE;STROKE","1;1",NA,NA,NA,NA,NA,NA,"C13 ARCHITECTURE, BUILT ENVIRONMENT AND PLANNING;C20 SOCIAL WORK AND SOCIAL POLICY","1;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2002,26,8.61538461538461,2.19230769230769,0.5,0.307692307692308,0.576923076923077,1.39024390243902,1.08333333333333,1.14285714285714,1.07142857142857,0.307692307692308,1,15,3,2,6,0.58,0.12,0.08,0.23,49.69,0.900733535858384,NA,0.423076923076923,0.692307692307692,0.427,0.242,0.262,0.277,"CARLO FERRARI;ERIC J. TOPOL;MASSIMO PILLI;DIEGO ARDISSINO;STEFANO CASCINU;SANDRO BARNI;GABRIELE MISSALE;CRISTINA MORI;P MANGANELLI;FRANCESCO BOIN;CRISTINA PONTI;LUCIO COCCO;EDOARDO PICETTI;AMALIA PENNA;VINCENZO CATALANO;GIORGIO ZAULI;LUCIANO BORTONE;MARCO VITALE;PAOLO GIORDANI;DAVIDE GIBELLINI","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MASSIMO PILLI;P MANGANELLI;EDOARDO PICETTI;LUCIANO BORTONE;PIERANNA FIETTA;CARLO FERRARI;ALBERTO PESCI;ROY N. KIRKWOOD;M. SOTTOCORONA;M MERGONI;F. DE RENSIS;FAUSTO SALAFFI;GABRIELE MISSALE;ERIC J. TOPOL;FRANCESCO BOIN;CRISTINA PONTI;LUCIO COCCO;GIOVANNA D’ANGELO;F. PISANO;GIORGIO ZAULI","1.2;0.83;0.83;0.83;0.5;0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.25;0.25;0.25;0.25;0.25;0.25","CARLO FERRARI;MASSIMO PILLI;DIEGO ARDISSINO;STEFANO CASCINU;GABRIELE MISSALE;CRISTINA MORI;P MANGANELLI;EDOARDO PICETTI;AMALIA PENNA;LUCIANO BORTONE;MARCO VITALE;RITA NIZZOLI;ALESSANDRO ZERBINI;ANNAMARIA GUAZZI;A. CAVALLI;FLAVIO TANCIONI;CORRADO PATTACINI;NADIA NALDI;M. SOTTOCORONA;STEFANIA FERRETTI","4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MASSIMO PILLI;P MANGANELLI;EDOARDO PICETTI;LUCIANO BORTONE;PIERANNA FIETTA;CARLO FERRARI;M. SOTTOCORONA;M MERGONI;F. DE RENSIS;GABRIELE MISSALE;M AFFANNI;MARCO VITALE;STEFANO CASCINU;DIEGO ARDISSINO;RITA NIZZOLI;CRISTINA MORI;AMALIA PENNA;STEFANIA FERRETTI;M. SIMONAZZI;M VANELLI","1.2;0.83;0.83;0.83;0.5;0.4;0.33;0.33;0.33;0.33;0.25;0.25;0.25;0.24;0.21;0.2;0.2;0.17;0.17;0.14","CARLO FERRARI;ANGELOS HATZAKIS;ANTONIETTA CARGNEL;CHRISTINE KATLAMA;COLM BERGIN;DOUGLAS T. DIETERICH;JÜRGEN ROCKSTROH;MARK SULKOWSKI;P. CACOUB;SANTIAGO MORENO;STEFAN MAUSS;THIERRY POYNARD;VINCENT SORIANO;GABRIELE MISSALE;MASSIMO PILLI;CAROLINA BONI;CRISTINA CAVALLO;G. ELIA;GIOVANNI RAIMONDO;MARCO MASSARI","794;456;456;456;456;456;456;456;456;456;456;456;456;338;283;174;174;174;174;174","CARLO FERRARI;GABRIELE MISSALE;MASSIMO PILLI;CAROLINA BONI;CRISTINA CAVALLO;G. ELIA;SIMONA URBANI;AMALIA PENNA;CRISTINA MORI;DIEGO ARDISSINO;STEFANO CASCINU;ALESSANDRO ZERBINI;T. GIUBERTI;A. CAVALLI;GIANFRANCO ELIA;PAOLA ZANELLI;V. LAMONACA;MARCO VITALE;LUCIANO BORTONE;EDOARDO PICETTI","794;338;283;174;174;174;174;164;164;152;104;92;92;72;72;72;72;35;19;18","CARLO FERRARI;DIEGO ARDISSINO;GABRIELE MISSALE;MASSIMO PILLI;STEFANO CASCINU;AMALIA PENNA;CRISTINA MORI;LUCIANO BORTONE;MARCO VITALE;RITA NIZZOLI;A. CAVALLI;ALESSANDRO ZERBINI;ANNAMARIA GUAZZI;ANNARITA TAGLIAFERRI;CAROLINA BONI;CECILIA BOZZETTI;CORRADO PATTACINI;CRISTINA CAVALLO;DIEGO ARDISSINIO;EDOARDO PICETTI","4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHILOSOPHY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE","21;9;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;PATHOLOGY;ONCOLOGY;VIROLOGY;ANESTHESIA;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;CELL BIOLOGY;MOLECULAR BIOLOGY;OPTICS;UROLOGY;ANIMAL SCIENCE;BIOMEDICAL ENGINEERING;BIOTECHNOLOGY;CHROMATOGRAPHY;DERMATOLOGY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;GYNECOLOGY;HUMANITIES;INTENSIVE CARE MEDICINE;LIBRARY SCIENCE;LINGUISTICS;NEUROSCIENCE;NUCLEAR MEDICINE;PEDIATRICS;PHARMACOLOGY;PSYCHIATRY;VETERINARY MEDICINE","14;8;7;6;5;5;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VIRUS;CANCER;HEPATITIS C;IMMUNE SYSTEM;ANTIGEN;CHEMOTHERAPY;CONFIDENCE INTERVAL;IN VITRO;MYOCARDIAL INFARCTION;BIOPSY;DIABETES MELLITUS;DISEASE;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOCYTOCHEMISTRY;INTERFERON;ODDS RATIO;ORAL LICHEN PLANUS;PATHOGENESIS;REGIMEN","7;6;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","HEPATITIS C VIRUS;CD8;COLORECTAL CANCER;CYTOTOXIC T CELL;T CELL;BREAST CANCER;CHRONIC HEPATITIS;FINE-NEEDLE ASPIRATION;GENE EXPRESSION;REGULATOR;TRANSCRIPTION FACTOR;ABDOMINOPLASTY;ACUTE CORONARY SYNDROME;ANTIMETABOLITE;ANTITHROMBIN;AUTOFLUORESCENCE;BRONCHOALVEOLAR LAVAGE;CHEMOTHERAPY REGIMEN;CONVENTIONAL PCI;DIABETIC COMA;DIABETIC KETOACIDOSIS;EPITOPE;EX VIVO;FIBRINOLYTIC AGENT;FLUOROURACIL;GLYCEMIC;HAZARD RATIO;HEPATITIS B VIRUS;IDIOPATHIC PULMONARY FIBROSIS;INTERSTITIAL LUNG DISEASE;MAJOR HISTOCOMPATIBILITY COMPLEX;MEDIAL COLLATERAL LIGAMENT;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;PLATELET ACTIVATION;POSTOPERATIVE NAUSEA AND VOMITING;PROGRESSIVE DISEASE;PULMONARY FIBROSIS;RESPIRATORY DISEASE;RESTENOSIS;REVASCULARIZATION;ST SEGMENT;STREPTOKINASE;THROMBIN;THROMBOPHLEBITIS;TYPE 1 DIABETES;UROTHELIUM;VIRAL DISEASE","6;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABCIXIMAB;CREB;JUNB;PROMOTER;CRYOGLOBULINEMIA;DISCOVERY AND DEVELOPMENT OF DIRECT THROMBIN INHIBITORS;ESTROGEN RECEPTOR;FOLINIC ACID;HEPACIVIRUS;HIRUDIN;KETOACIDOSIS;LYMPHEDEMA;OESTROGEN RECEPTOR;OXALIPLATIN;PERFORIN;RETEPLASE;RIBAVIRIN;SIDA;T-CELL RECEPTOR;THYMIDYLATE SYNTHASE;TIROFIBAN;TRANSCRIPTIONAL REGULATION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;HEPATITIS C, CHRONIC;HEPACIVIRUS;COLORECTAL NEOPLASMS;MYOCARDIAL INFARCTION;MIDDLE AGED;ADULT;AGED;CD4-POSITIVE T-LYMPHOCYTES;FIBRINOLYTIC AGENTS;RECOMBINANT PROTEINS;RNA, VIRAL;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTIVIRAL AGENTS;BIOMARKERS, TUMOR;IMMUNOGLOBULIN FAB FRAGMENTS;PLATELET AGGREGATION INHIBITORS","22;14;14;12;11;10;10;9;7;7;6;6;6;6;5;5;5;5;5;5","MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATITIS C INFECTION AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;ORAL MUCOSAL DISORDERS AND MALIGNANT TRANSFORMATION RISK;CANINE AND FELINE HEALTH AND NUTRITION RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ELBOW INJURIES AND TREATMENTS IN ATHLETES AND ADULTS;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;HEPATITIS B INFECTION AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MOLECULAR RESEARCH ON BREAST CANCER;NANOTECHNOLOGY AND IMAGING FOR CANCER THERAPY AND DIAGNOSIS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT","4;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","HEPATITIS C;ABCIXIMAB;HEPATITIS C VIRUS;JUNB;METASTATIC COLORECTAL CANCER;NK CELL ACTIVATION;NK CELL DEVELOPMENT;NK CELL RECEPTORS;NK CELL RECOGNITION;ORAL LICHEN PLANUS;PATHOGENESIS;REGIMEN;RESPONSE ELEMENT;TREATMENT;ABDOMINOPLASTY;AUTOFLUORESCENCE;BIOMARKER ANALYSIS;BOLUS (DIGESTION);CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT","4;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CHRONIC HEPATITIS;ACUTE CORONARY;C-FOS ACTIVATION;CELLULAR IMMUNE;COLORECTAL CANCER;CORONARY SYNDROMES;CREB TRANSCRIPTION;FINE NEEDLE;HCV-SPECIFIC CELLULAR;IMMUNE RESPONSE;KILLER CELLS;LICHEN PLANUS;NATURAL KILLER;NEEDLE ASPIRATION;ORAL LICHEN;PLANUS PATHOGENESIS;TRANSCRIPTION FACTOR;ACUTE HEPATITIS;ACUTE MYOCARDIAL;ALTERNATIVE MEDICINE;ARTERY BYPASS;ASPIRATION BIOPSY;AUTOFLUORESCENCE-BASED REAL;AYUR-VED CLINICAL;BIOLOGICAL PARAMETERS;BOLUS -FLUOROURACIL;BREAST CANCER;BYPASS GRAFTING;CARCINOMAS GISCAD;CDSUPSUPLYMPHOCYTES SHARE","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CO-INFECTED PATIENTS;LIVER DISEASE;ANTIRETROVIRAL THERAPY;CD CELL;HCV INFECTION;LACTIC ACIDOSIS;CD CELLS;HIVHCV CO-INFECTED;VIROLOGICAL RESPONSE;CELL COUNTS;HCV-SPECIFIC CD;CO-INFECTED INDIVIDUALS;HCV TREATMENT;HIV-INFECTED PATIENTS;MITOCHONDRIAL TOXICITY;NUCLEOSIDE ANALOGUES;ANTIRETROVIRAL DRUGS;COMBINATION THERAPY;RESPONSE RATE;SUSTAINED RESPONSE;SUSTAINED VIROLOGICAL;VERSUS MONTHS;ACTIVE ANTIRETROVIRAL;CHRONIC HEPATITIS;HCV RNA;HCV-RELATED LIVER;HIGHLY ACTIVE;HIV DISEASE;NK CELLS;PATIENTS RECEIVING","29;20;12;11;10;10;9;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5",3,0.12,4.5,2,0,0,0,0,1.75,0,2,2,0,0,0,0,0,0,0,0,0,0,0,25.5,25.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,4.5,377.67,7.5,0,0,169.33,0,0,0,0,2,0,1,0,0,3,0,0,0,0,0,0,0,2,1,0,3,0,0,0,0,0,0,0,0,0,"Belgium;Canada;Italy;United States","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES;4205 NURSING","3;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DENTAL/ORAL AND CRANIOFACIAL DISEASE;EYE DISEASE AND DISORDERS OF VISION;NUTRITION;PREVENTION;RARE DISEASES","3;2;2;1;1;1;1;1","CANCER","2","6.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1","HEAD AND NECK CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","1;1;1;1;1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","2;1",1,2170162,67817.56,6,32,14,1,9,290366.989163595,0.0895418589933147,"ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE LILLE;CENTRO REGIONAL DE HEMODONACIÓN;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;HEIDELBERG UNIVERSITY;HIPPOCRATION GENERAL HOSPITAL;HOSPITAL DE SANTA CRUZ;HOSPITAL DE SANTO ANTÓNIO;HOSPITAL SOUTH WEST JUTLAND;HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE;HÔTEL-DIEU DE PARIS;JAGIELLONIAN UNIVERSITY;KLINIKUM DARMSTADT;LEIDEN UNIVERSITY;LUIGI SACCO HOSPITAL;MANCHESTER UNIVERSITY NHS FOUNDATION TRUST;MATER MISERICORDIAE UNIVERSITY HOSPITAL;NHS GREATER GLASGOW AND CLYDE;OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI;OSPEDALE DI PARMA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","HEMATOLOGY","1",NA,NA,NA,NA,NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2003,22,8.86363636363636,3.13636363636364,0.636363636363636,0.363636363636364,0.636363636363636,1.30188679245283,1.16666666666667,1,1.16666666666667,0.181818181818182,0,12,3,2,5,0.55,0.14,0.09,0.23,46.59,0.880271229021429,NA,0.363636363636364,0.727272727272727,0.489,0.348,0.339,0.348,"STEFANO CASCINU;P MANGANELLI;PIERANNA FIETTA;PELLEGRINO CRAFA;ANNAMARIA GUAZZI;NADIA NALDI;MASSIMO PILLI;VINCENZO CATALANO;FRANCESCO FERRAÙ;CARLO FERRARI;VITTORIO FRANCIOSI;GABRIELE MISSALE;RITA NIZZOLI;CECILIA BOZZETTI;ROBERTA CAMISA;BRUNO ANDREI;GIAMPIETRO GASPARINI;GREGORY C. FANELLI;G. FAVALLI;FABIO CASTAGNETTI","5;4;4;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","P MANGANELLI;PIERANNA FIETTA;STEFANO CASCINU;MICHELE BIANCONCINI;ALFREDO L. GIANNINI;ROBERTA CAMISA;FABIO CASTAGNETTI;STEFANO BALDASSARRE;CARLO FUSCO;C FAIENZA;FRANCESCO PISANI;DONATELLODI MASCIO;ANNAMARIA GUAZZI;NADIA NALDI;RITA NIZZOLI;CECILIA BOZZETTI;STEFANIA SALVAGNI;FEDERICO QUAINI;ALESSANDRO D’ANGELO;EUGENIA MARTELLA","1.45;1.45;0.7;0.5;0.5;0.38;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.25","STEFANO CASCINU;P MANGANELLI;PIERANNA FIETTA;ANNAMARIA GUAZZI;NADIA NALDI;MASSIMO PILLI;VINCENZO CATALANO;FRANCESCO FERRAÙ;CARLO FERRARI;VITTORIO FRANCIOSI;GABRIELE MISSALE;RITA NIZZOLI;CECILIA BOZZETTI;ROBERTA CAMISA;GREGORY C. FANELLI;FABIO CASTAGNETTI;ALESSANDRO ZERBINI;S. CERIONI;A. CAVALLI;MICHELE BIANCONCINI","5;4;4;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","P MANGANELLI;PIERANNA FIETTA;STEFANO CASCINU;MICHELE BIANCONCINI;ROBERTA CAMISA;FABIO CASTAGNETTI;STEFANO BALDASSARRE;CARLO FUSCO;C FAIENZA;FRANCESCO PISANI;DONATELLODI MASCIO;ANNAMARIA GUAZZI;NADIA NALDI;RITA NIZZOLI;CECILIA BOZZETTI;VITTORIO FRANCIOSI;CESARE MANOTTI;MASSIMO PILLI;VINCENZO CATALANO;FRANCESCO FERRAÙ","1.45;1.45;0.7;0.5;0.38;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.29;0.29;0.29;0.24;0.17;0.15;0.15;0.15","CARLO FERRARI;GABRIELE MISSALE;MASSIMO PILLI;A. CAVALLI;AMALIA PENNA;ANTONIO BERTOLETTI;CAROLINA BONI;IRENE RAPTI;J.M. JENKINS;RUGGERO PANEBIANCO;S. CERIONI;SIMONA URBANI;V. LAMONACA;A GOUPIL;ANDRÉS CERVANTES;ANDRÉS POVEDA;B CHEVALLIER;C F DE OLIVEIRA;C SCARABELLI;C. MADROÑAL","309;309;309;234;234;234;234;234;234;234;234;234;234;196;196;196;196;196;196;196","CARLO FERRARI;GABRIELE MISSALE;MASSIMO PILLI;A. CAVALLI;AMALIA PENNA;CAROLINA BONI;IRENE RAPTI;S. CERIONI;SIMONA URBANI;V. LAMONACA;MAURO MELPIGNANO;STEFANO CASCINU;E. BENERICETTI;ERMANNO GIOMBELLI;A. ORLANDINI;ALESSANDRO ZERBINI;CRISTINA CAVALLO;GUIDO PELOSI;GREGORY C. FANELLI;P MANGANELLI","309;309;309;234;234;234;234;234;234;234;196;94;91;91;75;75;75;75;68;67","STEFANO CASCINU;P MANGANELLI;PIERANNA FIETTA;ANNAMARIA GUAZZI;CARLO FERRARI;CECILIA BOZZETTI;GABRIELE MISSALE;MASSIMO PILLI;NADIA NALDI;RITA NIZZOLI;VITTORIO FRANCIOSI;A. CAVALLI;A. ORLANDINI;ALBERTO BACCHI MODENA;ALESSANDRO ZERBINI;AMALIA PENNA;ANTONIO CACCHIOLI;BEATRICE DI BLASIO;C FAIENZA;CARLO FUSCO","5;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE","20;8;3;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;PATHOLOGY;SURGERY;BIOCHEMISTRY;ONCOLOGY;PHARMACOLOGY;ANESTHESIA;CANCER RESEARCH;GASTROENTEROLOGY;DERMATOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;UROLOGY;ANATOMY;ARTIFICIAL INTELLIGENCE;BIOTECHNOLOGY;CARDIOLOGY;CELL BIOLOGY;FISHERY;GEOMETRY;LAW;MECHANICAL ENGINEERING;METALLURGY;NUCLEAR MEDICINE;ORGANIC CHEMISTRY;PALEONTOLOGY;PEDIATRICS;QUANTUM MECHANICS;RADIOLOGY;STATISTICS;VIROLOGY","15;7;7;7;6;5;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;DISEASE;IMMUNE SYSTEM;IN VITRO;GENE;PATHOGENESIS;ARTHRITIS;BIOPSY;INFLAMMATION;MELANOMA;PATHOLOGICAL;POPULATION;REGIMEN;ABRASION (MECHANICAL);ALTERNATIVE MEDICINE;ANTIGEN;ANTITHROMBOTIC;APOPTOSIS;ATRIAL FIBRILLATION;BOLUS (DIGESTION);BONE MARROW;BONE REMODELING;BRACHIAL PLEXUS;BUPIVACAINE;CARTILAGE;CELL CULTURE;COAGULATION;COAGULOPATHY;CONCORDANCE;CONFIDENCE INTERVAL;CONNECTIVE TISSUE;CONTROL (MANAGEMENT);CYTOKINE;DIFFERENTIAL DIAGNOSIS;DRUG;EPINEPHRINE;FAMILY HISTORY;FENTANYL;FIBRIN;FIBROSIS;FIBROUS JOINT;FISH <ACTINOPTERYGII>;FLUORESCENCE;GLIOBLASTOMA;HEADACHES;HEMOSTASIS;HEPATITIS B;HEPATOCELLULAR CARCINOMA;HISTIOCYTE;HORMONE;IMMUNOCYTOCHEMISTRY;IMMUNOHISTOCHEMISTRY;IMMUNOPATHOLOGY;IN VIVO;INTERFERON;INTERPHALANGEAL JOINT;IODINE;LESION;LOCAL ANESTHETIC;LUNG CANCER;LYMPH;MEDLINE;MENOPAUSE;MIDDLE EAR;MIGRAINE;MYOCARDIAL INFARCTION;NAIL (FASTENER);NATURAL HISTORY;NAUSEA;NEUROSURGERY;NODAL;OSTEOPOROSIS;OTOPLASTY;OTORHINOLARYNGOLOGY;PARALYSIS;PERIOSTITIS;PLASTIC SURGERY;PLATELET;PRESENTATION (OBSTETRICS);PSORIASIS;RADIATION THERAPY;REDUCTION (MATHEMATICS);REGRESSION;REGRESSION ANALYSIS;RHEUMATOID ARTHRITIS;ROPIVACAINE;SECRETION;SHOULDER SURGERY;STAGE (STRATIGRAPHY);THROMBOSIS;THYROID;TOXICITY;TRANSDERMAL;TUMOR NECROSIS FACTOR ALPHA;VIRUS;WHITE BLOOD CELL","5;5;4;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYTOTOXIC T CELL;CISPLATIN;ALLELE;BREAST CANCER;CD8;GEMCITABINE;PROINFLAMMATORY CYTOKINE;T CELL;ACUTE CORONARY SYNDROME;AMIODARONE;ANTIMETABOLITE;AUTOFLUORESCENCE;BONE DENSITY;BONE MINERAL;CHEMOTHERAPY REGIMEN;CHROMOSOME;CYCLOPHOSPHAMIDE;CYTOPENIA;CYTOTOXICITY;DOXORUBICIN;ENDOMETRIAL CANCER;EPITOPE;FAMILY AGGREGATION;FINE-NEEDLE ASPIRATION;FIRST-DEGREE RELATIVES;HAZARD RATIO;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS;HEPATITIS B VIRUS;HISTIOCYTOSIS;IMMUNE DYSREGULATION;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTERFERON GAMMA;LEVOBUPIVACAINE;MACROPHAGE ACTIVATION SYNDROME;NEUTROPENIA;OTOLOGIC SURGICAL PROCEDURES;PANCREATIC CANCER;PANCYTOPENIA;PHASES OF CLINICAL RESEARCH;PLACEBO;PLATELET AGGREGATION;PSORIATIC ARTHRITIS;RESEARCH METHODOLOGY;RHEUMATOID NODULE;SCOPUS;SYSTEMIC DISEASE;THROMBIN;THROMBOLYSIS;THYROID FUNCTION;THYROID FUNCTION TESTS;THYROIDITIS;UNSTABLE ANGINA;VASCULITIS;VIREMIA","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;BLEEDING TIME;CANCER IMMUNOTHERAPY;CHURG-STRAUSS SYNDROME;CORONAVIRUS DISEASE 2019 (COVID-19);FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;HAPLOTYPE;HEMOPHAGOCYTOSIS;INTERLEUKIN 12;INTERLEUKIN 21;LAMIVUDINE;METASTATIC BREAST CANCER;MICROSATELLITE;NATURAL KILLER CELL;NORETHISTERONE;TIMI;VINCRISTINE;VINORELBINE;WEGENER GRANULOMATOSIS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;ADENOCARCINOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;MIDDLE AGED;ANTINEOPLASTIC AGENTS;CD8-POSITIVE T-LYMPHOCYTES;DEOXYCYTIDINE;AGED;PYRIMIDINES;TREATMENT OUTCOME;ANTIBIOTICS, ANTINEOPLASTIC;BIOMARKERS, TUMOR;BIOPSY, NEEDLE;CARCINOMA, HEPATOCELLULAR;CARCINOMA, NON-SMALL-CELL LUNG;CELL DIVISION","19;11;10;9;7;7;7;7;6;6;6;5;5;5;4;4;4;4;4;4","ADVANCEMENTS IN LUNG CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION;GYNECOLOGIC ONCOLOGY;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;HEPATITIS B INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;OSTEOPOROSIS;PANCREATIC CANCER RESEARCH AND TREATMENT;PHOTODYNAMIC THERAPY IN ONCOLOGY AND MICROBIOLOGY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PATHOGENESIS;BREAST CANCER;PROINFLAMMATORY CYTOKINE;REGIMEN;ABRASION (MECHANICAL);ACOUSTIC RHINOMETRY;ANTIGEN PRESENTATION;ATP-DEPENDENT TRANSPORTERS;AURICULAR;AUTOFLUORESCENCE;AUTOINFLAMMATORY SKIN DISORDERS;BLEEDING TIME;BOLUS (DIGESTION);BONE MINERAL DENSITY;BONE REMODELING;CANCER DETECTION;CANCER IMMUNOTHERAPY;CANCER PROGRESSION;CHEMOTHERAPY REGIMEN;CHURG-STRAUSS SYNDROME","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACTIVATION SYNDROME;ACTIVE REGIMEN;ACUTE CORONARY;ADMISSION WHITE;ADVANCED PANCREATIC;AMIODARONE-INDUCED THYROTOXICOSIS;ANDOR ANTHRACYCLINES;ANTERIOR ABRASION;ANTIGEN ENCODING;ASSISTED INTRAOPERATIVE;BIOLOGICAL PARAMETERS;BLOOD CELL;BONE LOSS;BRACHIAL PLEXUS;BREAST CANCER;BREAST CARCINOMAS;CANCER GISCAD;CANCER PATIENTS;CANCER PRETREATED;CARCINOMA DEFINITIVE;CELL COUNT;CELL LUNG;CELL RESPONSES;CHEMOTHERAPEUTIC REGIMEN;CHEMOTHERAPIC DRUGS;CHRONIC HEPATITIS;CHURG-STRAUSS SYNDROME;CISPLATIN CHEMOTHERAPY;CLINICAL CHARACTERISTICS;COMPLETE CONTROL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NK CELLS;RESPONSE RATE;PANCREATIC CANCER;AGENT DOX;BRACHIAL PLEXUS;CDDP MGMSUPSUP;CELLS HIV;CISPLATIN CDDP;CLINICAL BENEFIT;CONFIDENCE INTERVAL;DOX MGMSUPSUP;ENDOMETRIAL ADENOCARCINOMA;INTERSCALENE ANALGESIA;INTERSCALENE BRACHIAL;LOCAL ANESTHETIC;MIN INFUSION;MIN MIN;ML ML;MOTOR FUNCTION;NATURAL KILLER;ONSET TIME;PARTIAL RESPONSES;PERFORMANCE STATUS;POSTOPERATIVE ANALGESIA;ROPIVACAINE POSTOPERATIVE;SINGLE AGENT;SURGICAL BLOCK;TOXICITY CONSISTED;TOXICITY GRADE;ACCEPTABLE TOXICITY","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1",4,0.18,7.75,3.75,0,0,0,1,3.5,0,1,3.75,0,0,0,0,2,0,0,0,0,0,0.25,32.25,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,8.2,1675,9.62,2,0.4,120.4,0,0,0,0,4,0,1,0,0,5,0,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Italy;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;37 EARTH SCIENCES;3701 ATMOSPHERIC SCIENCES","5;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;KIDNEY DISEASE;PATIENT SAFETY;PREVENTION;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BREAST CANCER;CANCER;EYE DISEASE AND DISORDERS OF VISION;HEART DISEASE;HEMATOLOGY;HYPERTENSION;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES","4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;EYE;RENAL AND UROGENITAL","2;1;1;1","6.1 PHARMACEUTICALS","3","BREAST CANCER","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2004,35,7.2,2.31428571428571,0.6,0.285714285714286,0.6,1.3728813559322,1.10526315789474,1.25,1.10526315789474,0.314285714285714,3,12,9,5,9,0.34,0.26,0.14,0.26,35.2,0.748082829683938,NA,0.171428571428571,0.685714285714286,0.491,0.212,0.204,0.18,"ALESSANDRO GIOLLO;STEFANIA FERRETTI;P. CORTELLINI;PAOLA TORELLI;UMBERTO MAESTRONI;PIERANNA FIETTA;P MANGANELLI;GIULIANA GOBBI;ALESSANDRO ZERBINI;IVONNE SPONZILLI;ROBERTA MINARI;DIEGO ARDISSINO;VINCENZO DE LISI;ALESSANDRO DE FANTI;P. SALSI;CARLO FERRARI;MARCO VITALE;GABRIELE MISSALE;PRISCO MIRANDOLA;N. AZZOLINI","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PIERANNA FIETTA;PAOLA TORELLI;VINCENZO DE LISI;G. C. MANZONI;ALESSANDRO GIOLLO;UMBERTO MAESTRONI;P. CORTELLINI;FABIO CASTAGNETTI;FRANCIOSI;D DEVOTI;ANDREA ARDIZZONI;DOMENICO D’AMICO;DI MASCIO D;FRANCESCO POGLIACOMI;STEFANIA FERRETTI;ROBERTA MINARI;P. SALSI;ANDRÉA BARBIERI;P MANGANELLI;ALESSANDRO DE FANTI","2.12;1.5;1.04;1;0.77;0.6;0.51;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.43;0.34;0.34;0.33;0.29;0.28","ALESSANDRO GIOLLO;STEFANIA FERRETTI;P. CORTELLINI;PAOLA TORELLI;UMBERTO MAESTRONI;PIERANNA FIETTA;P MANGANELLI;GIULIANA GOBBI;ALESSANDRO ZERBINI;ROBERTA MINARI;DIEGO ARDISSINO;VINCENZO DE LISI;ALESSANDRO DE FANTI;P. SALSI;CARLO FERRARI;GABRIELE MISSALE;PRISCO MIRANDOLA;N. AZZOLINI;G. C. MANZONI;SIMONA URBANI","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PIERANNA FIETTA;PAOLA TORELLI;VINCENZO DE LISI;G. C. MANZONI;ALESSANDRO GIOLLO;UMBERTO MAESTRONI;P. CORTELLINI;D DEVOTI;ANDREA ARDIZZONI;DI MASCIO D;STEFANIA FERRETTI;ROBERTA MINARI;P. SALSI;P MANGANELLI;ALESSANDRO DE FANTI;N. AZZOLINI;GIULIANA GOBBI;PRISCO MIRANDOLA;ANDREA CASATI;ANTONIO FRATTINI","2.12;1.5;1.04;1;0.77;0.6;0.51;0.5;0.5;0.5;0.43;0.34;0.34;0.29;0.28;0.27;0.25;0.25;0.25;0.2","DIEGO ARDISSINO;PIERA ANGELICA MERLINI;ANTONIO MANARI;ANTONÍO MARZOCCHI;CIRO INDOLFI;CLAUDIO CAVALLINI;ERMINIO BONIZZONI;EZIO BRAMUCCI;FOR THE SES-SMART INVESTIGATORS;GIULIA ANGELONI;GIUSEPPE CAROSIO;MONICA REPETTO;STEFANIA COLUSSO;A. CERIBELLI;ALFREDO FALCONE;ANNA ILLIANO;CESARE GRIDELLI;CIRO GALLO;EMIDDIO BARLETTA;FRANCESCO PERRONE","330;330;321;321;321;321;321;321;321;321;321;321;321;164;164;164;164;164;164;164","ANTONIO MANARI;MONICA REPETTO;STEFANIA SALVAGNI;ANDREA CASATI;P MANGANELLI;F. DE RENSIS;G. RONCI;PIERANNA FIETTA;PAOLA TORELLI;VINCENZO DE LISI;ANNARITA TAGLIAFERRI;GIULIANA GOBBI;ENRICA TALARICO;G. C. MANZONI;ICILIO DODI;ALESSANDRO ZERBINI;CARLO FERRARI;GABRIELE MISSALE;SIMONA URBANI;NADIA NALDI","321;321;164;129;99;95;95;81;70;70;41;35;32;32;32;31;31;31;31;22","PAOLA TORELLI;PIERANNA FIETTA;UMBERTO MAESTRONI;ALESSANDRO ZERBINI;CARLO FERRARI;G. C. MANZONI;GABRIELE MISSALE;P MANGANELLI;SIMONA URBANI;VINCENZO DE LISI;A FINARDI;AMALIA PENNA;ANDREA CASATI;ANNA MARIA ANDREOLI;ANNARITA TAGLIAFERRI;ANTONIO MANARI;B CALBIANI;BARBARA AMADEI;C. F. FLAMMINI;CAROLINA BONI","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY","28;12;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;PATHOLOGY;BIOCHEMISTRY;GENETICS;CARDIOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;OPTICS;PEDIATRICS;PSYCHIATRY;UROLOGY;VIROLOGY;ANATOMY;CELL BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;GASTROENTEROLOGY;MOLECULAR BIOLOGY;NURSING;ONCOLOGY;PALEONTOLOGY;PHYSICAL THERAPY;RADIOLOGY","19;12;8;8;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;GENE;INCIDENCE (GEOMETRY);MIGRAINE;MYOCARDIAL INFARCTION;NEUROLOGY;POPULATION;VIRUS;ALTERNATIVE MEDICINE;ANTIGEN;DISEASE;HEADACHES;IMMUNE SYSTEM;PERFUSION;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;SARCOMA;URINARY SYSTEM;AMINO ACID;AMYLOIDOSIS;ANXIETY;AREA UNDER THE CURVE;ARTERY;ARTHRITIS;AXON;BACTERIA;BETA-2 MICROGLOBULIN;BLOOD PRESSURE;BONE REMODELING;BUBALUS;BUPIVACAINE;CARCINOMA;CARTILAGE;CELL CULTURE;CHEMOTHERAPY;COAGULATION;COGNITION;COHEN'S KAPPA;CONCOMITANT;CONFIDENCE INTERVAL;CONFOUNDING;CORONARY ARTERY DISEASE;CYTOKINE;DEPRESSION (ECONOMICS);DIPLOPIA;DISTRESS;EARLOBE;ENZYME;ERECTILE DYSFUNCTION;ESTROUS CYCLE;FIBRINOLYSIS;FIBROMYALGIA;FOLLICLE;FOLLICULAR PHASE;FUNCTIONAL IMPAIRMENT;GERMINATION;HAEMOPHILIA;HAIR LOSS;HEART FAILURE;HEMOLYTIC ANEMIA;HERNIA;HORMONE;HYPERMOBILITY (TRAVEL);IN VITRO;IN VIVO;INFLAMMATION;IRRITABLE BOWEL SYNDROME;KAPPA;KNEE JOINT;LESION;LUNG;LUNG CANCER;MONOCYTE;MULTIPLE MYELOMA;NASAL ADMINISTRATION;NAUSEA;NECROSIS;NEOPLASM;NEUROLOGICAL EXAMINATION;NEURON;NEUROSURGERY;OSTEOPOROSIS;OSTEOSCLEROSIS;OTOLOGY;PATHOGEN;PINNA;PLATELET;PREGNANCY;PROSPECTIVE COHORT STUDY;RADIOGRAPHY;RANDOMIZED CONTROLLED TRIAL;REPRODUCIBILITY;RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;RHEUMATOLOGY;RISK FACTOR;ROPIVACAINE;SEXUAL FUNCTION;SIGNAL TRANSDUCTION;SIROLIMUS;SLING (WEAPON);SPERM;SPINAL ANESTHESIA;STAGE (STRATIGRAPHY);STAINING;STATE (COMPUTER SCIENCE);STENT;STRAIN (INJURY);SULCUS;TEST (BIOLOGY);THALLIUM;THROMBOSIS;TOXICITY;TRIAMCINOLONE ACETONIDE;ULTRASOUND;URINARY BLADDER;URINARY INCONTINENCE","7;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AURA;BLADDER CANCER;CLUSTER HEADACHE;T CELL;16S RIBOSOMAL RNA;ACTIVATOR (GENETICS);AGONIST;ANXIETY DISORDER;ARGININE;ARTHRODESIS;ARTIFICIAL INSEMINATION;ARYLSULFATASE;BREAST CANCER;CANCER REGISTRY;CARCINOSARCOMA;CD8;CELL CYCLE;CEREBRAL VENOUS SINUS THROMBOSIS;CHRONIC MIGRAINE;CLINICAL ENDPOINT;CONVENTIONAL PCI;CORONARY ARTERIES;CYTOTOXIC T CELL;DENOSUMAB;DIHYDROERGOTAMINE;DOCETAXEL;DYSURIA;ELECTROCARDIOGRAPHY IN MYOCARDIAL INFARCTION;ERECTILE FUNCTION;EX VIVO;EXERCISE INTOLERANCE;EXON;FAMILIAL MEDITERRANEAN FEVER;HAEMOPHILIA A;HAZARD RATIO;HEREDITARY DISEASES;HUMAN LEUKOCYTE ANTIGEN;INGUINAL HERNIA;INSEMINATION;INTERLEUKIN;INTERLEUKIN 2;INTERNATIONAL CLASSIFICATION OF HEADACHE DISORDERS;INTERSTITIAL CYSTITIS;ISOMERASE;LEUKOPENIA;LEVOBUPIVACAINE;LUNG FUNCTION;LUNG VOLUMES;LYMPHOKINE;MAJOR HISTOCOMPATIBILITY COMPLEX;MUCOSITIS;MUTATION;MYCOBACTERIUM;NASAL SPRAY;NEUROPSYCHOLOGY;NEURORADIOLOGY;NEUROTROPIC VIRUS;NEUTROPENIA;ORTHOSTATIC VITAL SIGNS;OSTEOCLAST;OVULATION;PANIC;PANIC DISORDER;PERCUTANEOUS CORONARY INTERVENTION;PLATELET ACTIVATION;POWER DOPPLER;PREGNANCY RATE;PRIMING (AGRICULTURE);PROSTATE CANCER;PROTEIN SUBUNIT;PULMONARY EMPHYSEMA;RECOMBINANT DNA;RECORD LINKAGE;RESTENOSIS;REVASCULARIZATION;SPINDLE CELL SARCOMA;STREPTOKINASE;SUPERINFECTION;SYNOVITIS;TRADITIONAL CHINESE MEDICINE;VASCULITIS;VIRAL DISEASE;VIREMIA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MIGRAINE WITH AURA;ABCIXIMAB;ASTRAGALUS;BLADDER NEOPLASM;CHURG-STRAUSS SYNDROME;CYSTECTOMY;DIFFUSING CAPACITY;ELISPOT;HIV ANTIGENS;INTERLEUKIN 12;INTERLEUKIN 15;INTERLEUKIN 21;MHC CLASS I;MISSENSE MUTATION;NATURAL KILLER CELL;NATURAL KILLER T CELL;NEUROPSYCHOLOGICAL ASSESSMENT;ONCOGENE;ORTHOSTATIC INTOLERANCE;OSTEOPROTEGERIN;PROSTATECTOMY;RANKL;RETEPLASE;SUMATRIPTAN;TARGET LESION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;AGED;FEMALE;MIDDLE AGED;ADULT;CARCINOMA, NON-SMALL-CELL LUNG;HEPACIVIRUS;HEPATITIS B;LUNG NEOPLASMS;CLUSTER HEADACHE;FAMILIAL MEDITERRANEAN FEVER;MENTAL DISORDERS;MIGRAINE DISORDERS;MYOCARDIAL INFARCTION;RECOMBINANT PROTEINS;;ADOLESCENT;BREAST NEOPLASMS;CD8-POSITIVE T-LYMPHOCYTES","28;16;11;11;11;9;7;7;7;7;6;6;6;6;6;6;5;5;5;5","MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMINO ACID TRANSPORT AND METABOLISM IN HEALTH AND DISEASE;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;EVOLUTION AND USAGE OF ANATOMICAL NOMENCLATURE;HEPATITIS B INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MANAGEMENT AND TREATMENT OF HEMOPHILIA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLUSTER HEADACHE;NON-SMALL CELL LUNG CANCER;T CELL;TREATMENT;TUMOR MICROENVIRONMENT;ABCIXIMAB;AMINO ACID TRANSPORTERS;ANTICOAGULATION THERAPY;ANTIGEN PRESENTATION;ARYLSULFATASE;ASTRAGALUS;AURICULAR;BETA-2 MICROGLOBULIN;BIOCHEMICAL RECURRENCE;BLADDER CANCER;BLADDER DIVERTICULUM;BLADDER NEOPLASM;BONE REMODELING;BUBALUS;CARCINOSARCOMA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MYOCARDIAL INFARCTION;ACUTE MYOCARDIAL;ANTIVIRAL CD-MEDIATED;APICAL MYOCARDIAL;ARGININE TRANSPORT;ARTHRITIS ASSESSMENT;ARTHRODESIS DESCRIPTION;ASTRAGALUS TREATED;AUTOINFLAMMATORY DISEASES;BILATERALE NELLA;BLADDER CARCINOSARCOMA;BOVINE HERPESVIRUS;BREAST CANCER;BREAST CARCINOMA;BUBALUS BUBALIS;BUFFALOES BUBALUS;BULLOUS EMPHYSEMA;BUPIVACAINE ROPIVACAINE;C-ASSOCIATED OSTEOSCLEROSIS;CARCINOMA LESIONS;CD-MEDIATED RESPONSES;CELL LUNG;CELL PRIMING;CEREBRAL VENOUS;CHILDHOOD CLINICAL;CHRONIC HCV;CHRONIC HEMOLYTIC;CHURG-STRAUSS DESCRIZIONE;CLASSIC KAPOSIS;CLASSIFICATION CRITICISM","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDIAN KW;OVSYNCH PROTOCOL;CONCEPTION RATE;MEMBRANE STAINING;INTEROBSERVER REPRODUCIBILITY;KW RANGE;BUFFALOES VERSUS;FUNCTIONAL IMPAIRMENT;INHIBITOR DEVELOPMENT;NA CELLS;NON-CYCLIC BUFFALOES;PROGESTERONE SUPPLEMENTATION;PROSPECTIVE STUDY;SYSTEM YL;WEEKLY SCHEDULE;ADVANCED NSCLC;CELLS MEDIAN;CLASSIFICATION CRITERIA;EXTENT MMLMATHMMLMOMMLMOMMLMNMMLMNMMLMOMMLMOMMLMATH;GNRH ADMINISTRATION;GROWTH FACTORS;HAIR LOSS;HER-NEU EXPRESSION;HERNIA REPAIR;HYPERBARIC BUPIVACAINE;HYPERBARIC LEVOBUPIVACAINE;HYPERBARIC ROPIVACAINE;IMMUNOSTAINED CELLS;INDIVIDUALS BORN;INGUINAL HERNIA","6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.09,3,1.5,0,0,0,0,1,0,0,1.5,0,0,0,0,1.75,0,0,0,0,0,0,24.5,24.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,3,3654.6,10.91,2,0.33,135.33,0,0,0,1,3,0,1,1,0,6,0,0,0,0,0,0,0,6,0,0,5,0,0,0,1,0,0,0,0,0,"United States;Belgium","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES","6;4;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;PATIENT SAFETY;PEDIATRIC;RARE DISEASES;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;HEALTH SERVICES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;INFECTIOUS DISEASES;LUNG CANCER;PEDIATRIC CANCER;PNEUMONIA;PREVENTION","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS","3;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",1,2200000,550000,4,4,3,1,0,294533.655830262,0.118831920587609,"AIRIAL CONSEIL (FRANCE);HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE;OSPEDALE DI PARMA;UNIVERSITAT POLITÈCNICA DE VALÈNCIA","1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-IST - INFORMATION SOCIETY TECHNOLOGIES: THEMATIC PRIORITY UNDER THE SPECIFIC PROGRAMME ""INTEGRATING AND STRENGTHENING THE EUROPEAN RESEARCH AREA"" (2002-2006). (PROGRAMME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME)","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","CLINICAL RESEARCH;HEALTH SERVICES;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD)","1;1;1","GENERIC HEALTH RELEVANCE","1","7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2005,36,11.75,3.05555555555556,0.527777777777778,0.361111111111111,0.555555555555556,1.26436781609195,1.11764705882353,1.3,1.05263157894737,0.25,1,16,7,6,5,0.44,0.19,0.17,0.14,63.14,1.1925659661002,NA,0.277777777777778,0.583333333333333,0.448,0.229,0.339,0.31,"CARLO FERRARI;G. DANELLI;PAOLA FISICARO;BARBARA AMADEI;MARIA ANTONIETTA VALLI;GABRIELE MISSALE;SIMONA URBANI;ANDREA CASATI;JAN-MAARTEN VROLIJK;GREGORY C. FANELLI;CATERINA CAMINITI;RONEN TAL;WALTER SERRA;ROBERTO BERTONI;ESTHER LUKASIEWICZ;FRANCESCO NEGRO;ROBERTA MINELLI;LORENZO FINARDI;STEFAN ZEUZEM;ALESSANDRO COZZI‐LEPRI","6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LICIA DENTI;WALTER SERRA;A. CARBONI;CARLO FERRARI;ANDREA CASATI;LUIGI BENECCHI;ANNA MARIA PIERI;UMBERTO MAESTRONI;P MANGANELLI;PAOLA SEBASTIO;TAURO MARIA NERI;PIERANNA FIETTA;G. DANELLI;PAOLA FISICARO;BARBARA AMADEI;GABRIELE MISSALE;SIMONA URBANI;CATERINA CAMINITI;VESNA NOVAK JANKOVIČ;ANGELO GIANNI CASALINI","1;0.7;0.7;0.64;0.61;0.6;0.6;0.58;0.5;0.5;0.5;0.5;0.44;0.41;0.41;0.41;0.41;0.39;0.33;0.33","CARLO FERRARI;G. DANELLI;PAOLA FISICARO;BARBARA AMADEI;MARIA ANTONIETTA VALLI;GABRIELE MISSALE;SIMONA URBANI;ANDREA CASATI;GREGORY C. FANELLI;CATERINA CAMINITI;WALTER SERRA;ROBERTO BERTONI;LORENZO FINARDI;V. COIRO;LUIGI BENECCHI;R DELSIGNORE;CLELIA DI SECLÌ;UMBERTO MAESTRONI;ANGELA LUCIANA BARILLI;ANNA MARIA PIERI","6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LICIA DENTI;WALTER SERRA;A. CARBONI;CARLO FERRARI;ANDREA CASATI;LUIGI BENECCHI;ANNA MARIA PIERI;UMBERTO MAESTRONI;P MANGANELLI;TAURO MARIA NERI;PIERANNA FIETTA;G. DANELLI;PAOLA FISICARO;BARBARA AMADEI;GABRIELE MISSALE;SIMONA URBANI;CATERINA CAMINITI;ANGELO GIANNI CASALINI;MARIA MAJORI;LUIGI FECCI","1;0.7;0.7;0.64;0.61;0.6;0.6;0.58;0.5;0.5;0.5;0.44;0.41;0.41;0.41;0.41;0.39;0.33;0.33;0.33","ADALBERTO SESSA;ANNALISA PERNA;BOGDAN ENE‐IORDACHE;CARLO BASILE;CARMINE ZOCCALI;DANIELA LEONARDIS;ELENA PERTICUCCI;G GARINI;GIACOMINA LORIGA;GIANBATTISTA SORBA;GIUSEPPE REMUZZI;IVAN NEDIYALKOV CHAKARSKI;MARIADOMENICA LESTI;MARTA TURTURRO;MARÍA GANEVA;MIRELLA ALPA;PIERO RUGGENENTI;RENZO SCANZIANI;ANDREA CASATI;CARLO FERRARI","624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;624;474;426","G GARINI;ANDREA CASATI;CARLO FERRARI;G. DANELLI;GREGORY C. FANELLI;DAVIDE IMBERTI;EMANUELE NAGLIERI;FRANCESCO PAOLETTI;GIANCARLO AGNELLI;MARIO BAZZAN;PASQUALE PARISE;ROBERTO QUINTAVALLA;SERGIO BERTOGLIO;STEFANO MOSCA;WALTER AGENO;BARBARA AMADEI;GABRIELE MISSALE;PAOLA FISICARO;SIMONA URBANI;GIANFRANCO ELIA","624;474;426;319;319;293;293;293;293;293;293;293;293;293;293;258;258;258;258;147","CARLO FERRARI;ANDREA CASATI;BARBARA AMADEI;GABRIELE MISSALE;MARIA ANTONIETTA VALLI;PAOLA FISICARO;SIMONA URBANI;ANNA MARIA PIERI;CATERINA CAMINITI;LUIGI BENECCHI;ROBERTO BERTONI;A. FRANZÈ;A. ORLANDINI;ANGELA LUCIANA BARILLI;ANGELO GIANNI CASALINI;ANNAMARIA GUAZZI;ANNARITA TAGLIAFERRI;BERNARDO BIANCHI;CAROLINA BONI;CECILIA BOZZETTI","6;3;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS","34;8;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ANESTHESIA;IMMUNOLOGY;CARDIOLOGY;GASTROENTEROLOGY;GENETICS;VIROLOGY;ENDOCRINOLOGY;PATHOLOGY;RADIOLOGY;UROLOGY;BIOCHEMISTRY;FAMILY MEDICINE;MECHANICAL ENGINEERING;NURSING;ONCOLOGY;PALEONTOLOGY;PHYSICAL THERAPY;ANDROLOGY;ASTRONOMY;CELL BIOLOGY;CLINICAL PSYCHOLOGY;COMMUNICATION;DENTISTRY;DERMATOLOGY;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;GEOTECHNICAL ENGINEERING;GYNECOLOGY;INTENSIVE CARE MEDICINE;MACHINE LEARNING;MEDICAL PHYSICS;ORGANIC CHEMISTRY;PEDIATRICS;PHYSIOLOGY;PSYCHIATRY;QUANTUM MECHANICS;STATISTICS","24;14;8;7;5;5;5;5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VIRUS;CANCER;GENE;RANDOMIZED CONTROLLED TRIAL;BLOOD PRESSURE;CONFIDENCE INTERVAL;IMMUNE SYSTEM;INTERFERON;AIRWAY;ANTIBODY;DISEASE;HEART FAILURE;HEPATITIS C;IMMUNOHISTOCHEMISTRY;INTUBATION;KIDNEY;PRESENTATION (OBSTETRICS);PUBLIC HEALTH;THYROID;ADENOID;ADVERSE EFFECT;AFFECT (LINGUISTICS);ALTERNATIVE MEDICINE;ANALGESIC;ANTIGEN;ANXIETY;ARTERY;ARTIFICIAL NEURAL NETWORK;BEARING (NAVIGATION);BIOPSY;BLUNT;BODY MASS INDEX;BODY WEIGHT;BRONCHOSCOPY;CARCINOMA;CAROTID ARTERIES;CHEMOTHERAPY;CLINICAL PRACTICE;COAGULATION;COAGULATIVE NECROSIS;COHORT STUDY;COMBINATION THERAPY;CONCOMITANT;CONCORDANCE;CORONARY SINUS;CROSS-SECTIONAL STUDY;CUFF;DEFORMITY;DENTAL CARE;DOPAMINE;DRUG;EMBRYO;ENDOSCOPY;ENZYME;FENTANYL;FISTULA;FOREIGN BODY;HAEMOPHILIA;HELICOBACTER PYLORI;HEMANGIOMA;HEPARIN;HEPATITIS B;HEPATOLOGY;HORMONE;HOSTILITY;HUMAN FERTILIZATION;IN VITRO;KIDNEY DISEASE;KOWSAR;LARYNX;LIMITING;LIPOMATOSIS;LUNG;LUNG CANCER;METABOLIC DISEASE;METHYLPREDNISOLONE;MITRAL REGURGITATION;MUSCLE MASS;NAUSEA;NURSING RESEARCH;OBSERVATIONAL STUDY;ORAL SURGERY;OXYGEN;PATIENT SATISFACTION;PERFUSION;PERSISTENCE (DISCONTINUITY);PHYSICAL EXAMINATION;PNEUMOTHORAX;POISON CONTROL;PRIVATE PRACTICE;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;PSYCHOLOGICAL INTERVENTION;PULMONARY EMBOLISM;PYELOGRAM;QRS COMPLEX;REGIMEN;REPRODUCIBILITY;RESECTION;RESPIRATORY DISTRESS;RETROSPECTIVE COHORT STUDY;RHEUMATOLOGY;ROPIVACAINE;SARCOPENIA;SEDATION;SEVERE BLEEDING;SEXING;SHOCK (CIRCULATORY);SIROLIMUS;SPERM;SPINAL ANESTHESIA;STAGE (STRATIGRAPHY);STOMACH;SUFENTANIL;SURVIVAL RATE;TERM (TIME);TEST (BIOLOGY);TESTOSTERONE (PATCH);THROMBOSIS;URETER;URINARY SYSTEM;VENTILATION (ARCHITECTURE)","7;6;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CHRONIC HEPATITIS;HEPATITIS C VIRUS;ALPHA INTERFERON;CD8;COINFECTION;GRAVES' DISEASE;HAZARD RATIO;PROSTATE;PROSTATE CANCER;THYROID FUNCTION;THYROID PEROXIDASE;ADENOID CYSTIC CARCINOMA;AIRWAY MANAGEMENT;ALLELE;AMLODIPINE;ANGIOTENSIN-CONVERTING ENZYME;ATELECTASIS;AVIDITY;BLADDER CANCER;BREAST CANCER;CARCINOGENESIS;CAROTID ENDARTERECTOMY;CEREBRAL HYPOPERFUSION;CEREBRAL PERFUSION PRESSURE;CHEST TUBE;CLINICAL ENDPOINT;COAGULATION TESTING;COLORECTAL CANCER;CONSTRUCT VALIDITY;CORONARY ARTERIES;CYTOTOXIC T CELL;DEEP VEIN;DIABETIC NEPHROPATHY;DIASTOLE;DOPAMINERGIC;DOWNREGULATION AND UPREGULATION;EJECTION FRACTION;EMBRYOGENESIS;EPITOPE;EUTHYROID;FELODIPINE;GASTRIC MUCOSA;GASTRITIS;GEMCITABINE;GENOTYPE;GLOMERULONEPHRITIS;HAEMOPHILIA A;HEALTH ADMINISTRATION;HEALTH INFORMATICS;HEALTH SERVICES RESEARCH;HEART RATE;HEPATITIS A VIRUS;HEPATITIS B VIRUS;HEROIN;HETEROLOGOUS;HUMAN GENETICS;HYDRONEPHROSIS;HYPOXIA (ENVIRONMENTAL);IMMUNITY;INJURY PREVENTION;IRRITABILITY;KI-67;LARYNGEAL MASK AIRWAY;LARYNGOSCOPY;LEAN BODY MASS;LOW MOLECULAR WEIGHT HEPARIN;MULTICENTER STUDY;NEURAXIAL BLOCKADE;NEUTROPENIA;OOCYTE;PARKINSONISM;PEPSIN;PERFUSION SCANNING;PHASES OF CLINICAL RESEARCH;PLACEBO;RAMIPRIL;RANDOMIZATION;THROMBOELASTOGRAPHY;TOLERABILITY;TRIIODOTHYRONINE;TUMOR PROGRESSION;VASCULITIS;VENOGRAPHY;VIRAL DISEASE;VIRAL LOAD","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RIBAVIRIN;ACE INHIBITOR;ALPHA (FINANCE);ALPORT SYNDROME;ANTISOCIAL PERSONALITY DISORDER;ATROPHIC GASTRITIS;BREAST CARCINOMA;CARDIAC RESYNCHRONIZATION THERAPY;CELL MEDIATED IMMUNITY;DOPAMINE TRANSPORTER;DOPPLER IMAGING;FLAVIVIRIDAE;GIANT CELL ARTERITIS;HAEMOPHILIA B;HEPACIVIRUS;HER2/NEU;MULTICENTER TRIAL;OXALIPLATIN;POLYMORPHISM (COMPUTER SCIENCE);PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;RESPIRATORY RATE;SIDA;SPIRILLACEAE;TRANSITIONAL CELL CARCINOMA;TRASTUZUMAB;VARIABLE NUMBER TANDEM REPEAT;ZYGOTE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;HEPACIVIRUS;HEPATITIS C, CHRONIC;HEPATITIS C;ANTIVIRAL AGENTS;CD8-POSITIVE T-LYMPHOCYTES;;RNA, VIRAL;POSTOPERATIVE COMPLICATIONS;BRAIN ISCHEMIA;HEPATITIS B;INTERFERON TYPE I;INTUBATION, INTRATRACHEAL;KIDNEY DISEASES;PROTEINURIA","28;22;17;14;12;12;11;10;9;8;8;7;7;6;5;5;5;5;5;5","HEPATITIS C INFECTION AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;BODY CONTOURING TECHNIQUES AND PROCEDURES;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;DIAGNOSIS AND MANAGEMENT OF CHYLOTHORAX AND CHYLOUS ASCITES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATITIS B INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;HERBAL MEDICINE USE AND SAFETY MONITORING;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS","7;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;BRAIN OXYGENATION MONITORING;CEREBRAL BLOOD FLOW MEASUREMENT;ECHOCARDIOGRAPHY;HEPATITIS C;PRESENTATION (OBSTETRICS);PROSTATE CANCER;REGIONAL ANESTHESIA;THYROID PEROXIDASE;ACUPUNCTURE;ADENOID;ADENOID CYSTIC CARCINOMA;ADOLESCENT DRUG USE;ADRENAL VEIN SAMPLING;AFFECT (LINGUISTICS);ALCOHOL DEPENDENCE;ALPHA (FINANCE);ALPORT SYNDROME;ALTERNATIVE MEDICINE;AMLODIPINE","5;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CHRONIC HEPATITIS;RANDOMIZED CONTROLLED;VIRUS INFECTION;BIVENTRICULAR PACING;COMPARING DYNAMICALLY;CONTROLLED STUDY;CONTROLLED TRIAL;DYNAMICALLY INDIVIDUALIZED;ECHOCARDIOGRAPHIC METHOD;HEART FAILURE;INDIVIDUALIZED VERSUS;INTERNATIONAL MULTICENTER;MULTICENTER RANDOMIZED;STANDARD TREATMENT;STUDY COMPARING;TERM RESPONDERS;VERSUS STANDARD;ABDOMINAL SURGERY;ACUTE HEPATITIS;ACUTE PHASE;ADENOID CYSTIC;ADULT PATIENTS;ADVANCED NON-SMALL-CELL;AIRWAY-MANAGEMENT STRATEGIES;ALLELIC ASSOCIATION;ALPORT SYNDROME;ANTERIOR CRUCIATE;ANTIRETROVIRAL-NAIVE HIV-INFECTED;ANTISOCIAL BEHAVIOUR;ARTIFICIAL NEURAL","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BIV PACING;CEREBRAL DESATURATION;CD RESPONSES;LV DIMENSIONS;MIN NA;MINNESOTA SCORE;NON-BIV PACING;NYHA CLASS;QOL SCORE;SIGNIFICANTLY IMPROVED;SYSTOLIC WAVE;CD CELLS;ELDERLY PATIENTS;HCV INFECTION;INTRAOPERATIVE CEREBRAL;MONTHS NA;ABDOMINAL SURGERY;ACHIEVE HEMODYNAMIC;ACHIEVED EPICARDIALLY;ACHIEVING CARDIAC;ACTIVATEDGPL PTS;ACUTE BASIS;ADVANCED HF;ANTIRETROVIRAL THERAPY;ASSESSED INCLUDED;ASSESSING LV;BASELINE DATA;BIV DEFIBRILLATORS;BIV PACEMAKERS;BIV PACINGTHE","10;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",5,0.14,7,2,0,3,0,1,2,0,2,2,0,0,1,0,0,0,0,1,0,0,0,80,80,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4,889.12,9.88,1,0.12,77.5,0,0,1,1,5,0,0,1,0,7,1,0,0,0,0,0,0,7,0,1,8,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","8;5;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CANCER;RARE DISEASES;UROLOGIC DISEASES;AGING;AUTOIMMUNE DISEASE;CHRONIC PAIN;DIGESTIVE DISEASES;KIDNEY DISEASE;LUNG;LUNG CANCER;NUTRITION;ORPHAN DRUG;PAIN RESEARCH;PROSTATE CANCER","7;5;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1","LUNG CANCER;PROSTATE CANCER;STOMACH CANCER","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2006,44,7.40909090909091,2.84090909090909,0.545454545454545,0.363636363636364,0.568181818181818,1.32978723404255,1.14285714285714,1,1.19047619047619,0.477272727272727,4,21,9,1,10,0.48,0.2,0.02,0.23,73.91,1.44697895617243,NA,0.181818181818182,0.75,0.407,0.345,0.413,0.35,"CARLO FERRARI;GABRIELE MISSALE;ANDREA CASATI;GREGORY C. FANELLI;AVIDAN U. NEUMANN;ANA I. ROMERO;FRANCESCO NEGRO;KRISTOFFER HELLSTRAND;MARTIN LAGGING;STEFAN ZEUZEM;JEAN‐MICHEL PAWLOTSKY;BARBARA AMADEI;ELKE VERHEIJ‐HART;JOHAN WESTIN;AMAR P. DHILLON;PIERANNA FIETTA;P MANGANELLI;BART L. HAAGMANS;GIULIANA GOBBI;GIOVANNI GUARALDI","8;6;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","CARLO FERRARI;PIERANNA FIETTA;ANDREA CASATI;EDWARD G. BRIDGES;GIAN CAMILLO MANZONI;FABRIZIO UGO;GABRIELE MISSALE;P MANGANELLI;MARCO BACIARELLO;GREGORY C. FANELLI;BARBARA AMADEI;A. CASATI;Z. KOSCIELNIAK-NIELSEN;FRANCESCO SCIOSCIOLI;FILIPPO CADEMARTIRI;FEDERICO QUAINI;LAURA BONFANTI;LUIGI VIGNALI;GIANFRANCO CERVELLIN;FRANÇOIS SINGELYN","1.62;1.53;1.05;1;1;0.58;0.55;0.53;0.5;0.47;0.35;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","CARLO FERRARI;GABRIELE MISSALE;ANDREA CASATI;GREGORY C. FANELLI;BARBARA AMADEI;PIERANNA FIETTA;P MANGANELLI;GIULIANA GOBBI;D. TOLA;LAURA RINALDI;VALENTINA MAFFINI;B. GHIDINI;A. MOLINARI;PAOLA FISICARO;SIMONA SCHIVAZAPPA;FABIOLA FORNAROLI;BARBARA BIZZARRI;B. MAGITERI;FABRIZIO UGO;NICOLA DE’ANGELIS","8;6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CARLO FERRARI;PIERANNA FIETTA;ANDREA CASATI;EDWARD G. BRIDGES;GIAN CAMILLO MANZONI;FABRIZIO UGO;GABRIELE MISSALE;P MANGANELLI;MARCO BACIARELLO;GREGORY C. FANELLI;BARBARA AMADEI;A. CASATI;Z. KOSCIELNIAK-NIELSEN;FRANCESCO SCIOSCIOLI;FILIPPO CADEMARTIRI;LAURA BONFANTI;LUIGI VIGNALI;GIANFRANCO CERVELLIN;FRANÇOIS SINGELYN;GIULIANA GOBBI","1.62;1.53;1.05;1;1;0.58;0.55;0.53;0.5;0.47;0.35;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.31","CARLO FERRARI;GABRIELE MISSALE;SIMONA SCHIVAZAPPA;BARBARA AMADEI;D. TOLA;SIMONA URBANI;MARCO MASSARI;AMAR P. DHILLON;ANA I. ROMERO;AVIDAN U. NEUMANN;ELKE VERHEIJ‐HART;FRANCESCO NEGRO;JEAN‐MICHEL PAWLOTSKY;JOHAN WESTIN;KRISTOFFER HELLSTRAND;MARTIN LAGGING;STEFAN ZEUZEM;BART L. HAAGMANS;SOLKO W. SCHALM;ALESSANDRO COLOMBO","1562;1503;799;789;754;754;556;506;506;506;506;506;506;506;506;506;506;426;426;415","CARLO FERRARI;GABRIELE MISSALE;SIMONA SCHIVAZAPPA;BARBARA AMADEI;D. TOLA;SIMONA URBANI;MAURO MELPIGNANO;A. MOLINARI;ALESSANDRO ZERBINI;AMALIA PENNA;CLAUDIA SCHIANCHI;GUIDO PELOSI;MASSIMO PILLI;PAOLA FISICARO;A. ORLANDINI;CRISTINA MORI;LUCA SACCHELLI;A. CASATI;MARCO VITALE;CRISTINA MICHELONI","1562;1503;799;789;754;754;415;306;243;243;243;243;243;233;198;198;198;179;155;145","CARLO FERRARI;GABRIELE MISSALE;BARBARA AMADEI;A. CASATI;A. MOLINARI;ANDREA CASATI;ANNA DEGLI ANTONI;D. TOLA;MARCO VITALE;P MANGANELLI;PAOLA FISICARO;SIMONA SCHIVAZAPPA;SIMONA URBANI;A. ORLANDINI;A.R. TÜRKYILMAZ;ALESSANDRO ZERBINI;AMALIA PENNA;ANDREA FANELLI;ANDREA SAVI;ANGELO ROLLI","8;6;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;SOCIOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE","40;16;5;4;3;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;ANESTHESIA;GENETICS;SURGERY;BIOCHEMISTRY;VIROLOGY;GASTROENTEROLOGY;PATHOLOGY;PSYCHIATRY;CARDIOLOGY;RADIOLOGY;CELL BIOLOGY;NEUROSCIENCE;OPTICS;PEDIATRICS;ANATOMY;COMMUNICATION;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GYNECOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;SOCIAL PSYCHOLOGY;SOCIAL SCIENCE","24;15;9;9;9;8;8;7;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","VIRUS;GENE;IMMUNE SYSTEM;IN VITRO;ANTIBODY;APOPTOSIS;CONFIDENCE INTERVAL;DISEASE;HEPATITIS C;INCIDENCE (GEOMETRY);PREGNANCY;RANDOMIZED CONTROLLED TRIAL;ANALGESIC;ARTERY;CANCER;CARCINOMA;CARDIAC SURGERY;CELL;HEART FAILURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INTERFERON;LOGISTIC REGRESSION;MIGRAINE;MULTIVARIATE ANALYSIS;MYOCARDIAL INFARCTION;NEUROLOGY;PERCUTANEOUS;POPULATION;PROSPECTIVE COHORT STUDY;RESPIRATORY SYSTEM;ROPIVACAINE;STIMULATION","10;7;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEPATITIS C VIRUS;VIRAL LOAD;CD8;CYTOTOXIC T CELL;GENOTYPE;T CELL;HEPATITIS B VIRUS;LEVOBUPIVACAINE;ADJUVANT THERAPY;ALPHA INTERFERON;ARTICULATION (SOCIOLOGY);AURA;AUTOIMMUNE DISEASE;AUTOIMMUNITY;AUTOPHAGY;BIG FIVE PERSONALITY TRAITS;BREAST CANCER;CANCER SCREENING;CARDIAC OUTPUT;CARDIOVERSION;CAROTID ENDARTERECTOMY;CD34;CEPHALALGIA;CHEST RADIOGRAPH;CHRONIC HEPATITIS;CHRONIC INFECTION;CHRONIC TOXICITY;CLINICAL ENDPOINT;COCAINE DEPENDENCE;COINFECTION;CORONARY ARTERY BYPASS SURGERY;CROSS REACTIONS;CYCLOPHOSPHAMIDE;DIGOXIN;ENDOMETRIAL CANCER;ERYTHROPOIESIS;EXOCRINE GLAND;GESTATION;HAEMATOPOIESIS;HAZARD RATIO;HEADACHE DISORDERS;HETEROLOGOUS;HYDROGEN SULFIDE;IMMUNITY;IMMUNOTHERAPY;INFERIOR ALVEOLAR NERVE;INTERNATIONAL CLASSIFICATION OF HEADACHE DISORDERS;LINGUAL NERVE;LYMPHOPROLIFERATIVE DISORDERS;MANDIBULAR CANAL;MANDIBULAR THIRD MOLAR;MORPHOGENESIS;MOTOR BLOCK;MULTICELLULAR ORGANISM;NEPHRECTOMY;NERVE STIMULATION;NEURORADIOLOGY;OFFSPRING;OPEN ANGLE GLAUCOMA;PARKINSON'S DISEASE;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE;PLASMID;PROGENITOR CELL;PROGRAMMED CELL DEATH;PROTEIN KINASE A;RANDOMIZATION;REFLUX;RELIABILITY (SEMICONDUCTOR);REMIFENTANIL;RENAL ARTERY;REPRODUCTIVE TOXICITY;RESPIRATORY TRACT;RNA;ROTAVIRUS;SINUS RHYTHM;SPINAL CORD INJURY;SYSTEMIC DISEASE;TIBIAL NERVE;TRANSCRANIAL MAGNETIC STIMULATION;TRANSFECTION;TROPONIN;TROPONIN I;UNIVARIATE ANALYSIS;VASCULITIS;VIRAL REPLICATION;VIREMIA","8;4;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPACIVIRUS;RIBAVIRIN;ANTIRETROVIRAL THERAPY;CARDIAC INDEX;CROSS-REACTIVITY;DISEASE MANAGEMENT;ELISPOT;HEPATITIS B VIRUS DNA POLYMERASE;IL-2 RECEPTOR;INTERFERON ALFA;LAMIVUDINE;MAMMOGRAPHY;MIGRAINE WITH AURA;NECROPTOSIS;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PATERNAL CARE;POLYARTERITIS NODOSA;REOVIRIDAE;RNA INTERFERENCE;ROTAVIRUS GASTROENTERITIS;ROTAVIRUS VACCINE;SMALL HAIRPIN RNA;SMALL INTERFERING RNA;STEM CELL FACTOR;SYSTEMIC VASCULITIS","4;4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;HEPACIVIRUS;MALE;HEPATITIS C, CHRONIC;MIDDLE AGED;ADULT;;RNA, VIRAL;HEPATITIS C;INTERFERON-ALPHA;RIBAVIRIN;AGED;ANTIVIRAL AGENTS;POLYETHYLENE GLYCOLS;ITALY;MYOCARDIAL INFARCTION;T-LYMPHOCYTES;VASCULITIS;CD8-POSITIVE T-LYMPHOCYTES","32;23;18;17;14;14;12;11;10;9;9;9;8;7;7;6;6;6;6;5","HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF APOPTOSIS AND CELL DEATH;NATURAL KILLER CELLS IN IMMUNITY;ANESTHESIA AND SEDATION MANAGEMENT;ATRIAL FIBRILLATION;BIOMEDICAL OPTICAL IMAGING AND SPECTROSCOPY;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;CONE-BEAM COMPUTED TOMOGRAPHY IN DENTISTRY;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EMBODIED COGNITION AND SOCIAL INTERACTION;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA","7;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PEGYLATED INTERFERON;HEPATITIS C;CARDIAC IMAGING;CARDIOVASCULAR EVALUATION;LEVOBUPIVACAINE;POSTOPERATIVE PAIN;ROPIVACAINE;TREATMENT;ADJUVANT THERAPY;ADOLESCENT DRUG USE;ALLOGRAFT VASCULOPATHY;ANTIBODY;ANTICOAGULANT THERAPY;ANTIRETROVIRAL THERAPY;APOPTOSIS;ARTICULATION (SOCIOLOGY);ATRIAL FIBRILLATION;BOLUS (DIGESTION);BRAIN OXYGENATION MONITORING;BREAST CANCER SCREENING","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PROSPECTIVE RANDOMIZED;ACUTE HEPATITIS;HCV INFECTION;RANDOMIZED DOUBLE-BLIND;VIRAL KINETICS;ACTIVE CELL;ACUTE ATRIAL;ACUTE MYOCARDIAL;ADJUVANT CHEMOTHERAPY;AFFECTS VERBAL;AGE DETERMINES;ALLOGRAFT PRELIMINARY;ALVEOLAR NERVE;ANOMALOUS LEFT;ANTERIOR DESCENDING;ANTI-REFLUX TECHNIQUE;ANTIVIRAL MEMORY;ANTIVIRAL TREATMENT;APOPTOSIS-INDUCING LIGAND;ARTERY EMBOLISATION;ATRIAL FIBRILLATION;AURA OBSERVATIONS;BRAIN MONITORING;BREAST CANCER;BYPASS SYSTEM;CANCER DUE;CARCINOMA LIVER;CARCINOMA RESULTS;CARDIAC COMPLICATIONS;CARDIAC TROPONIN","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HCV RNA;CHRONIC HEPATITIS;PUBMED SCOPUS;CROSSREF PUBMED;VIRAL LOAD;SD RANGE;VIROLOGIC RESPONSE;UL SD;DOSE REDUCTION;PEGYLATED IFN-Α-B;IP- LEVELS;PAIN RELIEF;BODY MASS;CARDIOPULMONARY BYPASS;CD RESPONSES;CORONARY ARTERY;HEPATOCELLULAR CARCINOMA;HISTOLOGIC METAVIR;MASS INDEX;PEGYLATED IFN;SD BASELINE;SUSTAINED VIROLOGIC;BASELINE CHARACTERISTICS;CD CELLS;COMBINATION THERAPY;INDEPENDENT PREDICTORS;LOGISTIC REGRESSION;RESPONSE SVR;ΜG ML;ACUTE AF","25;15;15;14;14;12;12;10;8;8;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4",10,0.23,9,8,1,4.75,0,3.5,5.5,0,1,9.5,0,0,6.25,0,3,1,1,4.75,0,0,0,106.75,106.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,9.43,1055.29,7.61,3,0.43,207,0,0,1,0,5,0,0,1,0,6,1,0,0,0,0,0,0,5,1,1,7,0,0,0,0,0,0,0,0,0,"United States;Italy","6;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","7;5;4;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LUNG;PATIENT SAFETY;RARE DISEASES;AGING;BREAST CANCER;DRUG ABUSE (NIDA ONLY);EMERGING INFECTIOUS DISEASES;GENETICS;LUNG CANCER;LYMPHOMA;PREVENTION;PROSTATE CANCER;SUBSTANCE MISUSE;UROLOGIC DISEASES","7;6;5;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION","5;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","5;2;1;1",1,2177810,7805.77,11,279,36,1,38,149512.542593271,0.294289691264873,"HOSPITAL BASE;ADDENBROOKE'S HOSPITAL;ALEXANDER FLEMING BIOMEDICAL SCIENCES RESEARCH CENTER;ALL INDIA INSTITUTE OF MEDICAL SCIENCES;ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY;ANHUI PROVINCIAL HOSPITAL;ANKARA ONKOLOJI EĞITIM VE ARAŞTIRMA HASTANESI;ANTONI VAN LEEUWENHOEK HOSPITAL;ARGERICH HOSPITAL;ASSOCIATION FOR CANCER SURGERY;ASTRAZENECA (UNITED KINGDOM);AUSTRIAN BREAST & COLORECTAL CANCER STUDY GROUP;AUTONOMOUS UNIVERSITY OF BARCELONA;BETH ISRAEL DEACONESS MEDICAL CENTER;BIRMINGHAM CHILDREN'S HOSPITAL;BOX HILL HOSPITAL;BRADFORD ROYAL INFIRMARY;CAIRO UNIVERSITY;CANCER CARE ONTARIO;CANCER INSTITUTE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","INTRAMURAL (PROJECT CATEGORY)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1;1","BREAST CANCER","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2007,44,9.59090909090909,3.77272727272727,0.568181818181818,0.386363636363636,0.818181818181818,1.40677966101695,1.08695652173913,1.21428571428571,1.24137931034483,0.386363636363636,2,24,11,5,4,0.55,0.25,0.11,0.09,216.05,4.09363141643641,NA,0.363636363636364,0.886363636363636,0.408,0.356,0.331,0.339,"FILIPPO CADEMARTIRI;ERICA MAFFEI;NICO R. MOLLET;ALESSANDRO PALUMBO;CARLO FERRARI;MASSIMO MIDIRI;GABRIËL P. KRESTIN;ALESSANDRO ZERBINI;ROBERTO MALAGÒ;DIEGO ARDISSINO;GIUSEPPE RUNZA;GABRIELE MISSALE;GREGORY C. FANELLI;GIULIANA GOBBI;N. BUSI;E. CAPOCASALE;MASSIMO PILLI;VALERIO BRAMBILLA;G. DANELLI;MARCO BERTI","8;8;8;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MARCO VITALE;PIERANNA FIETTA;FILIPPO CADEMARTIRI;ERICA MAFFEI;NICO R. MOLLET;ALESSANDRO PALUMBO;GIROLAMO CRISI;GIULIANA GOBBI;CARLO FERRARI;N. BUSI;E. CAPOCASALE;M.P. MAZZONI;PRISCO MIRANDOLA;GREGORY C. FANELLI;G. DANELLI;MASSIMO MIDIRI;GABRIËL P. KRESTIN;ALESSANDRO ZERBINI;GABRIELE MISSALE;MARCO BERTI","1.23;1;0.75;0.75;0.75;0.69;0.5;0.48;0.44;0.42;0.42;0.42;0.39;0.38;0.38;0.37;0.37;0.36;0.36;0.35","FILIPPO CADEMARTIRI;ERICA MAFFEI;NICO R. MOLLET;ALESSANDRO PALUMBO;CARLO FERRARI;ALESSANDRO ZERBINI;DIEGO ARDISSINO;GABRIELE MISSALE;GREGORY C. FANELLI;GIULIANA GOBBI;N. BUSI;E. CAPOCASALE;MASSIMO PILLI;G. DANELLI;MARCO BERTI;LUIGI VIGNALI;MARCO VITALE;ALBERTO MENOZZI;M.P. MAZZONI;DILETTA LACCABUE","8;8;8;7;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2","MARCO VITALE;PIERANNA FIETTA;FILIPPO CADEMARTIRI;ERICA MAFFEI;NICO R. MOLLET;ALESSANDRO PALUMBO;GIROLAMO CRISI;GIULIANA GOBBI;CARLO FERRARI;N. BUSI;E. CAPOCASALE;M.P. MAZZONI;PRISCO MIRANDOLA;GREGORY C. FANELLI;G. DANELLI;ALESSANDRO ZERBINI;GABRIELE MISSALE;MARCO BERTI;CESARE BEGHI;NICOLA GAIBAZZI","1.23;1;0.75;0.75;0.75;0.69;0.5;0.48;0.44;0.42;0.42;0.42;0.39;0.38;0.38;0.36;0.36;0.35;0.33;0.33","DIEGO ARDISSINO;C. MICHAEL GIBSON;CAROLYN H. MCCABE;ELLIOTT M. ANTMAN;EUGENE BRAUNWALD;F.-J. NEUMANN;GILLES MONTALESCOT;GOVINDA J. WEERAKKODY;JEFFREY RIESMEYER;SABINA A. MURPHY;SHMUEL GOTTLIEB;STEFANO DE SERVI;STEPHEN D. WIVIOTT;WITOLD RUŻYŁŁO;CARLO FERRARI;ALESSANDRO ZERBINI;GABRIELE MISSALE;A. CAVALLI;ANTONIO BERTOLETTI;BARBARA AMADEI","6542;6362;6362;6362;6362;6362;6362;6362;6362;6362;6362;6362;6362;6362;1218;1181;1181;842;842;842","DIEGO ARDISSINO;CARLO FERRARI;ALESSANDRO ZERBINI;GABRIELE MISSALE;A. CAVALLI;ANTONIO BERTOLETTI;BARBARA AMADEI;CAROLINA BONI;CATERINA VALDATTA;DILETTA LACCABUE;PAOLA DI VINCENZO;PAOLA FISICARO;T. GIUBERTI;G. DANELLI;GREGORY C. FANELLI;MARCO BERTI;ERICA MAFFEI;A. ORLANDINI;AMALIA PENNA;MASSIMO PILLI","6542;1218;1181;1181;842;842;842;842;842;842;842;842;842;422;422;377;369;339;339;339","ERICA MAFFEI;CARLO FERRARI;ALESSANDRO ZERBINI;GABRIELE MISSALE;DIEGO ARDISSINO;FILIPPO CADEMARTIRI;G. DANELLI;GREGORY C. FANELLI;MARCO BERTI;MASSIMO PILLI;N. BUSI;ALBERTO MENOZZI;LUIGI VIGNALI;A. CASATI;A. ORLANDINI;ALESSANDRO PALUMBO;AMALIA PENNA;ANNACHIARA ALDROVANDI;DANIELA GHISI;DILETTA LACCABUE","8;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;SOCIOLOGY;CHEMISTRY;HISTORY","36;13;4;2;2;2;2;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;NUCLEAR MEDICINE;ANESTHESIA;GENETICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;UROLOGY;BIOCHEMISTRY;CANCER RESEARCH;CELL BIOLOGY;GASTROENTEROLOGY;ONCOLOGY;VIROLOGY;BIOTECHNOLOGY;DEMOGRAPHY;GEOMETRY;NURSING","21;14;10;9;9;9;6;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2","IMMUNE SYSTEM;MYOCARDIAL INFARCTION;ANGIOGRAPHY;STENOSIS;CANCER;COMPUTED TOMOGRAPHY;DIAGNOSTIC ACCURACY;POPULATION;VIRUS;ALTERNATIVE MEDICINE;ANASTOMOSIS;CHEST PAIN;GENE;NEUROLOGY;ROPIVACAINE;STENT;TRANSPLANTATION;URETER;ANALGESIC;ARTERY;ASPIRIN;CIRRHOSIS;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;DISEASE;FIBROSIS;HEPATITIS C;HEPATOCELLULAR CARCINOMA;IN VITRO;IN VIVO;INCIDENCE (GEOMETRY);KIDNEY;KIDNEY DISEASE;LIDOCAINE;LIGATION;LOCAL ANESTHETIC;LUNG CANCER;MULTISLICE;NEGLECT;NEUROSURGERY;PATHOLOGICAL;RECEPTOR;RECTUM;THORACOTOMY;ULTRASOUND;URINARY SYSTEM","6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;COLORECTAL CANCER;HEPATITIS C VIRUS;MULTISLICE COMPUTED TOMOGRAPHY;T CELL;ACUTE CORONARY SYNDROME;BREAST CANCER;CANCER INCIDENCE;CANCER REGISTRY;CD8;CLOPIDOGREL;CYTOTOXIC T CELL;HEPATITIS B VIRUS;KIDNEY TRANSPLANTATION;NEPHRECTOMY;NEURORADIOLOGY;PLACEBO;PROSTATE CANCER;STOMACH CANCER;ACQUIRED IMMUNE SYSTEM;ADENOCARCINOMA;AMAUROSIS FUGAX;ASCENDING AORTA;AUTOCRINE SIGNALLING;AUTOFLUORESCENCE;BALLOON DILATION;CD34;CELLULAR DIFFERENTIATION;CHRONIC HEPATITIS;CHRONIC INFECTION;CORONARY ARTERIES;DIASTOLE;DIFFUSION MRI;ECHO-PLANAR IMAGING;EX VIVO;FEMORAL NERVE BLOCK;FLUOROURACIL;GENOTYPE;HAZARD RATIO;HEMIDESMOSOME;HETERODUPLEX;IDIOPATHIC PULMONARY FIBROSIS;IN VIVO MAGNETIC RESONANCE SPECTROSCOPY;INTROITUS;IODINATED CONTRAST;LAMININ;LEVOBUPIVACAINE;LUNG VOLUMES;MAMMARY ARTERY;METASTASIS;MUTATION;NATIONALITY;PARACRINE SIGNALLING;PATENT FORAMEN OVALE;PERCUTANEOUS CORONARY INTERVENTION;PERFUSION SCANNING;PERIPHERAL NEUROPATHY;PLATELET AGGREGATION;PLATELET AGGREGATION INHIBITOR;POSITIVE PREDICATIVE VALUE;PREDICTIVE MARKER;PROGRAMMED CELL DEATH;PROTEIN KINASE A;PROTOCOL (SCIENCE);RADIOFREQUENCY ABLATION;REFLUX;RESTENOSIS;SEROTONIN;SIGMOID COLON;SINUS (BOTANY);THERMAL ABLATION;VAGINOPLASTY;VASCULITIS;VIREMIA","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BILATERAL NEPHRECTOMY;CORONARY STENT;DIFFUSION IMAGING;FORAMEN OVALE (HEART);GRANULOMATOSIS WITH POLYANGIITIS;GRANZYME B;GROUND-GLASS OPACITY;HEPADNAVIRIDAE;HOMOVANILLIC ACID;HONEYCOMBING;IL-2 RECEPTOR;INTERLEUKIN 21;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);LYMPHOVASCULAR INVASION;MICROSCOPIC POLYANGIITIS;MONONEURITIS MULTIPLEX;MONONEUROPATHY;PARADOXICAL EMBOLISM;PERFORIN;PLATELET INHIBITION;PRASUGREL;RIBAVIRIN;THYMIDYLATE SYNTHASE;TIROFIBAN;USUAL INTERSTITIAL PNEUMONIA;VESICOURETERAL REFLUX;VESICOURETERIC REFLUX","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;CORONARY ANGIOGRAPHY;AGED;ADULT;TOMOGRAPHY, X-RAY COMPUTED;CD8-POSITIVE T-LYMPHOCYTES;HEPATITIS C, CHRONIC;TICLOPIDINE;HEPACIVIRUS;ITALY;;ACUTE CORONARY SYNDROME;ANESTHETICS, LOCAL;APOPTOSIS REGULATORY PROTEINS;CORONARY DISEASE;PAIN, POSTOPERATIVE;PLATELET AGGREGATION INHIBITORS","34;25;23;18;14;13;12;11;9;9;9;8;8;7;7;6;6;6;6;6","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;HEPATITIS C INFECTION AND TREATMENT;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;EFFECTS OF CHILDHOOD TRAUMA AND ADVERSITY;FACTORS AFFECTING MEAT QUALITY AND PRESERVATION;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;HEPATITIS B INFECTION AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT","5;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CARDIOVASCULAR RISK ASSESSMENT;TREATMENT;CORONARY STENTS;MULTISLICE COMPUTED TOMOGRAPHY;POSTOPERATIVE PAIN;RENAL TRANSPLANTATION;ROPIVACAINE;BILATERAL NEPHRECTOMY;BREAST CANCER SCREENING;CANCER INCIDENCE;CLOPIDOGREL;HEPATITIS C;KIDNEY TRANSPLANTATION;MULTI-ENERGY CT;MULTISLICE;NEURORADIOLOGY;STOMACH CANCER;THORACOTOMY","7;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;SLICE CT;COMPUTED TOMOGRAPHY;DIAGNOSTIC ACCURACY;ACUTE CORONARY;CANCER INCIDENCE;CHILDHOOD NEGLECT;CHRONIC HEPATITIS;CORONARY SYNDROMES;CT CORONARY;IMMUNE SYSTEM;KIDNEY TRANSPLANT;NATIVE URETER;OBSERVED CANCER;SLICE COMPUTED;TOMOGRAPHY CORONARY;TREATMENT OUTCOME;VALIDATION STUDY;VIRUS INFECTION;ACID HVA;ADAPTIVE IMMUNE;ADDICTED PATIENTS;ADDICTS RELATION;ALTERNATIVE BIOLOGIC;ANAESTHETIC VOLUME;ANALGESIC THERAPY;ANOMALIES METHODOLOGY;ANTIMICROBIAL EFFECT;ANTIRETROVIRAL TREATMENT;ARTERY STENT","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","FEMORAL NERVE;SHOULDER PAIN;IPSILATERAL SHOULDER;ML CI;CD CELLS;HCV-SPECIFIC CD;CI ML;INCIDENCE RATES;NERVE BLOCK;NERVE STIMULATION;CANCER REGISTRIES;HBV INFECTION;PERIPHERAL NEUROPATHY;PHRENIC NERVE;RANDOMLY ALLOCATED;AVI FILES;AVI MB;DOWNLOAD AVI;FILES VIDEO;HR CI;KNEE ARTHROSCOPY;MM NA;NERVE INFILTRATION;NONCORONARY SINUS;PATIENTS RECEIVING;RESPIRATORY FUNCTION;ROPIVACAINE ML;ROPIVACAINE REQUIRED;THORACIC EPIDURAL;UNASSISTED AMBULATION","10;10;8;8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",14,0.32,3,1,2,6,0,4,8,1,1,3.75,0,1,6.5,0,9,0,0,5,3,0,0,130.75,131,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,5,3,1.81,4,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO","1;1;1","AZIENDA OSPEDALIERO UNIVERSITA;MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","2;1;1","BIOTECHNOLOGY;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","A61K35/12;A61K35/23;A61P13/12;C12N5/071;C12N5/074","1;1;1;1;1","A61K35/12;A61P13/12;A61P19/08;A61P25/00;A61P43/00;C12N2500/25;C12N2501/11;C12N2501/12;C12N2501/39;C12N2501/395","1;1;1;1;1;1;1;1;1;1",16,5.69,976.93,13.91,4,0.25,94.69,0,0,3,0,9,0,2,2,0,13,2,0,0,0,0,0,0,14,2,0,14,1,0,0,1,0,0,0,0,0,"Italy;United States;Canada;Switzerland","8;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","16;12;5;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;KIDNEY DISEASE;LUNG;NEUROSCIENCES;PATIENT SAFETY;PREVENTION;BRAIN DISORDERS;DIGESTIVE DISEASES;HEART DISEASE;LUNG CANCER;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BREAST CANCER;COLO-RECTAL CANCER;DIABETES;HEART DISEASE - CORONARY HEART DISEASE;HYPERTENSION","14;12;5;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;METABOLIC AND ENDOCRINE","5;4;2;2;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","14;3;1","LUNG CANCER;COLON AND RECTAL CANCER;BREAST CANCER","3;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","5",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2008,52,9.80769230769231,3.17307692307692,0.461538461538462,0.307692307692308,0.538461538461538,1.62376237623762,1.41176470588235,1.33333333333333,1.33333333333333,0.288461538461538,1,30,7,8,4,0.58,0.13,0.15,0.08,44,0.801868050940308,NA,0.403846153846154,0.807692307692308,0.393,0.441,0.382,0.431,"FILIPPO CADEMARTIRI;ERICA MAFFEI;ALESSANDRO PALUMBO;CARLO FERRARI;DIEGO ARDISSINO;ANNACHIARA ALDROVANDI;ROBERTO MALAGÒ;ALESSANDRO ZERBINI;MASSIMO MIDIRI;GABRIELE MISSALE;NICO R. MOLLET;MASSIMO PILLI;VALERIO BRAMBILLA;PAOLA FISICARO;LUDOVICO LA GRUTTA;CAROLINA BONI;GIROLAMO CRISI;GABRIËL P. KRESTIN;DANIELA LINA;PATRIZIA BERTOLINI","11;9;7;7;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3","FILIPPO CADEMARTIRI;PIERANNA FIETTA;ERICA MAFFEI;DIEGO ARDISSINO;ANNACHIARA ALDROVANDI;ALESSANDRO PALUMBO;CARLO FERRARI;MARSILIO SACCAVINI;ANDREA NISTRI;C. GHETTI;ELENA SPIRITELLI;MARZIA CAPELLETTI;GUIDO RINDI;ANDREA ARDIZZONI;MARCELLO TISEO;ALESSANDRO ZERBINI;GABRIELE MISSALE;ROBERTO MALAGÒ;MARIA ALBERTA CATTABIANI;GABRIËL P. KRESTIN","1.13;1;0.86;0.73;0.66;0.65;0.61;0.5;0.5;0.45;0.4;0.4;0.4;0.4;0.4;0.39;0.39;0.35;0.34;0.33","FILIPPO CADEMARTIRI;ERICA MAFFEI;ALESSANDRO PALUMBO;CARLO FERRARI;DIEGO ARDISSINO;ANNACHIARA ALDROVANDI;ALESSANDRO ZERBINI;GABRIELE MISSALE;MASSIMO PILLI;PAOLA FISICARO;CAROLINA BONI;GIROLAMO CRISI;DANIELA LINA;PATRIZIA BERTOLINI;GREGORY C. FANELLI;ELENA SPIRITELLI;ANSELMO ALESSANDRO PALUMBO;MARZIA CAPELLETTI;MARIA ALBERTA CATTABIANI;GUIDO RINDI","11;9;7;7;6;6;4;4;3;3;3;3;3;3;2;2;2;2;2;2","FILIPPO CADEMARTIRI;PIERANNA FIETTA;ERICA MAFFEI;DIEGO ARDISSINO;ANNACHIARA ALDROVANDI;ALESSANDRO PALUMBO;CARLO FERRARI;MARSILIO SACCAVINI;C. GHETTI;ELENA SPIRITELLI;MARZIA CAPELLETTI;GUIDO RINDI;ANDREA ARDIZZONI;MARCELLO TISEO;ALESSANDRO ZERBINI;GABRIELE MISSALE;MARIA ALBERTA CATTABIANI;PATRIZIA BERTOLINI;NICOLA SVERZELLATI;MAURIZIO ZOMPATORI","1.13;1;0.86;0.73;0.66;0.65;0.61;0.5;0.45;0.4;0.4;0.4;0.4;0.4;0.39;0.39;0.34;0.33;0.29;0.29","CARLO FERRARI;GIOVANNI RAIMONDO;TERESA POLLICINO;JEAN‐MICHEL PAWLOTSKY;ALESSANDRO ZANETTI;ANTONINA SMEDILE;ANTONIO CRAXÌ;CHRISTIAN TRÉPO;DANIEL SHOUVAL;DANIELE PRATI;DIDIER SAMUEL;DING‐SHINN CHEN;ERICA VILLA;FABIEN ZOULIM;FRANCESCO DONATO;GIOVANNI BATTISTA GAETA;GIOVANNI SQUADRITO;HANS WILL;JEAN‐PIERRE ALLAIN;MARIE-ANNICK BUENDIA","1107;908;908;792;784;784;784;784;784;784;784;784;784;784;784;784;784;784;784;784","CARLO FERRARI;ERICA MAFFEI;FILIPPO CADEMARTIRI;ANNACHIARA ALDROVANDI;CAROLINA BONI;PAOLA FISICARO;ALESSANDRO ZERBINI;MICHELE FUSARO;GIROLAMO CRISI;A. ORLANDINI;AMALIA PENNA;GABRIELE MISSALE;MASSIMO PILLI;PAOLA DI VINCENZO;T. GIUBERTI;MAURIZIO ZOMPATORI;ALESSANDRO PALUMBO;C. GHETTI;MASSIMO FRANCHINI;CORRADO MAGNANI","1031;342;295;243;239;239;200;195;147;124;124;124;124;124;124;114;108;93;86;84","FILIPPO CADEMARTIRI;ERICA MAFFEI;CARLO FERRARI;ANNACHIARA ALDROVANDI;ALESSANDRO PALUMBO;ALESSANDRO ZERBINI;MAURIZIO ZOMPATORI;GABRIELE MISSALE;CAROLINA BONI;DANIELA LINA;DIEGO ARDISSINO;PAOLA FISICARO;PATRIZIA BERTOLINI;GIROLAMO CRISI;ALBERTO MENOZZI;ANDREA ARDIZZONI;C. GHETTI;ELENA SPIRITELLI;FABRIZIO UGO;GREGORY C. FANELLI","8;7;6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;PHILOSOPHY;SOCIOLOGY;GEOLOGY;MATHEMATICS","48;17;9;3;3;3;3;2;2;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;RADIOLOGY;IMMUNOLOGY;GENETICS;SURGERY;CANCER RESEARCH;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;OPTICS;VIROLOGY;ANESTHESIA;NEUROSCIENCE;PEDIATRICS;UROLOGY;ANIMAL SCIENCE;ASTROBIOLOGY;DEMOGRAPHY;ECOLOGY;GASTROENTEROLOGY;GYNECOLOGY;MACHINE LEARNING;MECHANICAL ENGINEERING;MICROBIOLOGY;OBSTETRICS;ONCOLOGY;PSYCHIATRY","35;15;13;13;10;9;9;6;5;5;5;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;CANCER;GENE;ARTERY;CORONARY ARTERY DISEASE;ALTERNATIVE MEDICINE;DISEASE;POPULATION;VIRUS;COMPUTED TOMOGRAPHY;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);ANGIOGRAPHY;COAGULATION;DIABETES MELLITUS;ANTIBIOTICS;ANTIGEN;BIOPSY;BODY MASS INDEX;CARCINOMA;CHEMOTHERAPY;CHEST PAIN;FIBRINOGEN;HEPATITIS B;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;LUMEN (ANATOMY);MULTISLICE;PLEURAL EFFUSION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;REFRACTORY (PLANETARY SCIENCE);SIGNIFICANT DIFFERENCE;STENOSIS;THORACOSCOPY;THROMBOSIS;URINARY SYSTEM;VENTILATION (ARCHITECTURE);WILMS' TUMOR","10;9;7;6;6;5;5;5;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;HEPATITIS B VIRUS;CORONARY ARTERIES;PLACEBO;ALLELE;ANTIBIOTIC PROPHYLAXIS;CIPROFLOXACIN;COMPUTED TOMOGRAPHY ANGIOGRAPHY;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIGENETICS;HEPATITIS C VIRUS;IMMUNODEFICIENCY;MULTISLICE COMPUTED TOMOGRAPHY;OCCULT;PARTIAL THROMBOPLASTIN TIME;SMALL-CELL CARCINOMA;ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE;ADENOCARCINOMA;ANGINA;ANTIOXIDANT CAPACITY;AORTIC SINUS;ARTIFICIAL INSEMINATION;BRACHYDACTYLY;BREAST CANCER;BRONCHODILATOR;CANCER REGISTRY;CARCINOGENESIS;CARDIAC OUTPUT;CAUSE OF DEATH;CD34;CELIAC ARTERY;CELL FUNCTION;CEREBRAL HYPOPERFUSION;CERVICAL CANCER;CERVIX;CHRONIC HEPATITIS;CLUSTERIN;COGNITIVE IMPAIRMENT;COHORT EFFECT;COMMON VARIABLE IMMUNODEFICIENCY;CORONARY ATHEROSCLEROSIS;CORONARY THROMBOSIS;CORPUS LUTEUM;DEMENTIA;DENDRITIC CELL;DYSOSTOSIS;EJECTION FRACTION;ENDOTRACHEAL INTUBATION;EPITOPE;ESOPHAGEAL CANCER;EUTHYROID;EXCESS MORTALITY;GENE EXPRESSION;GENOTYPE;GESTATION;HEART RATE;HEPATITIS A VIRUS;HETEROLOGOUS;HUMAN CHORIONIC GONADOTROPIN;HYPOGAMMAGLOBULINEMIA;HYPOXIA (ENVIRONMENTAL);HYPOXIA-INDUCIBLE FACTORS;IMATINIB;IMMUNITY;IMMUNOSENESCENCE;IMMUNOSTAINING;IMMUNOTHERAPY;IMPRINTING (PSYCHOLOGY);INSEMINATION;INSULIN RESISTANCE;LACTATION;LIVER CANCER;LOCUS (GENETICS);LUTEAL PHASE;MALLEOLUS;MEDIAL MALLEOLUS;MESENTERIC ISCHEMIA;METHYLATION;NEURORADIOLOGY;ORNITHINE DECARBOXYLASE;OVULATION;PERCUTANEOUS CORONARY INTERVENTION;PERFUSION SCANNING;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE;PLASMA GLUCOSE;POST PARTUM;PREGNANCY RATE;PRIMARY IMMUNODEFICIENCY;PROSTATE;PROSTATE CANCER;RADIOFREQUENCY ABLATION;RESTENOSIS;RNA;SPINAL CORD INJURY;SPIRAL COMPUTED TOMOGRAPHY;SYRINGOMYELIA;T CELL;THERMAL ABLATION;THROMBOELASTOGRAPHY;THROMBOELASTOMETRY;THROMBOPLASTIN;TUMOR MICROENVIRONMENT;TYPE 2 DIABETES;UNSTABLE ANGINA;UTERINE CANCER;VASCULAR RESISTANCE;VIRAL DISEASE;VIRAL INFECTION;VIRAL LOAD;VITAMIN E;WILMS TUMOUR","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GEFITINIB;NORFLOXACIN;RIGHT CORONARY ARTERY;ANTIGEN-PRESENTING CELL;CARDIAC INDEX;CD117;CHIARI MALFORMATION;COGNITIVE DECLINE;COPD EXACERBATION;CORONARY ARTERY ECTASIA;CORONARY STENT;CORPUS UTERI;CROSSOVER STUDY;DNA METHYLATION;EQUINE CHORIONIC GONADOTROPIN;ESOPHAGECTOMY;FASTING GLUCOSE;FRACTIONAL FLOW RESERVE;ICE CALVING;IMATINIB MESYLATE;IPRATROPIUM BROMIDE;MAMMOGRAPHY;MEAN ARTERIAL PRESSURE;POLYMORPHISM (COMPUTER SCIENCE);PROSTATECTOMY;RIBAVIRIN;SIDA;TROLOX","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;CORONARY ARTERY DISEASE;TOMOGRAPHY, X-RAY COMPUTED;;CORONARY ANGIOGRAPHY;HEPATITIS B VIRUS;ITALY;LIVER NEOPLASMS;AGED, 80 AND OVER;HEPATITIS B, CHRONIC;MYOCARDIAL INFARCTION;WILMS TUMOR;CARCINOMA, HEPATOCELLULAR;CARCINOMA, SMALL CELL;PLEURAL NEOPLASMS","40;29;28;22;21;17;17;15;11;9;9;9;8;7;7;7;7;6;6;6","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;HEPATITIS B INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;ASTHMA;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;BREAST CANCER SCREENING TECHNOLOGY;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EMBODIED COGNITION AND SOCIAL INTERACTION;ENDODONTIC RESEARCH AND PRACTICE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;ESOPHAGEAL INTERVENTION TECHNIQUES;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;GENETICS AND DEVELOPMENT OF CRANIOFACIAL ABNORMALITIES;GENOMIC IMPRINTING AND PARENTAL GENE EXPRESSION CONTROL;HEPATITIS C INFECTION AND TREATMENT","6;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORONARY ARTERIES;CONTINUOUS GLUCOSE MONITORING;CORONARY ARTERY DISEASE;HBV INFECTION;HEPATITIS B;LUMEN (ANATOMY);MULTISLICE;MULTISLICE COMPUTED TOMOGRAPHY;MYOCARDIAL INFARCTION;MYOCARDIAL PERFUSION;OCCULT;REFRACTORY (PLANETARY SCIENCE);SMALL-CELL LUNG CANCER;THORACOSCOPY;TREATMENT;URODYNAMIC PRACTICES;ACTION OBSERVATION","9;6;6;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","COMPUTED TOMOGRAPHY;CORONARY ANGIOGRAPHY;CORONARY ARTERY;MYOCARDIAL INFARCTION;ARTERY DISEASE;CT CORONARY;ACUTE MYOCARDIAL;ANTIBIOTIC PROPHYLAXIS;CELL CARCINOMA;HEPATOCELLULAR CARCINOMA;INVASIVE URODYNAMICS;MULTISLICE COMPUTED;OCCULT HEPATITIS;POSTMENOPAUSAL SUBJECTS;PROSPECTIVE STUDY;RADIOFREQUENCY THERMAL;REFRACTORY PLEURAL;SHORTENED APTT;THERMAL ABLATION;VIRUS INFECTION;WILMS TUMOUR;ACTIVITY CONFERRED;ACUTE EXACERBATION;AESTHETIC TREATMENT;AGEPERIODCOHORT ANALYSIS;AIRWAY DISTENSIBILITY;ANATOMICAL VARIANTS;ANGIOGRAPHY CORRELATIONS;ANGIOGRAPHY DIAGNOSTIC;ANKLE FRACTURE","5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CORONARY ARTERY;POST PARTUM;CORONARY ANGIOGRAPHY;HBV-SPECIFIC T-CELL;MYOCARDIAL INFARCTION;T-CELL RESPONSES;ACUTE MYOCARDIAL;CD T-CELL;CORONARY ARTERIES;EXCESS MORTALITY;LUTEAL ACTIVITY;MINOR CRITERIA;MORTALITY RATES;SIGNIFICANT CORONARY;CANCER REGISTRIES;DAY POST;GASTRIC TUBE;HBV DNA;HIV RNA;PORTAL HYPERTENSION;PREGNANCY RATE;SLICE CT;VIRUS-SPECIFIC T-CELL;ANTI-HBCNEGATIVE PATIENTS;ANTI-HBCPOSITIVE PATIENTS;ANTIRETROVIRAL TREATMENT;ARTERY STENOSIS;BLOOD SAMPLES;CD NORMAL;CERVICAL CANCER","6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2",9,0.17,6,2,0,0,0,0,1.5,0,1,3,0,0,1.5,0,0,1,1,1,0,0,0,70,70,2,0,0,2,0,0,0,0,0,0,0,0,1,0,1,1,3.5,4.27,2.5,0,1,2,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ROMAGNANI PAOLA;ROMAGNANI SERGIO;ANNUNZIATO FRANCESCO;MAGGI ENRICO;MAGGI NRICO","2;2;1;1;1","AZIENDA OSPEDALIERO UNIVERSITA;MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO","2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES","4;2;1","BIOTECHNOLOGY;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","A61K35/00;A61K35/12;A61K35/23;A61K35/28;A61P13/12;C12N5/00;C12N5/071;C12N5/074;G01N33/569","1;1;1;1;1;1;1;1;1","A61P13/12;A61P25/00;A61P43/00;A61K35/12;A61K35/28;A61P1/16;A61P1/18;A61P11/00;A61P11/02;A61P13/00","2;2;2;1;1;1;1;1;1;1",20,4.14,823.94,20.62,6,0.3,168,0,0,4,0,9,0,5,2,0,17,0,0,0,0,0,0,0,18,1,1,17,3,0,0,0,0,0,0,0,0,"Italy;United States","9;7","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","19;10;9;4;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;HEMATOLOGY;LUNG;NEUROSCIENCES;ORPHAN DRUG;PAIN RESEARCH;BREAST CANCER;CHRONIC PAIN;GENETICS;HEART DISEASE;LUNG CANCER;TRANSPLANTATION;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING","16;12;8;8;6;4;4;4;3;3;3;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;BLOOD;RESPIRATORY;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;RENAL AND UROGENITAL","9;3;2;2;1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.7 PHYSICAL;7.3 MANAGEMENT AND DECISION MAKING","13;2;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LIVER CANCER;MYELOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;STOMACH CANCER","2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","10;2;2;1;1;1",2,2161326,245858.05,5.5,9.5,4,1,152.5,109748.521354094,0.473810483808038,"OSPEDALE DI PARMA;EUROPEAN BIOINFORMATICS INSTITUTE;FRAUNHOFER SOCIETY;GLAXOSMITHKLINE (UNITED KINGDOM);ISTITUTI FISIOTERAPICI OSPITALIERI;LIGAND PHARMACEUTICALS (UNITED KINGDOM);LINK CONSULTING;PFIZER (UNITED STATES);PLANET;RESEARCH COMPLEX AT HARWELL;STMICROELECTRONICS (ITALY);TECHNICAL UNIVERSITY OF MADRID;UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF BRISTOL;UNIVERSITY OF CALIFORNIA, IRVINE;UNIVERSITY OF IOANNINA;UNIVERSITY OF OXFORD;UNIVERSITY OF URBINO","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENGINEERING AND PHYSICAL SCIENCES RESEARCH COUNCIL;EUROPEAN COMMISSION","1;1","COALITION S;EC & ERC - EUROPEAN UNION;UKRI - UK RESEARCH AND INNOVATION","2;1;1","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);FELLOWSHIP (PROJECT CATEGORY);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2007-2 (CALL FOR PROPOSAL)","1;1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;46 INFORMATION AND COMPUTING SCIENCES","2;1;1;1;1","BIOTECHNOLOGY;BIOENGINEERING;CANCER;GENETIC TESTING;GENETICS;HUMAN GENOME","2;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;MENTAL HEALTH;NEUROLOGICAL","1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1;1;1;1","NOT SITE-SPECIFIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1;1","A01 CLINICAL MEDICINE;B08 CHEMISTRY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2009,76,10.1447368421053,3.03947368421053,0.513157894736842,0.381578947368421,0.526315789473684,1.69852941176471,1.44444444444444,1.38095238095238,1.37931034482759,0.31578947368421,1,47,12,5,9,0.62,0.16,0.07,0.12,43.67,0.944091550110398,NA,0.421052631578947,0.81578947368421,0.481,0.543,0.535,0.534,"FILIPPO CADEMARTIRI;ERICA MAFFEI;ALESSANDRO PALUMBO;ANNICK C. WEUSTINK;CHIARA MARTINI;ENRICO MARIA SILINI;CARLO FERRARI;GABRIELE MISSALE;NICO R. MOLLET;ARSENIO SPINILLO;BARBARA DAL BELLO;BÁRBARA GARDELLA;DIEGO ARDISSINO;SARA SEITUN;GABRIËL P. KRESTIN;ALESSANDRO ZERBINI;GIOVANNI DELSANTE;PAOLA ALBERIZZI;STEFANO FERRETTI;VINCENZO DE LISI","20;12;11;11;11;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4","FILIPPO CADEMARTIRI;GIOVANNI DELSANTE;PIERANNA FIETTA;ERICA MAFFEI;ALESSANDRO PALUMBO;CHIARA MARTINI;ENRICO MARIA SILINI;GIROLAMO CRISI;ANNICK C. WEUSTINK;BARBARA DAL BELLO;ARSENIO SPINILLO;GABRIELE MISSALE;BÁRBARA GARDELLA;CARLO FERRARI;PAOLA ALBERIZZI;STEFANIA CESARI;NICO R. MOLLET;M SIANESI;E. CAPOCASALE;SERGIO CALLEGARI","2.86;1.83;1.83;1.09;1.05;1.02;0.97;0.93;0.92;0.88;0.84;0.77;0.77;0.68;0.6;0.6;0.59;0.53;0.53;0.5","FILIPPO CADEMARTIRI;ERICA MAFFEI;ALESSANDRO PALUMBO;ANNICK C. WEUSTINK;CHIARA MARTINI;ENRICO MARIA SILINI;CARLO FERRARI;GABRIELE MISSALE;NICO R. MOLLET;DIEGO ARDISSINO;SARA SEITUN;ALESSANDRO ZERBINI;VINCENZO DE LISI;ANNACHIARA ALDROVANDI;CATERINA VALDATTA;GIROLAMO CRISI;PIERANNA FIETTA;ELISABETTA BIASINI;A. MOLINARI;PAOLA FISICARO","20;12;11;11;11;7;7;7;7;5;5;4;4;4;4;4;4;3;3;3","FILIPPO CADEMARTIRI;PIERANNA FIETTA;ERICA MAFFEI;ALESSANDRO PALUMBO;CHIARA MARTINI;ENRICO MARIA SILINI;GIROLAMO CRISI;ANNICK C. WEUSTINK;GABRIELE MISSALE;CARLO FERRARI;NICO R. MOLLET;P. LA MONTANARA;GIANNI RASTELLI;C. GHETTI;GIULIANO VEZZANI;DIEGO ARDISSINO;SARA SEITUN;ALESSANDRO ZERBINI;CATERINA VALDATTA;RAFFAELE DALLA VALLE","2.86;1.83;1.09;1.05;1.02;0.97;0.93;0.92;0.77;0.68;0.59;0.5;0.5;0.5;0.5;0.41;0.38;0.38;0.38;0.37","CARLO FERRARI;GABRIELE MISSALE;CATERINA VALDATTA;PAOLA FISICARO;MARCO MASSARI;DIEGO ARDISSINO;ENRICO MARIA SILINI;PIERA ANGELICA MERLINI;ALISTAIR S. HALL;ANDREAS ZIEGLER;ANIKA GROßHENNIG;ANNETTE PETERS;ANTHONY J. BALMFORTH;ARNE SCHILLERT;ARNE SCHÄFER;ARNIKA KATHLEEN WAGNER;BEN WRIGHT;BENJAMIN F. VOIGHT;CHRISTA MEISINGER;CHRISTIAN HENGSTENBERG","847;723;722;722;721;704;681;526;491;491;491;491;491;491;491;491;491;491;491;491","CARLO FERRARI;GABRIELE MISSALE;CATERINA VALDATTA;PAOLA FISICARO;DIEGO ARDISSINO;ENRICO MARIA SILINI;ELISABETTA BIASINI;LUCA SACCHELLI;MARIA CRISTINA CAVALLO;ERICA MAFFEI;ALESSANDRO ZERBINI;A. ORLANDINI;CAROLINA BONI;CRISTINA MORI;LIDIA SACCHELLI;CHIARA MARTINI;TITO POLI;VINCENZO DE LISI;SARA SEITUN;ALESSANDRO PALUMBO","847;723;722;722;691;681;449;448;448;287;274;273;273;273;273;238;201;185;183;167","ERICA MAFFEI;CHIARA MARTINI;FILIPPO CADEMARTIRI;ALESSANDRO PALUMBO;ENRICO MARIA SILINI;GABRIELE MISSALE;CARLO FERRARI;SARA SEITUN;ALESSANDRO ZERBINI;ANNACHIARA ALDROVANDI;DIEGO ARDISSINO;PIERANNA FIETTA;CATERINA VALDATTA;PAOLA FISICARO;A. MOLINARI;ELISABETTA BIASINI;VINCENZO DE LISI;A. CUTTONE;ALBERTO MENOZZI;ANSELMO ALESSANDRO PALUMBO","12;9;9;8;7;7;7;5;4;4;4;4;4;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;PHYSICS;PSYCHOLOGY;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY","71;32;7;5;4;4;4;2;1;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;IMMUNOLOGY;VIROLOGY;ONCOLOGY;PSYCHIATRY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;NUCLEAR MEDICINE;BIOCHEMISTRY;GASTROENTEROLOGY;PALEONTOLOGY;BOTANY;MECHANICAL ENGINEERING;PEDIATRICS","53;27;18;16;14;12;11;11;9;9;8;8;7;7;6;6;6;4;4;4","CANCER;VIRUS;GENE;CORONARY ARTERY DISEASE;IMMUNE SYSTEM;MYOCARDIAL INFARCTION;POPULATION;ANGIOGRAPHY;CONFIDENCE INTERVAL;NEUROLOGY;CHEMOTHERAPY;COMPUTED TOMOGRAPHY;INTERVENTIONAL RADIOLOGY;RADIATION THERAPY;ARTERY;BIOPSY;CARCINOMA;HUMAN PAPILLOMAVIRUS;LYMPH NODE;STAGE (STRATIGRAPHY)","19;11;10;8;8;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4","BREAST CANCER;CERVICAL CANCER;NEURORADIOLOGY;GENOTYPE;CHRONIC HEPATITIS;ACQUIRED IMMUNE SYSTEM;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORONARY ANGIOGRAPHY;HEPATITIS B VIRUS;IMMUNOTHERAPY;INNATE IMMUNE SYSTEM;METASTASIS;NEPHRECTOMY;T CELL;CANCER REGISTRY;COLORECTAL CANCER;CORONARY ARTERIES;CORONARY ARTERY CALCIUM;CYTOTOXIC T CELL;HEART RATE;HEPATITIS C VIRUS;HOUNSFIELD SCALE;IMAGE QUALITY;NECK DISSECTION;POSITIVE PREDICATIVE VALUE;SINUS RHYTHM;SKIN CANCER;STEADY-STATE FREE PRECESSION IMAGING;VIRAL LOAD","7;6;6;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CERVICAL INTRAEPITHELIAL NEOPLASIA;SENTINEL LYMPH NODE;COLPOSCOPY;CORONARY CALCIUM SCORE;HPV INFECTION;MASTECTOMY;SENTINEL NODE;ANTIRETROVIRAL THERAPY;ANTIVIRAL THERAPY;ASCUS (BRYOZOA);BARE METAL;BRAIN METASTASIS;BREAST CARCINOMA;CANCER IMMUNOTHERAPY;CARBOXYHEMOGLOBIN;CD137;CONTROL OF CHROMOSOME DUPLICATION;DISTANT METASTASIS;EUKARYOTIC DNA REPLICATION;GASTRIC VARICES;GENE EXPRESSION PROFILING;HELICAL SCAN;HEPACIVIRUS;HEPATITIS B VIRUS DNA POLYMERASE;INNATE LYMPHOID CELL;INTERLEUKIN 21;INTRAEPITHELIAL NEOPLASIA;LAMIVUDINE;MAMMOGRAPHY;METAPLASTIC CARCINOMA;NEOADJUVANT THERAPY;OXALIPLATIN;PAPILLOMAVIRIDAE;PATTERN RECOGNITION RECEPTOR;PD-L1;PERMISSIVENESS;PLEURAL DISEASE;PRIMARY TUMOR;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;T HELPER CELL","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;MALE;ADULT;TOMOGRAPHY, X-RAY COMPUTED;AGED;CORONARY ANGIOGRAPHY;;ITALY;PAPILLOMAVIRUS INFECTIONS;CARCINOMA, SQUAMOUS CELL;CERVICAL INTRAEPITHELIAL NEOPLASIA;CORONARY ARTERY DISEASE;PAPILLOMAVIRIDAE;UTERINE CERVICAL NEOPLASMS;BREAST NEOPLASMS;CORONARY STENOSIS;SENSITIVITY AND SPECIFICITY;YOUNG ADULT","55;38;32;30;24;23;21;21;18;15;14;11;11;11;11;11;10;10;10;10","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;HEPATITIS B INFECTION AND TREATMENT;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;HEPATITIS C INFECTION AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HEME OXYGENASE AND CARBON MONOXIDE RESEARCH;MELANOMA;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;BREAST CANCER SCREENING TECHNOLOGY;CANCER IMMUNOTHERAPY;CHOLANGIOCARCINOMA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","12;5;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","CARDIAC IMAGING;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CARDIOVASCULAR RISK ASSESSMENT;CARDIOVASCULAR MRI;NEURORADIOLOGY;INTERVENTIONAL RADIOLOGY;HPV VACCINATION;TREATMENT;DUAL-ENERGY CT;NK CELL RECOGNITION;CARDIAC ELECTROPHYSIOLOGY;CORONARY ARTERIES;CORONARY CALCIUM;CORONARY CALCIUM SCORE;HEPATITIS C;HOUNSFIELD SCALE;HYPONATREMIA;LEFT VENTRICULAR FUNCTION;LIVING KIDNEY DONORS;MELANOMA","15;9;8;6;6;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;COMPUTED TOMOGRAPHY;CORONARY ARTERY;HUMAN PAPILLOMAVIRUS;TOMOGRAPHY CORONARY;CHRONIC HEPATITIS;ARTERY DISEASE;CT CORONARY;DONOR NEPHRECTOMY;AIRTUM STUDY;BREAST CANCER;CALCIUM SCORE;CANCER REGISTRIES;CELL CARCINOMA;CERVICAL INTRAEPITHELIAL;CHEST PAIN;CINE B-SSFP;CLINICAL OUTCOME;DIAGNOSTIC ACCURACY;HAART ERA;HBV INFECTION;HEPATOCELLULAR CARCINOMA;INTRAEPITHELIAL NEOPLASIA;ITALIAN NETWORK;JOINT PRACTICE;LAPAROSCOPIC TECHNIQUE;LEFT VENTRICULAR;LIVING DONOR;MULTIPLE HUMAN;NODE LOCALIZATION","8;6;5;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HBV INFECTION;CHRONIC HEPATITIS;HCV RNA;HR CI;HBV PERSISTENCE;INTRAHEPATIC LYMPHOCYTES;ONSET AF;CENTRAL DIABETES;CHRONIC HBV;CO-DOMINANT MODEL;DAY MORTALITY;DIABETES INSIPIDUS;GENETIC POLYMORPHISMS;HBV-SPECIFIC CD;HCC DEVELOPMENT;HEART RATE;MM PATIENTS;MSC CELLS;PATIENT POPULATION;RECESSIVE MODEL;ADJUSTED HR;ATRIAL FIBRILLATION;BIOPSY SPECIMENS;BRAIN METASTASES;CLINICAL OUTCOMES;CONE BIOPSY;CONFIDENCE INTERVAL;CORONARY ARTERIES;ECG TRIGGERING;GENE EXPRESSION","10;8;8;8;6;6;6;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3",11,0.14,3,2,0,0,0,0,8,0,1,2.5,0,0,1,0,1.75,0,0,1,0,0,0,76.5,77,2,0,0,2,0,0,0,0,0,0,0,0,1,0,1,1,2.5,2.16,2,1,1,2,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ANNUNZIATO FRANCESCO;MAGGI ENRICO;MIRABELLA CARLO;ROMAGNANI PAOLA;ROMAGNANI SERGIO","1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITA;MIRABELLA CARLO;REGIONE TOSCANA","2;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3206 MEDICAL BIOTECHNOLOGY","2;2;1;1",NA,NA,NA,NA,"A61K35/28;A61L27/20","1;1","A61P43/00;A61K35/28;A61L27/20;A61L27/22;A61L27/3633;A61L27/38;A61L27/3804;A61L27/3834;A61L27/56;A61L27/60","2;1;1;1;1;1;1;1;1;1",10,6.8,457.33,7.75,4,0.4,145.8,0,0,1,0,6,0,2,1,0,9,0,0,0,0,0,0,0,6,1,3,9,1,0,0,0,0,0,0,0,0,"United States;Italy;Japan","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4207 SPORTS SCIENCE AND EXERCISE;46 INFORMATION AND COMPUTING SCIENCES;4611 MACHINE LEARNING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","9;5;3;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;AGING;ORPHAN DRUG;PATIENT SAFETY;PROSTATE CANCER;UROLOGIC DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CARDIOVASCULAR;CEREBRAL PALSY;COMPLEMENTARY AND INTEGRATIVE HEALTH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEMATOLOGY;HIV/AIDS;INFECTIOUS DISEASES;LYMPHOMA;MENTAL HEALTH","8;7;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","5;1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS","7;3;2","NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2010,84,9.28571428571429,2.9047619047619,0.5,0.380952380952381,0.523809523809524,1.60927152317881,1.16666666666667,1.45454545454545,1.18918918918919,0.428571428571429,0,45,14,4,15,0.54,0.17,0.05,0.18,45.4,1.0047392225726,NA,0.416666666666667,0.75,0.427,0.493,0.475,0.47,"FILIPPO CADEMARTIRI;ERICA MAFFEI;GIUSEPPE LIPPI;CHIARA MARTINI;DIEGO ARDISSINO;ANNICK C. WEUSTINK;MASSIMO FRANCHINI;SARA SEITUN;GIANCARLO MESSALLI;ANNACHIARA ALDROVANDI;CARLO FERRARI;ALESSANDRO PALUMBO;ANSELMO ALESSANDRO PALUMBO;NICO R. MOLLET;ALESSANDRO ZERBINI;EMANUELE CROCETTI;PAOLO CARBOGNANI;GIUSEPPE TARANTINI;ELENA BERTI;ROBERTO GRILLI","15;12;10;10;9;7;6;6;5;5;5;4;4;4;3;3;3;3;3;3","GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;ERICA MAFFEI;GIOVANNI TARGHER;MASSIMO FRANCHINI;DIEGO ARDISSINO;MARIO PLEBANI;CHIARA MARTINI;GIULIO MARCHESINI;ANDREA FABBRI;FRANCO SERVADEI;ANNACHIARA ALDROVANDI;ANNICK C. WEUSTINK;EMMANUEL J. FAVALORO;PAOLO CARBOGNANI;GIOVANNI DELSANTE;L ARSENIO;S CARONNA;F. CIONI;ELISABETTA DALL’AGLIO","3.18;1.51;1.25;1.17;1.07;1.02;1;0.99;0.6;0.6;0.6;0.58;0.56;0.53;0.52;0.5;0.5;0.5;0.5;0.5","FILIPPO CADEMARTIRI;ERICA MAFFEI;GIUSEPPE LIPPI;CHIARA MARTINI;DIEGO ARDISSINO;MASSIMO FRANCHINI;SARA SEITUN;GIANCARLO MESSALLI;ANNACHIARA ALDROVANDI;CARLO FERRARI;ALESSANDRO PALUMBO;ANSELMO ALESSANDRO PALUMBO;ALESSANDRO ZERBINI;PAOLO CARBOGNANI;GIULIO MARCHESINI;VINCENZO DE LISI;ANDREA FABBRI;GABRIELE MISSALE;ANDREA IGOREN GUARICCI;FRANCO SERVADEI","15;12;10;10;9;6;6;5;5;5;4;4;3;3;3;3;3;3;3;3","GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;ERICA MAFFEI;MASSIMO FRANCHINI;DIEGO ARDISSINO;CHIARA MARTINI;GIULIO MARCHESINI;ANDREA FABBRI;FRANCO SERVADEI;ANNACHIARA ALDROVANDI;PAOLO CARBOGNANI;L ARSENIO;S CARONNA;F. CIONI;ELISABETTA DALL’AGLIO;PIERANNA FIETTA;ALESSANDRO PALUMBO;STEFANIA FERRETTI;ANTONIO FRATTINI;SARA SEITUN","3.18;1.51;1.25;1.07;1.02;0.99;0.6;0.6;0.6;0.58;0.52;0.5;0.5;0.5;0.5;0.5;0.49;0.48;0.48;0.47","DIEGO ARDISSINO;CARLO FERRARI;BASIL S. LEWIS;CHRISTOPHER P. CANNON;DANIEL WOJDYLA;FREDERIC KONTNY;HUGO A. KATUS;HÅKAN EMANUELSSON;LARS WALLENTIN;MATYÀS KELTAI;NARDEV S. KHURMI;PHILIPPE GABRÍEL STEG;RICHARD C. BECKER;ROBERT A. HARRINGTON;ROBERT F. STOREY;STEEN HUSTED;STEFAN JAMES;A. BENEDETTI;A. PICCIOTTO;AGOSTINO COLLI","995;826;646;646;646;646;646;646;646;646;646;646;646;646;646;646;646;386;386;386","DIEGO ARDISSINO;CARLO FERRARI;ALESSANDRO ZERBINI;GABRIELE MISSALE;ANGELO GIANNI CASALINI;DILETTA LACCABUE;GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;ERICA MAFFEI;A. MOLINARI;CHIARA MARTINI;VINCENZO DE LISI;BARBARA AMADEI;PAOLA FISICARO;SIMONA URBANI;SARA SEITUN;ELISA NEGRI;FRANCESCO FAGNONI;GUIDO PELOSI;MASSIMO PILLI","995;826;358;358;272;251;239;233;227;189;182;178;176;176;176;168;167;167;167;167","ERICA MAFFEI;FILIPPO CADEMARTIRI;CHIARA MARTINI;GIUSEPPE LIPPI;DIEGO ARDISSINO;CARLO FERRARI;ANNACHIARA ALDROVANDI;SARA SEITUN;ALESSANDRO PALUMBO;ALESSANDRO ZERBINI;ANSELMO ALESSANDRO PALUMBO;FRANCO SERVADEI;GABRIELE MISSALE;VINCENZO DE LISI;A. CUTTONE;A. MOLINARI;ALBERTA CALEFFI;ALESSANDRO MARIA BUDILLON;ANDREA ARDIZZONI;ANTONIO FRATTINI","11;10;9;9;7;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS;PHILOSOPHY;BUSINESS;GEOGRAPHY;GEOLOGY;POLITICAL SCIENCE","74;28;9;7;7;4;4;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;ENDOCRINOLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;VIROLOGY;BIOCHEMISTRY;PALEONTOLOGY;PSYCHIATRY;ANESTHESIA;CANCER RESEARCH;CELL BIOLOGY;NUCLEAR MEDICINE;ONCOLOGY;OPTICS;PEDIATRICS","55;18;17;15;15;13;12;11;10;7;7;6;6;6;5;5;5;5;5;5;5","POPULATION;MYOCARDIAL INFARCTION;GENE;CORONARY ARTERY DISEASE;CANCER;DISEASE;VIRUS;DIABETES MELLITUS;COHORT;CONFIDENCE INTERVAL;MAGNETIC RESONANCE IMAGING;PREGNANCY;ANGIOGRAPHY;ASYMPTOMATIC;CHOLESTEROL;HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);RECEPTOR;ALTERNATIVE MEDICINE;ANTIBODY;ARTERY;HEAD INJURY;IN VITRO;KIDNEY;LUNG CANCER;NEUROLOGY;ODDS RATIO;PLATELET;RANDOMIZED CONTROLLED TRIAL;RISK FACTOR;THROMBOSIS","13;12;11;9;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONARY ANGIOGRAPHY;GENOTYPE;HAZARD RATIO;CORONARY ARTERIES;LIPOPROTEIN;NEURORADIOLOGY;ALLELE;ARTIFICIAL INSEMINATION;CHRONIC HEPATITIS;CLINICAL ENDPOINT;CYTOTOXIC T CELL;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;GENE EXPRESSION;HEPATITIS C VIRUS;INSEMINATION;OVULATION;PROTEIN KINASE A;PROTEINURIA;RADIOFREQUENCY ABLATION;THERMAL ABLATION;UNSTABLE ANGINA;VENOUS THROMBOSIS","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;APPLANATION TONOMETRY;AUTOPHOSPHORYLATION;CORONARY ANGIOGRAM;CORONAVIRUS DISEASE 2019 (COVID-19);CXCL1;CYSTECTOMY;DIABETES MANAGEMENT;EGFR INHIBITORS;ENDOTHELIAL PROGENITOR CELL;ESTRUS SYNCHRONIZATION;FACTOR V LEIDEN;FLUORESCENCE IN SITU HYBRIDIZATION;GEFITINIB;GENE DELIVERY;GENE EXPRESSION PROFILING;GESTATIONAL DIABETES;GLUTAMINE SYNTHETASE;GLYCATED HEMOGLOBIN;HAEMOPHILIA B;HBSAG;INTERLEUKIN 12;INTERLEUKIN 21;LDL RECEPTOR;LIPOPROTEIN(A);MACE;MAMMOGRAPHY;MMP2;NATURAL KILLER CELL;NKG2D;P2Y12;PANCREAS TRANSPLANTATION;PAPILLARY THYROID CANCER;POLYMORPHISM (COMPUTER SCIENCE);PRENATAL DIAGNOSIS;REPORTER GENE;RIGHT CORONARY ARTERY;TAQMAN;TICAGRELOR;VIRAL VECTOR","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;TOMOGRAPHY, X-RAY COMPUTED;;CORONARY ANGIOGRAPHY;ITALY;MYOCARDIAL INFARCTION;CARCINOMA, HEPATOCELLULAR;CARDIOVASCULAR DISEASES;LIVER NEOPLASMS;AGED, 80 AND OVER;CORONARY ARTERY DISEASE;ADOLESCENT;YOUNG ADULT;ACUTE CORONARY SYNDROME;CHILD","64;44;42;30;30;25;18;17;17;16;14;13;13;13;12;11;10;9;8;8","ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CHOLESTEROL-LOWERING TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;ADVANCEMENTS IN LUNG CANCER RESEARCH;GENETIC ADAPTATION OF LACTASE PERSISTENCE IN HUMANS;LABORATORY MEDICINE AND TESTING PROCEDURES;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;NATURAL KILLER CELLS IN IMMUNITY;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;THROMBOSIS AND COAGULATION DISORDERS;;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;BREATH ANALYSIS TECHNOLOGY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES","8;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CARDIOVASCULAR RISK ASSESSMENT;TREATMENT;CANCER INCIDENCE;CARDIOVASCULAR MRI;CORONARY ARTERIES;NEURORADIOLOGY;CANCER RISK;CHOLESTEROL-LOWERING;CLINICAL ENDPOINT;CLINICAL PRACTICE;COMPUTED TOMOGRAPHY;CONTINUOUS GLUCOSE MONITORING;CORONARY CALCIUM;DIABETES;ECHOCARDIOGRAPHY;EGFR MUTATIONS;ETIOLOGY;HOMO SAPIENS","10;8;7;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;CORONARY ANGIOGRAPHY;CT CORONARY;COMPUTED TOMOGRAPHY;CORONARY ARTERY;HEAD INJURY;HEPATOCELLULAR CARCINOMA;ARTERY DISEASE;BLOOD DONORS;BOUTIQUE LABORATORIES;CANCER INCIDENCE;EPIDERMAL GROWTH;FACTOR RECEPTOR;FOCUSED FACTORIES;GROWTH FACTOR;HISTOLOGICAL ANALYSIS;HOMO SAPIENS;LUNG CANCER;MILD HEAD;RADIOFREQUENCY THERMAL;SLICE COMPUTED;THERMAL ABLATION;VALUABLE FOOD;ACQUIRED VON;ACTIVATED PARTIAL;ACUTE CORONARY;ACUTE INFECTION;ACUTE MYOCARDIAL;ACUTE NECROTIZING;ADIPOSE-DERIVED STROMAL","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;LDL CHOLESTEROL;MYOCARDIAL INFARCTION;CHOLESTEROL LEVELS;NK CELLS;RISK FACTORS;CORONARY ARTERY;OBSTRUCTIVE CAD;PREMATURE MI;TOTAL CHOLESTEROL;ACUTE PHASE;CHEST WALL;FACTOR RECEPTOR;GENET -CROSSREF;GROWTH FACTOR;ADIPOSE-DERIVED STROMAL;ARTERY DISEASE;EPIDERMAL GROWTH;HR CI;SINGLE NUCLEOTIDE;STROMAL CELLS;EARLY-ONSET MYOCARDIAL;ATVB COHORT;AUTOSOMAL DOMINANT;DM PATIENTS;HOBBS HH;MED -CROSSREF;NUCLEOTIDE POLYMORPHISMS;PATIENTS HR","37;25;14;14;13;13;12;10;10;9;9;8;8;8;8;8;7;7;7;7;7;7;6;5;5;5;5;5;5;5",22,0.26,6,3,0,2,0,4.75,5.5,0,2,3.75,0,1,2,0,1,0,1,2,1,0,0,83.75,83.75,2,0,0,1,1,0,0,0,0,0,0,0,2,0,0,1,2,1.65,2,1,1,2,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ENRICO MAGGI;MIRABELLA CARLO;PAOLA ROMAGNANI;SERGIO ROMAGNANI","1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITA;MIRABELLA CARLO;REGIONE TOSCANA","2;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","3;1;1;1","BIOTECHNOLOGY;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH","1;1;1;1",NA,NA,"A61K35/12;A61K35/23;A61L27/20;A61P13/12;C12N5/071;C12N5/074","1;1;1;1;1;1","A61P43/00;A61K35/12;A61L27/20;A61L27/22;A61L27/3633;A61L27/38;A61L27/3804;A61L27/3834;A61L27/56;A61L27/60","2;1;1;1;1;1;1;1;1;1",13,8.73,576,9.49,3,0.23,123.92,0,0,7,0,4,0,1,1,0,10,1,0,0,0,0,0,0,9,2,2,11,2,0,0,0,0,0,0,0,0,"United States;United Kingdom;Italy;Japan","11;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY","13;9;9;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;LUNG CANCER;PATIENT SAFETY;RARE DISEASES;BIOENGINEERING;AGING;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;BREAST CANCER;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;KIDNEY DISEASE;NANOTECHNOLOGY;ORPHAN DRUG","11;10;8;4;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","9;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.4 POPULATION SCREENING;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.2 CELLULAR AND GENE THERAPIES","11;2;2;1;1;1","LUNG CANCER;PROSTATE CANCER;BREAST CANCER;GENITAL SYSTEM, MALE;SARCOMA","4;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","7;2;1;1;1",1,2999500,176441.18,5,17,8,1,17,145036.756648212,0.579163530274901,"DÉLÉGATION PARIS 11;HANNOVER MEDICAL SCHOOL;IMPERIAL COLLEGE LONDON;INSERM TRANSFERT;INSTITUT PASTEUR DU MAROC;LMU KLINIKUM;MENOUFIA UNIVERSITY;MOSAIQUES DIAGNOSTICS AND THERAPEUTICS (GERMANY);NATIONAL RESEARCH CENTRE;OSPEDALE DI PARMA;UNIVERSITY HOSPITAL COLOGNE;UNIVERSITY HOSPITAL OF LAUSANNE;UNIVERSITY MEDICAL CENTER FREIBURG;UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF GENEVA;UNIVERSITY OF NAVARRA;VACSERA (EGYPT)","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP-SICA - SMALL/MEDIUM-SCALE FOCUSED RESEARCH PROJECT FOR SPECIFIC COOPERATION ACTIONS DEDICATED TO INTERNATIONAL COOPERATION PARTNER COUNTRIES(SICA) (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2010-SINGLE-STAGE (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE","1;1;1;1;1;1;1;1","INFECTION","1",NA,NA,"LIVER CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1","A01 CLINICAL MEDICINE","1",NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY","6;3;2;1","CLINICAL RESEARCH;INFECTIOUS DISEASES;INFLUENZA;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;LIVER DISEASE;PNEUMONIA & INFLUENZA;EMERGING INFECTIOUS DISEASES;HIV/AIDS","3;3;3;2;2;2;2;2;1;1","INFECTION","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","3;2","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","2;1",NA,NA,"3 GOOD HEALTH AND WELL BEING","1"
"AOU_PARMA",2011,80,8.5875,2.525,0.5375,0.25,0.5375,1.71186440677966,1.53571428571429,1.42857142857143,1.53571428571429,0.3125,2,40,14,13,9,0.5,0.17,0.16,0.11,25.94,0.60980215827338,NA,0.375,0.75,0.495,0.491,0.495,0.491,"GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;ERICA MAFFEI;CHIARA MARTINI;GIAN LUCA SALVAGNO;SARA SEITUN;ROSALIA ALOE;TERESA ARCADI;GIAN CESARE GUIDI;C. TEDESCHI;ANNICK C. WEUSTINK;ANNACHIARA ALDROVANDI;ANDREA IGOREN GUARICCI;GIANFRANCO CERVELLIN;MARTINA MONTAGNANA;ONOFRIO A. CATALANO;STEFANIA FERRETTI;ANDREA ARDIZZONI;DIEGO ARDISSINO;STEFAN ZEUZEM","21;14;9;9;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4","GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;MASSIMO FRANCHINI;GIAN LUCA SALVAGNO;ROSALIA ALOE;MARIO PLEBANI;ANGELICA BARONE;GIANFRANCO CERVELLIN;GIAN CESARE GUIDI;MARIELLA MERCADANTI;ERICA MAFFEI;CHIARA MARTINI;ANNACHIARA ALDROVANDI;PAOLA AVANZINI;SARA SEITUN;TITO POLI;ARAELSIS ROMERO;DIEGO ARDISSINO;C. TEDESCHI;ENRICO SESENNA","4.74;1.23;1.14;1.08;1.02;1;1;0.94;0.94;0.78;0.78;0.78;0.68;0.65;0.63;0.58;0.58;0.55;0.54;0.53","GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;ERICA MAFFEI;CHIARA MARTINI;SARA SEITUN;ROSALIA ALOE;ANNACHIARA ALDROVANDI;GIANFRANCO CERVELLIN;STEFANIA FERRETTI;ANDREA ARDIZZONI;DIEGO ARDISSINO;DAVIDE CAMPOBASSO;P. CORTELLINI;PAOLA AVANZINI;ENRICO SESENNA;TITO POLI;MARIELLA MERCADANTI;CARLO FERRARI;ANNALISA VOLPI;MATTEO MORETTI","21;14;9;9;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;2","GIUSEPPE LIPPI;FILIPPO CADEMARTIRI;MASSIMO FRANCHINI;ROSALIA ALOE;ANGELICA BARONE;GIANFRANCO CERVELLIN;MARIELLA MERCADANTI;ERICA MAFFEI;CHIARA MARTINI;ANNACHIARA ALDROVANDI;PAOLA AVANZINI;SARA SEITUN;TITO POLI;ARAELSIS ROMERO;DIEGO ARDISSINO;ENRICO SESENNA;MARCO BERTI;C. GHETTI;P. CORTELLINI;ANNALISA VOLPI","4.74;1.23;1.14;1.02;1;0.94;0.78;0.78;0.78;0.68;0.65;0.63;0.58;0.58;0.55;0.53;0.5;0.5;0.49;0.46","GIUSEPPE LIPPI;GIAN LUCA SALVAGNO;GIAN CESARE GUIDI;AVIDAN U. NEUMANN;BART L. HAAGMANS;CARLO FERRARI;FILIPPO CADEMARTIRI;FRANCESCO NEGRO;GABRIELE MISSALE;JEAN‐MICHEL PAWLOTSKY;KRISTOFFER HELLSTRAND;MARTIN LAGGING;PIERRE‐YVES BOCHUD;STEFAN ZEUZEM;STÉPHANIE BIBERT;ALFONSO MARCHIANÒ;CARLO LA VECCHIA;NICOLA SVERZELLATI;UGO PASTORINO;ANDREA ARDIZZONI","626;298;288;249;249;249;249;249;249;249;249;249;249;249;249;235;235;235;235;233","GIUSEPPE LIPPI;CARLO FERRARI;NICOLA SVERZELLATI;CHIARA MARTINI;ERICA MAFFEI;GABRIELE MISSALE;COSTANZA ANNAMARIA LAGRASTA;ENRICO MARIA SILINI;PELLEGRINO CRAFA;ROSALIA ALOE;S. CAPELLI;FILIPPO CADEMARTIRI;C. GHETTI;PAOLA AVANZINI;DIEGO ARDISSINO;ANDREA ARDIZZONI;GIULIO SERRELI;O. ORTENZIA;MARIA FRANCESCA NOTARANGELO;DANIELA LINA","625;249;157;152;152;149;143;143;143;143;143;122;120;115;92;90;83;83;77;76","GIUSEPPE LIPPI;CHIARA MARTINI;ERICA MAFFEI;ROSALIA ALOE;ANNACHIARA ALDROVANDI;DAVIDE CAMPOBASSO;GIANFRANCO CERVELLIN;P. CORTELLINI;PAOLA AVANZINI;STEFANIA FERRETTI;ANDREA ARDIZZONI;CARLO FERRARI;TITO POLI;ANNALISA VOLPI;ENRICO SESENNA;MARIELLA MERCADANTI;A. MOLINARI;ANNA DEGLI ANTONI;ANTONELLA VEZZANI;C. GHETTI","20;8;8;6;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;PHYSICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;HISTORY;PHILOSOPHY;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","77;23;10;6;6;4;4;4;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CHROMATOGRAPHY;ONCOLOGY;PSYCHIATRY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;VIROLOGY;ANESTHESIA;PEDIATRICS;ANDROLOGY;BOTANY;DEMOGRAPHY;NUCLEAR MEDICINE;PHYSICAL THERAPY;STATISTICS","60;18;16;15;13;13;12;9;8;8;8;8;7;6;6;5;5;4;4;4;4;4;4","MYOCARDIAL INFARCTION;GENE;CORONARY ARTERY DISEASE;POPULATION;VIRUS;ALTERNATIVE MEDICINE;ANGIOGRAPHY;DISEASE;HEMOLYSIS;CANCER;CLINICAL TRIAL;EMERGENCY DEPARTMENT;ENZYME;HEMOGLOBIN;LUNG CANCER;ODDS RATIO;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;HEMATOCRIT;HEPATITIS C;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INTERIM;RETROSPECTIVE COHORT STUDY","12;9;8;8;7;6;6;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","CORONARY ANGIOGRAPHY;GENOTYPE;LACTATE DEHYDROGENASE;ACUTE CORONARY SYNDROME;CHRONIC HEPATITIS;HEPATITIS C VIRUS;INTERIM ANALYSIS;ADENOCARCINOMA;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORONARY ARTERIES;GEMCITABINE;GENE EXPRESSION;HEPATITIS B VIRUS;MEAN CORPUSCULAR VOLUME;METASTASIS;OSTEOARTHRITIS;TROPONIN I;UNSTABLE ANGINA;VIRAL LOAD;AEROBIOLOGY;ALCOHOL CONSUMPTION;ALKALINE PHOSPHATASE;ALLELE;AMBROSIA;AMOXICILLIN;ANTIBIOTIC PROPHYLAXIS;ARTERIAL EMBOLIZATION;ATRIAL MYXOMA;AUTOANTIBODY;BIRTH CERTIFICATE;BLADDER CANCER;BLOOD CANCER;BLOOD COAGULATION FACTORS;BREAST CANCER;BRONCHOSPASM;CAPILLARY HEMANGIOMA;CARDIAC MAGNETIC RESONANCE IMAGING;CEREBELLOPONTINE ANGLE;CISPLATIN;CLINICAL ENDPOINT;CLOPIDOGREL;COAGULATION DISORDER;COLORECTAL CANCER;COLORECTAL SURGERY;CONTRAINDICATION;CORONARY ARTERY CALCIUM;CYTIDINE DEAMINASE;DEMENTIA;DESENSITIZATION (MEDICINE);DOMPERIDONE;DORMANCY;EJECTION FRACTION;ENZYME REPLACEMENT THERAPY;EPIDERMAL GROWTH FACTOR RECEPTOR;EPISODIC MEMORY;FABRY DISEASE;FETUS;GAMMA-GLUTAMYLTRANSFERASE;GENOME;GESTATION;GESTATIONAL AGE;GLYCAN;GLYCOLYSIS;HAZARD RATIO;HEAD AND NECK CANCER;HEMOGLOBIN A2;IMMUNOADSORPTION;IN SITU HYBRIDISATION;INFARCTION;INJURY PREVENTION;INTERSTITIAL LUNG DISEASE;INTERVENTRICULAR SEPTUM;JAW JERK REFLEX;KIDNEY TRANSPLANTATION;LACTOBACILLUS;LEFT VENTRICULAR HYPERTROPHY;LINGUAL GYRUS;LUNG CANCER SCREENING;MEAN PLATELET VOLUME;MULTICENTER STUDY;MULTISLICE COMPUTED TOMOGRAPHY;NEPHRECTOMY;NEURORADIOLOGY;NEUTROPENIA;NORTHERN ITALY;OCCULT;ONDANSETRON;OPIOID;PARKINSON'S DISEASE;PATIENT SAFETY;PERCUTANEOUS CORONARY INTERVENTION;PLASMAPHERESIS;PNEUMOPERITONEUM;POSTERIOR CINGULATE;PRECUNEUS;PSEUDOANEURYSM;RAGWEED;RENAL ARTERY;RENAL COLIC;RESTLESS LEGS SYNDROME;REVASCULARIZATION;RITUXIMAB;SEMANTIC MEMORY;STABLE ANGINA;SUICIDE PREVENTION;SUPRAVENTRICULAR TACHYCARDIA;TENOFOVIR;TRADITIONAL CHINESE MEDICINE;TRAUMA CENTER;TROPONIN;ULCERATIVE COLITIS;UNIVARIATE;VIRAL DISEASE;VISUAL MEMORY;WORKING MEMORY","7;7;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RIBAVIRIN;HEPACIVIRUS;MEAN CORPUSCULAR HEMOGLOBIN;MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION;PRIMARY TUMOR;SINGLE-NUCLEOTIDE POLYMORPHISM;AGATSTON SCORE;BIFIDOBACTERIUM;BLOOD STASIS;BUPRENORPHINE;CARBOHYDRATE DEFICIENT TRANSFERRIN;CARBOPLATIN;CUNEUS;CYSTECTOMY;DEOXYCYTIDINE;ERLOTINIB;FEBRILE NEUTROPENIA;FETAL HEMOGLOBIN;GENE EXPRESSION PROFILING;HBSAG;HEXOKINASE;IDIOPATHIC INTERSTITIAL PNEUMONIA;KNEE ARTHRITIS;LAMIVUDINE;OPIOID USE DISORDER;POSTERIOR CORTICAL ATROPHY;POUCHITIS;PRASUGREL;PROCTOCOLECTOMY;SEED DORMANCY;SPATIAL MEMORY;SUICIDE ATTEMPT;THIENOPYRIDINE;TICAGRELOR;TRANSCRIPTOME;TRASTUZUMAB;USUAL INTERSTITIAL PNEUMONIA;ZIDOVUDINE","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;ITALY;AGED;BLOOD SPECIMEN COLLECTION;CORONARY STENOSIS;TOMOGRAPHY, X-RAY COMPUTED;;CORONARY ANGIOGRAPHY;CORONARY ARTERY DISEASE;LUNG NEOPLASMS;HIV INFECTIONS;SENSITIVITY AND SPECIFICITY;THROMBOSIS;HEMATOLOGIC TESTS;KIDNEY;PREDICTIVE VALUE OF TESTS","65;39;35;29;26;18;17;17;17;15;14;14;13;12;10;10;10;8;8;8","LABORATORY MEDICINE AND TESTING PROCEDURES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;HEPATITIS C INFECTION AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CANCER OF UNKNOWN PRIMARY SITE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF FACIAL PARALYSIS;DIAGNOSIS AND MANAGEMENT OF FETAL AND NEONATAL TUMORS;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME","11;10;5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;COMPUTED TOMOGRAPHY ANGIOGRAPHY;HEMATOLOGY ANALYZERS;HEMOLYSIS INTERFERENCE;TREATMENT;CARDIOVASCULAR MRI;CORONARY CALCIUM;DIAGNOSTIC ERRORS;HEPATITIS C;INTERIM;INTERIM ANALYSIS;BLOOD PRESERVATION;BLOOD TRANSFUSION;COMPUTED TOMOGRAPHY;CONFUSION;CORONARY ARTERIES;HEMOCYTOMETER;IDENTIFICATION (BIOLOGY);MEAN CORPUSCULAR HEMOGLOBIN","10;9;8;8;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2","CORONARY ANGIOGRAPHY;COMPUTED TOMOGRAPHY;TOMOGRAPHY CORONARY;DIAGNOSTIC ACCURACY;LUNG CANCER;CHRONIC HEPATITIS;REGISTRY DATA;REVASCULARISATION REGISTRY;SLICE COMPUTED;CALCIUM SCORE;CANCER SCREENING;CLINICAL PRACTICE;CORONARY ARTERY;INTERIM RESULTS;MYOCARDIAL INFARCTION;PATIENTS AFFECTED;PREGNANCY OUTCOMES;ABO-INCOMPATIBLE LIVING;ACQUIRED HEMOPHILIA;ACUTE CORONARY;ACUTE GASTROENTERITIS;ADENOSINE-INDUCED SEVERE;ADMINISTRATIVE CODING;ADOLESCENT RUNNERS;ADVANCED HIV;ADVANCED NON-SMALL-CELL;ADVANCED NSCLC;ALFA-A PEG-IFNΑ-A;ALL-OUT -KM;ALLERGIC CLINICAL","8;7;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","VASCULAR MALFORMATIONS;MYOCARDIAL INFARCTION;PUBMED SCOPUS;POTENTIALLY SIGNIFICANT;PAPILLARY MUSCLE;APPROXIMIATELY MMOLL;CONCENTRATION APPROXIMIATELY;CORONARY ATHEROSCLEROSIS;GLUCOSE CONCENTRATION;GLUCOSE LEVELS;HCV RNA;HEMOLYSIS INDEX;MONTHS IPI;MUSCLE INFARCTION;PLASMA GLUCOSE;PREGNANT WOMEN;THORAC SURG;VERSUS MONTHS;BASELINE IP-;CARDIOVASCULAR EVENTS;CAVERNOUS HEMANGIOMA;CDC-C WOMEN;CELL-FREE HEMOGLOBIN;CLINICAL PRACTICE;CROSSREF PUBMED;EARLY-ONSET MYOCARDIAL;ELECTRONIC DIARY;ENDOTHELIAL MALFORMATIONS;ENZYMATIC ACTIVITY;FASTING PLASMA","8;7;7;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",13,0.16,3,2,0,1,0,0,1,1,1,2,0,0,2,0,0,1,1,3,2,0,0,54,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,7.11,965.95,18.58,10,0.48,190.76,0,0,5,0,11,0,1,4,0,16,3,0,0,0,0,0,0,18,2,1,19,2,0,0,0,0,0,0,0,0,"United States;Italy","11;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","20;12;9;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;BREAST CANCER;AGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;LUNG;LUNG CANCER;PREVENTION;ATHEROSCLEROSIS;CARDIOVASCULAR;ESTROGEN;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEPATITIS;INFECTIOUS DISEASES","19;13;12;9;7;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;INFECTION;CARDIOVASCULAR;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM","10;3;2;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","15;4;2;1;1;1;1;1;1","LIVER CANCER;BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;ESOPHAGEAL / OESOPHAGEAL CANCER;NEUROBLASTOMA;PROSTATE CANCER","4;3;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","9;4;2;2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PARMA",2012,103,9.66990291262136,2.59223300970874,0.495145631067961,0.271844660194175,0.563106796116505,1.74509803921569,1.75862068965517,1.4,1.65714285714286,0.398058252427184,2,56,15,12,14,0.54,0.15,0.12,0.14,44.79,1.07225743982734,7.35449735449734,0.330097087378641,0.796116504854369,0.526,0.599,0.559,0.566,"GIUSEPPE LIPPI;ROSALIA ALOE;MARTINA MONTAGNANA;GIAN CESARE GUIDI;GIANFRANCO CERVELLIN;GIAN LUCA SALVAGNO;GABRIELE MISSALE;CARLO FERRARI;TIZIANA MESCHI;CAMILLO PORTA;ANDREA ARDIZZONI;DIEGO ARDISSINO;BRUNO DANIELE;PAOLA AVANZINI;ARMANDO SANTORO;IVAN BORBATH;JEAN‐LUC VAN LAETHEM;ANTONIO GASBARRINI;STEFANIA SALVAGNI;HANS VAN VLIERBERGHE","37;11;9;9;9;8;8;7;6;5;5;5;5;5;5;4;4;4;4;4","GIUSEPPE LIPPI;ROSALIA ALOE;GIANFRANCO CERVELLIN;MARTINA MONTAGNANA;GIAN CESARE GUIDI;GIAN LUCA SALVAGNO;TIZIANA MESCHI;S. DAVID;PAOLA AVANZINI;LORIS BORGHI;GABRIELE MISSALE;SILVIA PIPITONE;DIEGO ARDISSINO;CARLO FERRARI;ALFREDO CHETTA;IVAN COMELLI;DARIO OLIVIERI;GERALDO PICHETH;EMMANUEL J. FAVALORO;GABRIEL LIMA-OLIVEIRA","7.85;2.01;1.69;1.67;1.42;1.31;1.14;1;0.99;0.75;0.71;0.62;0.61;0.6;0.58;0.51;0.5;0.5;0.5;0.5","GIUSEPPE LIPPI;ROSALIA ALOE;GIANFRANCO CERVELLIN;GABRIELE MISSALE;CARLO FERRARI;TIZIANA MESCHI;ANDREA ARDIZZONI;DIEGO ARDISSINO;PAOLA AVANZINI;STEFANIA SALVAGNI;T. GIUBERTI;ALBERTO MENOZZI;ANNA DEGLI ANTONI;ENRICO MARIA SILINI;DILETTA LACCABUE;MARCELLO TISEO;SILVIA PIPITONE;IVAN COMELLI;LORIS BORGHI;LUCIO MANENTI","37;11;9;8;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;2","GIUSEPPE LIPPI;ROSALIA ALOE;GIANFRANCO CERVELLIN;TIZIANA MESCHI;S. DAVID;PAOLA AVANZINI;LORIS BORGHI;GABRIELE MISSALE;SILVIA PIPITONE;DIEGO ARDISSINO;CARLO FERRARI;ALFREDO CHETTA;IVAN COMELLI;DARIO OLIVIERI;LUIGI IPPOLITO;M. COSMAI;RAMLI MUSA;ANDREA ARDIZZONI;C. CATTABIANI;ENRICO MARIA SILINI","7.85;2.01;1.69;1.14;1;0.99;0.75;0.71;0.62;0.61;0.6;0.58;0.51;0.5;0.42;0.4;0.39;0.38;0.37;0.33","DIEGO ARDISSINO;GIUSEPPE LIPPI;ALEXANDER PARKHOMENKO;ALİ OTO;ANTHONY J. DALBY;ASSEN GOUDEV;BÉLA MERKELY;CHRISTIAN W. HAMM;CHUEN‐DEN TSENG;DARREN K. MCGUIRE;DEEPAK L. BHATT;DORAIRAJ PRABHAKARAN;E. MAGNUS OHMAN;EILEEN B. BROWN;FELIPE A. MARTÍNEZ;GRACITA O. TOPACIO;GREGORY PAVLIDES;HARVEY D. WHITE;JAN H. CORNEL;JOSÉ CARLOS NICOLAU","857;839;822;822;822;822;822;822;822;822;822;822;822;822;822;822;822;822;822;822","DIEGO ARDISSINO;GIUSEPPE LIPPI;CARLO FERRARI;GABRIELE MISSALE;T. GIUBERTI;STEFANIA SALVAGNI;DILETTA LACCABUE;ARIANNA ALFIERI;SIMONA SCHIVAZAPPA;CAROLINA BONI;MARCO PESCI;ALBERTO MENOZZI;ROSALIA ALOE;NICOLA SVERZELLATI;ANNACHIARA ALDROVANDI;FLORIAN VON KNOBELSDORFF‐BRENKENHOFF;GERHARD SCHÜLER;HÖLGER THIELE;IACOPO CARBONE;INGO EITEL","857;839;697;677;636;580;476;408;408;402;334;331;229;200;172;172;172;172;172;172","GIUSEPPE LIPPI;ROSALIA ALOE;GABRIELE MISSALE;GIANFRANCO CERVELLIN;CARLO FERRARI;PAOLA AVANZINI;ALBERTO MENOZZI;ANDREA ARDIZZONI;ANNA DEGLI ANTONI;DIEGO ARDISSINO;T. GIUBERTI;STEFANIA SALVAGNI;DILETTA LACCABUE;LORIS BORGHI;TIZIANA MESCHI;A. CAVALLI;ANDREA GRASSI;ARIANNA ALFIERI;C. CATTABIANI;CAROLINA BONI","37;10;8;8;6;5;4;4;4;4;4;4;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;PSYCHOLOGY;HISTORY;PHILOSOPHY;POLITICAL SCIENCE","96;26;23;11;3;3;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;CARDIOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;GENETICS;ONCOLOGY;CHROMATOGRAPHY;ENDOCRINOLOGY;GASTROENTEROLOGY;PATHOLOGY;VIROLOGY;ANESTHESIA;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;OPTICS;RADIOLOGY;CANCER RESEARCH;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;PEDIATRICS;PHYSICAL THERAPY","74;27;25;20;18;14;13;13;13;11;11;11;10;7;6;6;6;6;6;5;5;5;5;5","GENE;MYOCARDIAL INFARCTION;POPULATION;CANCER;ANTIBODY;RANDOMIZED CONTROLLED TRIAL;VIRUS;EMERGENCY DEPARTMENT;HEPATOCELLULAR CARCINOMA;COHORT;DISEASE;HEMOLYSIS;CONFIDENCE INTERVAL;IMMUNE SYSTEM;ALTERNATIVE MEDICINE;ANTIGEN;CHEMOTHERAPY;HEART FAILURE;IN VIVO;INCIDENCE (GEOMETRY);STENT","15;13;13;10;9;9;9;7;7;6;6;6;5;5;4;4;4;4;4;4;4","HEPATITIS B VIRUS;CLINICAL ENDPOINT;PERCUTANEOUS CORONARY INTERVENTION;SORAFENIB;CONVENTIONAL PCI;EPIDERMAL GROWTH FACTOR RECEPTOR;HAZARD RATIO;IMMUNOASSAY;MUTATION;TROPONIN;ADENOCARCINOMA;CD8;CHRONIC HEPATITIS;COLORECTAL CANCER;EPITOPE;GENOTYPE;HEPATITIS C VIRUS;MESSENGER RNA;VIRAL LOAD;ACUTE CORONARY SYNDROME;ALLELE;BORTEZOMIB;CYTOTOXIC T CELL;EJECTION FRACTION;EX VIVO;EXON;FETUS;GENETIC PREDISPOSITION;MARAVIROC;METABOLIC SYNDROME;NEURORADIOLOGY;NEUTROPENIA;PLACEBO;POLYSOMNOGRAPHY;RESTENOSIS;REVASCULARIZATION;T CELL;TOLERABILITY;TROPONIN I;VITAMIN D DEFICIENCY","6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;DRUG-ELUTING STENT;GEFITINIB;HBSAG;KRAS;MACE;RETICULOCYTE;SANGER SEQUENCING;TARGET LESION;ACRYLAMIDE;ADIPOKINE;ALTERNATIVE COMPLEMENT PATHWAY;ANTI-NUCLEAR ANTIBODY;ARGINASE;ATYPICAL HEMOLYTIC UREMIC SYNDROME;AUTOPHOSPHORYLATION;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CD137;CENTRAL SLEEP APNEA;CHEMILUMINESCENT IMMUNOASSAY;CHEMOKINE RECEPTOR;COMPLEMENT FACTOR B;COMPLEMENT FACTOR I;DIFFUSING CAPACITY;ECULIZUMAB;EGFR INHIBITORS;ERLOTINIB;FACTOR H;GP41;GRANULOMATOSIS WITH POLYANGIITIS;ICE CALVING;INJURY SEVERITY SCORE;INTERFERON ALFA;INTRAUTERINE GROWTH RESTRICTION;K-COMPLEX;LARYNGOSCOPES;MEAN ARTERIAL PRESSURE;MEGAKARYOCYTE;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;MICROSCOPIC POLYANGIITIS;NUCLEATED RED BLOOD CELL;OSTEOCYTE;PAXILLIN;PEMETREXED;PHARMACOGENETICS;PLACENTA;PRASUGREL;PROSTATE-SPECIFIC ANTIGEN;PROTEIN KINASE DOMAIN;PROVIRUS;SEX HORMONE-BINDING GLOBULIN;SHORT QT SYNDROME;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL HAIRPIN RNA;SOCS3;STAT;STAT PROTEIN;TBARS;THIOBARBITURIC ACID;TISSUE TROPISM;TUMOR-INFILTRATING LYMPHOCYTES;UMBILICAL ARTERY;V3 LOOP","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;BLOOD SPECIMEN COLLECTION;MYOCARDIAL INFARCTION;ANTIVIRAL AGENTS;HEPATITIS C, CHRONIC;AGED, 80 AND OVER;HEPATITIS B, CHRONIC;HIV INFECTIONS;IMMUNOASSAY;LIVER NEOPLASMS;TREATMENT OUTCOME;CORONARY ARTERY DISEASE;HEPATITIS B VIRUS;DIABETES MELLITUS","73;51;43;39;34;30;28;15;15;14;14;13;13;13;13;13;13;12;12;11","LABORATORY MEDICINE AND TESTING PROCEDURES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;HEPATITIS C INFECTION AND TREATMENT;HEPATITIS B INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MECHANISMS AND TREATMENT OF LIVER FIBROSIS;NATURAL KILLER CELLS IN IMMUNITY;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;VITAMIN D AND HEALTH OUTCOMES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BODY COMPOSITION ASSESSMENT AND ANALYSIS;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHARGE SYNDROME AND RELATED GENETIC DISORDERS","14;5;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1","HEMATOLOGY ANALYZERS;HEMOLYSIS INTERFERENCE;TREATMENT;CLINICAL ENDPOINT;CORONARY STENTS;DRUG-ELUTING STENTS;ANTIRETROVIRAL THERAPY;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL LABORATORY GUIDELINES;CREATINE KINASE;EGFR MUTATIONS;RALTEGRAVIR;AGE GROUPS;CARDIAC IMAGING;CONCOMITANT;CREATINE;D-DIMER;DARUNAVIR;EGFR;ELECTROCARDIOGRAM INTERPRETATION","10;6;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","HEPATOCELLULAR CARCINOMA;CHRONIC HEPATITIS;CARCINOMA HCC;EMERGENCY DEPARTMENT;RANDOMIZED CONTROLLED;CANCER PATIENTS;CELL LUNG;CONTROLLED PHASE;DIABETIC PATIENTS;LUNG CANCER;PATIENTS PTS;SPURIOUS HEMOLYSIS;TIVANTINIB ARQ;TRIAL RCT;ACUTE MYOCARDIAL;ADVANCED HEPATOCELLULAR;APNEA SYNDROME;ARTERY DISEASE;BECKMAN COULTER;COLORECTAL CANCER;COULTER AU;CREATINE KINASE;EPIDERMAL GROWTH;FACTOR RECEPTOR;FINAL RESULTS;GROWTH FACTOR;HBEAG-NEGATIVE CHRONIC;HEPARIN TUBES;HIGHLY SENSITIVE;INCOMPLETE FILLING","6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;PATIENTS TREATED;HBV INFECTION;HCV INFECTION;NUCLEOSTIDE ANALOGUES;RENAL COLIC;HR CI;MM PATIENTS;ANTIGEN POSITIVE;DOPPLER RI;EMERGENCY DEPARTMENT;HAZARD RATIO;HBV DNA;OSTEOCYTE VIABILITY;SURFACE ANTIGEN;ADULT PATIENTS;DEPARTMENT ED;DIAGNOSTIC PERFORMANCE;GROWTH FACTOR;HEMORRHAGIC SHOCK;LATE LOSS;MONTHS HR;MOTOR EVENTS;RATIO CI;SYMPTOMATIC MM;T-CELL FUNCTIONS;T-CELL RESPONSES;VACUUM TUBES;VIABLE OSTEOCYTES;ACUTE HEPATITIS","12;9;8;8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4",29,0.28,3.5,3,1,1,0,1,7.75,0,1,4,0,1,3,0,1,1,1,3,1,0,0,61,64,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,5.95,817.8,15.28,12,0.55,123.68,0,1,7,0,9,0,1,4,0,18,2,0,0,0,0,0,0,19,3,0,20,2,0,0,0,0,0,0,0,0,"United States;Germany;Italy","9;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;4205 NURSING;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","20;13;7;4;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE;LUNG;LYMPHOMA;BREAST CANCER;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEART DISEASE;HEPATITIS - C;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY","20;15;13;9;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CANCER;INFECTION;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;RESPIRATORY","11;4;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","16;6;2;1;1;1;1;1;1;1","LIVER CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;MYELOMA;OVARIAN CANCER","4;4;3;3;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","13;4;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","3;2;1;1","CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE;RARE DISEASES","1;1;1;1;1;1;1;1;1","INFECTION","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","1;1","LIVER CANCER","1",NA,NA
"AOU_PARMA",2013,86,12.4302325581395,2.51162790697674,0.430232558139535,0.372093023255814,0.476744186046512,1.38064516129032,1.23333333333333,1.68421052631579,1.28125,0.453488372093023,2,50,16,10,6,0.58,0.19,0.12,0.07,24.09,0.690491612455058,7.35813953488372,0.325581395348837,0.802325581395349,0.474,0.388,0.513,0.435,"GIUSEPPE LIPPI;ROSALIA ALOE;CARLO FERRARI;GIANFRANCO CERVELLIN;DIEGO ARDISSINO;GABRIELE MISSALE;ENRICA TAMBURRINI;GIAN LUCA SALVAGNO;M. RAVIZZA;MARCO FLORIDIA;FRANCO AVERSA;GIORGIO DA RIN;AUGUSTO VAGLIO;ELISA DANESE;ARSENIO SPINILLO;LUIGI VIGNALI;GIULIA MASUELLI;GIAN CESARE GUIDI;MARIA GRAZIA ALESSIO;PAOLA AVANZINI","17;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","GIUSEPPE LIPPI;GIANFRANCO CERVELLIN;NICOLA SVERZELLATI;MARCO MANFREDI;ROSALIA ALOE;CARLO FERRARI;GIORGIO DA RIN;DIEGO ARDISSINO;GABRIELE MISSALE;ANTONIO BERTOLETTI;GIAN LUCA SALVAGNO;ELISABETTA CARIANI;SILVIA PIPITONE;PAOLA AVANZINI;ELISA DANESE;GIAN CESARE GUIDI;LUIGI VIGNALI;L COPPINI;DOMENICO PLANTONE;FRANCA SANDEI","3.6;1.62;1;1;0.89;0.87;0.77;0.75;0.71;0.58;0.58;0.5;0.5;0.49;0.45;0.45;0.43;0.42;0.4;0.37","GIUSEPPE LIPPI;ROSALIA ALOE;CARLO FERRARI;GIANFRANCO CERVELLIN;DIEGO ARDISSINO;GABRIELE MISSALE;GIAN LUCA SALVAGNO;FRANCO AVERSA;AUGUSTO VAGLIO;ELISA DANESE;LUIGI VIGNALI;GIAN CESARE GUIDI;PAOLA AVANZINI;ALBERTO MENOZZI;A. ORLANDINI;DOMENICO PLANTONE;FRANCA SANDEI;MARIA FRANCESCA NOTARANGELO;LIVIA RUFFINI;MARTINA MONTAGNANA","17;6;6;6;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2","GIUSEPPE LIPPI;GIANFRANCO CERVELLIN;NICOLA SVERZELLATI;MARCO MANFREDI;ROSALIA ALOE;CARLO FERRARI;DIEGO ARDISSINO;GABRIELE MISSALE;GIAN LUCA SALVAGNO;SILVIA PIPITONE;PAOLA AVANZINI;ELISA DANESE;GIAN CESARE GUIDI;LUIGI VIGNALI;DOMENICO PLANTONE;FRANCA SANDEI;C. QUILIGOTTI;MARIA FRANCESCA NOTARANGELO;LUCA GUARDOLI;ENRICO VAIENTI","3.6;1.62;1;1;0.89;0.87;0.75;0.71;0.58;0.5;0.49;0.45;0.45;0.43;0.4;0.37;0.33;0.33;0.33;0.33","ELIO JOVINE;FAUSTO CATENA;GREGORIO TUGNOLI;LUCA ANSALONI;MICHELE MASETTI;NAZARENO SMERIERI;SALOMONE DI SAVERIO;GIUSEPPE LIPPI;ANDREW B. PEITZMAN;ANTONIO PINNA;ARI LEPPÄNIEMI;CINO BENDINELLI;ERNEST E. MOORE;FEDERICO COCCOLINI;FREDERICK A. MOORE;GEORGE C. VELMAHOS;GUSTAVO PEREIRA FRAGA;HARRY VAN GOOR;J JEEKEL;MARICA GALATI","286;286;286;286;286;286;286;277;225;225;225;225;225;225;225;225;225;225;225;225","FAUSTO CATENA;GIUSEPPE LIPPI;CARLO FERRARI;AUGUSTO VAGLIO;ALBERTO MENOZZI;GIOVANNA ARTIOLI;GIUSEPPE MARLETTA;MARCELLO SCARDINO;MONICA AMPOLLINI;RACHELE LA SALA;DAVIDE MARTORANA;LIVIA RUFFINI;ROSALIA ALOE;CAROLINA BONI;DIEGO ARDISSINO;FRANCESCO CORRADI;P. VESCOVI;CAROLINA BRONZONI;FRANCO SERVADEI;R. SCIOLLA","286;277;199;131;124;118;118;118;118;118;111;92;92;87;77;74;68;67;67;65","GIUSEPPE LIPPI;CARLO FERRARI;GIANFRANCO CERVELLIN;ROSALIA ALOE;GABRIELE MISSALE;ALBERTO MENOZZI;A. ORLANDINI;PAOLA AVANZINI;AUGUSTO VAGLIO;ALBERTA CALEFFI;CARLO BUZIO;DIEGO ARDISSINO;DOMENICO PLANTONE;E. GNAPPI;FAUSTO CATENA;FRANCA SANDEI;FRANCESCO CORRADI;FRANCO AVERSA;LIVIA RUFFINI;MARCELLO TISEO","17;6;6;6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;POLITICAL SCIENCE;ART;BUSINESS;GEOGRAPHY;GEOLOGY;MATERIALS SCIENCE","81;15;11;10;5;5;5;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;VIROLOGY;PATHOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;ONCOLOGY;RADIOLOGY;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;OPTICS;PEDIATRICS;CHROMATOGRAPHY;ANESTHESIA;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;BIOCHEMISTRY;GENETICS","61;19;17;15;12;12;9;9;8;8;8;7;7;7;7;6;5;5;5;4;4","VIRUS;MYOCARDIAL INFARCTION;CHEMOTHERAPY;POPULATION;CANCER;CONFIDENCE INTERVAL;HEPATITIS C;IMMUNE SYSTEM;ANTIGEN;COHORT;INCIDENCE (GEOMETRY);ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ANTIBODY;DISEASE;EMERGENCY DEPARTMENT;HEART FAILURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LUNG CANCER;MAGNETIC RESONANCE IMAGING;PREGNANCY;REGIMEN;STROKE (ENGINE);TRANSPLANTATION;VIRAL HEPATITIS","13;12;8;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CHRONIC HEPATITIS;ACUTE CORONARY SYNDROME;HEPATITIS C VIRUS;CISPLATIN;CLINICAL ENDPOINT;CLOPIDOGREL;HEPATITIS B VIRUS;PERCUTANEOUS CORONARY INTERVENTION;TROPONIN;BREAST CANCER;CARDIAC MAGNETIC RESONANCE;COLORECTAL CANCER;DOCETAXEL;FETUS;GENOTYPE;GESTATIONAL AGE;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;LIVER FIBROSIS;PACLITAXEL;PROGRESSIVE DISEASE;TENOFOVIR;TROPONIN I;URINALYSIS","8;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RIBAVIRIN;CARBOPLATIN;DRUG-ELUTING STENT;HBSAG;LAMIVUDINE;OXALIPLATIN;SMALL FOR GESTATIONAL AGE;TICAGRELOR;ADVANCED MATERNAL AGE;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIBIOGRAM;ANTIRETROVIRAL THERAPY;BIVALIRUDIN;CAPECITABINE;CHEMOKINE RECEPTOR;CONTRAST-TO-NOISE RATIO;DUCTUS VENOSUS;ERLOTINIB;FEBRILE NEUTROPENIA;GLOBUS PALLIDUS;GLYCATED HEMOGLOBIN;IDIOPATHIC NEPHROTIC SYNDROME;INTRAUTERINE GROWTH RESTRICTION;JOB ATTITUDE;JOB DESIGN;MODIFIED RANKIN SCALE;OSTEOCYTE;OSTEONECROSIS OF THE JAW;PLACENTA;PRASUGREL;QUANTITATIVE COMPUTED TOMOGRAPHY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SEQUESTOSOME 1;SINGLE-NUCLEOTIDE POLYMORPHISM;STROKE VOLUME;SUGAMMADEX;SUPRACLAVICULAR LYMPH NODES;TAXANE;TRANSIENT ELASTOGRAPHY;UMBILICAL ARTERY;USUAL INTERSTITIAL PNEUMONIA","5;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;HEPATITIS C, CHRONIC;ITALY;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSPECTIVE STUDIES;ACUTE CORONARY SYNDROME;ADOLESCENT;PLATELET AGGREGATION INHIBITORS;STROKE;ANTIVIRAL AGENTS;CHILD;FOLLOW-UP STUDIES","53;38;35;32;29;26;19;13;13;13;13;10;9;8;8;8;8;7;7;7","HEPATITIS C INFECTION AND TREATMENT;HEPATITIS B INFECTION AND TREATMENT;LABORATORY MEDICINE AND TESTING PROCEDURES;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DISEASES RELATED TO BLOOD GROUP VARIANTS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;ANALYSIS OF GENE INTERACTION NETWORKS;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CARDIOTOXICITY OF CANCER TREATMENTS;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT","8;5;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;HEPATITIS C;TROPONIN ASSAYS;CLINICAL ENDPOINT;REGIMEN;STROKE (ENGINE);VIRAL HEPATITIS;ANEMIA;CARBOPLATIN;CARDIAC MAGNETIC RESONANCE;DIAGNOSTIC CRITERIA;DIAGNOSTIC ERRORS;DRUG-ELUTING STENTS;ENTECAVIR;HEMATOLOGY ANALYZERS;HEMOLYSIS INTERFERENCE;LIVER BIOPSY;PEGINTERFERON ALFA-2A;PLATELET REACTIVITY;REFERENCE VALUES","10;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CHRONIC HEPATITIS;EMERGENCY DEPARTMENT;MULTICENTER STUDY;CELL LUNG;CROSS-SECTIONAL INVESTIGATION;ENDEAVOR SPRINT;HEART FAILURE;HEPATOCELLULAR CARCINOMA;ITALIAN URINALYSIS;LIVER FIBROSIS;LUNG CANCER;MULTIPLE SCLEROSIS;PATIENTS TREATED;PLATO STUDY;PREGNANCY OUTCOMES;SYSMEX UFI;TROPONIN IMMUNOASSAYS;ZOTAROLIMUS-ELUTING ENDEAVOR;ACCESS PROGRAMME;ACS TRIAL;ACUTE APPENDICITIS;ACUTE BRAIN-INJURED;ACUTE EXERCISE;ACUTE HCV;ACUTE LEUKEMIA;ADAPTIVE IMMUNE;ADDITIONAL PEG-INTERFERON;ADULT THALASSEMIA;ADVANCED MATERNAL;ADVANCED NEUROENDOCRINE","9;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","STUDY MEDICATION;CELL DEATH;DE NOVO;JOB SATISFACTION;PATIENTS TREATED;PROTEASOME INHIBITORS;VIRAL INFECTIONS;BD VACUTAINER;CONFIDENCE INTERVAL;NOVO DSA;PROFESSIONAL COMMITMENT;TI PATIENTS;ABSOLUTE HUMIDITY;BIVENTRICULAR PARAMETERS;CHRONIC HEPATITIS;HCV RNA;INFECTED PATIENTS;ISCHAEMIC EVENTS;LV MASS;NEUROLOGIC IMPROVEMENT;NOISE REDUCTION;OSTEOCYTE VIABILITY;PLANNED DISCONTINUATION;PLATO STUDY;PRIMARY ENDPOINT;STUDY POPULATION;TOOTH EXTRACTIONS;VERSUS MGDL;ACUTE CORONARY;ACUTE PHASE","9;6;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3",26,0.3,3,4.5,2.25,1,0,1,1,0,1.25,4.5,0,0,4,0,1,1,2,3,1,0,0,68,68,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7.18,619.92,16.11,14,0.58,166.96,1,1,2,2,9,0,0,9,0,22,2,0,0,0,0,0,0,22,2,0,24,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;United Kingdom;Finland;France;Greece;Poland;Spain;Switzerland","10;4;3;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","23;13;11;5;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;LUNG;LYMPHOMA;PREVENTION;BREAST CANCER;AGING;BRAIN DISORDERS;CARDIOVASCULAR;DIGESTIVE DISEASES;ESTROGEN;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG CANCER;NEUROSCIENCES","23;19;13;10;6;5;5;4;4;3;2;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RESPIRATORY;STROKE","11;4;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY","17;6;3;2;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","4;3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","9;3;2;1;1;1",1,11940343,519145.35,6,23,7,1,83,141042.231285893,0.60974645122905,"AUTONOMOUS UNIVERSITY OF MADRID;AZIENDA SANITARIA DI FIRENZE;CARDIFF METROPOLITAN UNIVERSITY;CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE;DÉLÉGATION PARIS 11;EVERCYTE (AUSTRIA);FRIEDRICH SCHILLER UNIVERSITY JENA;GERMAN INSTITUTE OF HUMAN NUTRITION;IRCCS OSPEDALE SAN RAFFAELE;ISTITUTO NAZIONALE DI RIPOSO E CURA PER ANZIANI;LIFE LENGTH (SPAIN);MADRID HEALTH SERVICE;MOSAIQUES DIAGNOSTICS AND THERAPEUTICS (GERMANY);NATIONAL RESEARCH COUNCIL;OSPEDALE DI PARMA;SERVICIO DE SALUD DE CASTILLA LA MANCHA;SISTEMAS GENÓMICOS;UNIVERSITY OF BEDFORDSHIRE;UNIVERSITY OF BORDEAUX;UNIVERSITY OF CASTILLA-LA MANCHA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2012-INNOVATION-1 (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1","AGING;CLINICAL RESEARCH;PREVENTION","1;1;1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1",NA,NA,27,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","26;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;46 INFORMATION AND COMPUTING SCIENCES;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;38 ECONOMICS","39;6;5;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;EMERGING INFECTIOUS DISEASES;ATHEROSCLEROSIS;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;DRUG ABUSE (NIDA ONLY);HEPATITIS;HEPATITIS - C;HIV/AIDS;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;RARE DISEASES;SUBSTANCE MISUSE","4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;METABOLIC AND ENDOCRINE","2;2;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","2;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","13;3;1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"AOU_PARMA",2014,78,13.5384615384615,2.37179487179487,0.358974358974359,0.269230769230769,0.423076923076923,1.58119658119658,1.16666666666667,1.10526315789474,1.17857142857143,0.320512820512821,1,35,21,6,11,0.45,0.27,0.08,0.14,30.24,0.800270664841877,7.01978021978022,0.282051282051282,0.846153846153846,0.41,0.335,0.326,0.329,"DIEGO ARDISSINO;GIOVANNI DELSANTE;GIAN LUIGI DE’ANGELIS;FILIPPO BENASSI;MARCELLO TISEO;ALARICO ARIANI;ENRICO MARIA SILINI;GIUSEPPE PROCOPIO;GIUSEPPE LIPPI;GABRIELE MISSALE;SILVIA NOVELLO;FEDERICO CAPPUZZO;FEDERICA LUMETTI;SEBASTIANO BUTI;FRANCESCA VINCENZI;DOMENICO GALETTA;EDOARDO PICETTI;SVATI H. SHAH;DOMENICO GIRELLI;MUREDACH P. REILLY","6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","GIOVANNI DELSANTE;MARCO MANFREDI;GIUSEPPE LIPPI;FILIPPO BENASSI;GIAN LUIGI DE’ANGELIS;ALARICO ARIANI;ANTONELLA VEZZANI;PIERANNA FIETTA;ENRICO MARIA SILINI;FRANCESCA VINCENZI;GIAN LUCA SALVAGNO;EDOARDO PICETTI;DAVIDE GIAVARINA;FEDERICA LUMETTI;NICOLA SVERZELLATI;MARIO SILVA;TIZIANO GHERLI;ALBERTO MOLARDI;DIEGO ARDISSINO;FEDERICA GAIANI","1.09;1;0.93;0.87;0.65;0.59;0.5;0.5;0.48;0.47;0.45;0.45;0.39;0.39;0.39;0.39;0.38;0.37;0.34;0.33","DIEGO ARDISSINO;GIOVANNI DELSANTE;GIAN LUIGI DE’ANGELIS;FILIPPO BENASSI;MARCELLO TISEO;ALARICO ARIANI;ENRICO MARIA SILINI;GIUSEPPE LIPPI;GABRIELE MISSALE;FEDERICA LUMETTI;SEBASTIANO BUTI;FRANCESCA VINCENZI;EDOARDO PICETTI;FEDERICA GAIANI;ANDREA ARDIZZONI;SILVIA IULIANO;ANTONELLA VEZZANI;BARBARA BIZZARRI;ALESSIA GHISELLI;ALBERTO MENOZZI","6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","GIOVANNI DELSANTE;MARCO MANFREDI;GIUSEPPE LIPPI;FILIPPO BENASSI;GIAN LUIGI DE’ANGELIS;ALARICO ARIANI;ANTONELLA VEZZANI;ENRICO MARIA SILINI;FRANCESCA VINCENZI;EDOARDO PICETTI;FEDERICA LUMETTI;TIZIANO GHERLI;ALBERTO MOLARDI;DIEGO ARDISSINO;FEDERICA GAIANI;SILVIA IULIANO;ALESSIA GHISELLI;FLAVIO MOZZANI;G. LUCCHINI;MARIA LETIZIA URBAN","1.09;1;0.93;0.87;0.65;0.59;0.5;0.48;0.47;0.45;0.39;0.38;0.37;0.34;0.33;0.33;0.33;0.32;0.32;0.32","DIEGO ARDISSINO;DOMENICO GIRELLI;HUGH WATKINS;MUREDACH P. REILLY;NATHAN O. STITZIEL;RUTH MCPHERSON;SEKAR KATHIRESAN;SVATI H. SHAH;ANUJ GOEL;MARTIN FARRALL;ALBERTO MENOZZI;ALEX P. REINER;STACEY GABRIEL;ALAIDE CHIEFFO;ANTONIO COLOMBO;ARIAN FRASHERI;BRUNO MARIO CESANA;EDOARDO PUCCI;GENNARO GIUSTINO;GENNARO SARDELLA","781;730;730;730;730;730;730;730;689;689;450;427;427;402;402;402;402;402;402;402","DIEGO ARDISSINO;ALBERTO MENOZZI;FAUSTO CATENA;GABRIELE MISSALE;EDOARDO PICETTI;FRANCO SERVADEI;CORRADO IACCARINO;GIUSEPPE LIPPI;ALESSANDRA FORNARO;BENEDETTA TOMBERLI;CHIARA PESCUCCI;CRISTINA BASSO;FRANCESCA GIROLAMI;FRANCESCA TORRICELLI;FRANCO CECCHI;GIUSEPPINA MARSEGLIA;IACOPO OLIVOTTO;LAURA PEZZOLI;MARIA ELENA SANA;MARIA IASCONE","781;450;247;180;140;138;104;100;79;79;79;79;79;79;79;79;79;79;79;79","DIEGO ARDISSINO;MARCELLO TISEO;FILIPPO BENASSI;GIAN LUIGI DE’ANGELIS;GABRIELE MISSALE;GIOVANNI DELSANTE;GIUSEPPE LIPPI;ALARICO ARIANI;ANTONELLA VEZZANI;ALBERTO MENOZZI;ANDREA ARDIZZONI;EDOARDO PICETTI;TIZIANO GHERLI;ALESSIA GHISELLI;BARBARA BIZZARRI;ENRICO MARIA SILINI;FEDERICA GAIANI;FRANCESCA VINCENZI;SILVIA IULIANO;ALBERTO MOLARDI","6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;ENGINEERING;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;GEOGRAPHY;GEOLOGY;MATERIALS SCIENCE;PSYCHOLOGY;BUSINESS;ECONOMICS;HISTORY;PHILOSOPHY","71;18;8;8;4;4;3;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;VIROLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;STATISTICS;ANESTHESIA;BIOCHEMISTRY;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;UROLOGY;CELL BIOLOGY;COMBINATORICS;DEMOGRAPHY;ENDOCRINOLOGY;GENERAL SURGERY;OBSTETRICS;PSYCHIATRY","57;17;15;15;13;10;9;8;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","CANCER;MYOCARDIAL INFARCTION;COHORT;GENE;CLINICAL TRIAL;DISEASE;POPULATION;HEPATOCELLULAR CARCINOMA;LUNG;LUNG CANCER;RETROSPECTIVE COHORT STUDY;VIRUS;ADVERSE EFFECT;ANTIBODY;CHEMOTHERAPY;PULMONARY FUNCTION TESTING;CELL CULTURE;CONFIDENCE INTERVAL;HEART FAILURE;OBSERVATIONAL STUDY;PERCUTANEOUS;ULTRASOUND","14;9;8;8;7;7;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3","CLINICAL ENDPOINT;INTERSTITIAL LUNG DISEASE;PERCUTANEOUS CORONARY INTERVENTION;BREAST CANCER;COLORECTAL CANCER;GENOTYPE;HAZARD RATIO;LUNG FUNCTION;ACUTE CORONARY SYNDROME;ALLELE;BONE DENSITY;CERVICAL CANCER;CHRONIC HEPATITIS;CISPLATIN;CLOPIDOGREL;COINFECTION;GLUTAMINE;HEPATITIS B VIRUS;IMMUNOASSAY;INFLIXIMAB;MALIGNANT PLEURAL EFFUSION;MULTICENTER STUDY;MUTATION;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;REFLUX;REVASCULARIZATION;SORAFENIB;TROPONIN I","4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DIFFUSING CAPACITY;EXOME SEQUENCING;ALLELE FREQUENCY;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLPOSCOPY;HBSAG;HPV INFECTION;KRAS;QUANTITATIVE COMPUTED TOMOGRAPHY;TAMOXIFEN;TIMI;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN RECEPTOR;ANTIANDROGEN;ANTIRETROVIRAL THERAPY;BREAST SURGERY;CARBOPLATIN;CRIZOTINIB;DNA METHYLATION;DRUG-ELUTING STENT;ENDOTHELIAL PROGENITOR CELL;ERLOTINIB;FRONTOTEMPORAL DEMENTIA;GASTRO-;GEFITINIB;GENETIC VARIANTS;GENOTYPING;GERD;GLUTAMINE SYNTHETASE;HAPLOTYPE;HEPATITIS DELTA;HYPOVITAMINOSIS;INTRAEPITHELIAL NEOPLASIA;LAMIVUDINE;LOSS FUNCTION;MASTECTOMY;MEAN ARTERIAL PRESSURE;MONOCLONAL;NON-SMALL CELL LUNG CANCER (NSCLC);PRASUGREL;PROBAND;REVERSE TRANSCRIPTASE;RIGHT CORONARY ARTERY;SANGER SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;THIENOPYRIDINE;TICAGRELOR","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;LUNG NEOPLASMS;CARCINOMA, RENAL CELL;CORONARY ARTERY DISEASE;KIDNEY NEOPLASMS;ACUTE CORONARY SYNDROME;FOLLOW-UP STUDIES;TREATMENT OUTCOME","39;38;30;29;21;20;20;11;11;11;10;10;10;10;9;9;9;8;8;8","ADVANCEMENTS IN LUNG CANCER RESEARCH;RENAL CELL CARCINOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;GENOMIC STUDIES AND ASSOCIATION ANALYSES;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES","4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;TREATMENT;DLCO;ECHOCARDIOGRAPHY;HIGH-RESOLUTION CT;STROKE (ENGINE);CANCER THERAPY;CARDIOVASCULAR EVALUATION;COMPARABILITY;EGFR MUTATIONS;EVEROLIMUS;EXOME;HBV INFECTION;HEMATOLOGY;HEPATITIS D;INTERQUARTILE RANGE;INTRACRANIAL PRESSURE;KURTOSIS;MYOCARDIAL REVASCULARIZATION;NON-SMALL CELL LUNG CANCER","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LUNG CANCER;OBSERVATIONAL STUDY;CELL LUNG;HEPATOCELLULAR CARCINOMA;INTERSTITIAL LUNG;LUNG DISEASE;METASTATIC RENAL;MYOCARDIAL INFARCTION;RENAL CELL;ANTIPLATELET THERAPY;BRAIN INJURY;CARDIAC SURGERY;CELL CARCINOMA;CERVICAL INTRAEPITHELIAL;CHRONIC HEPATITIS;COHORT STUDY;DUAL ANTIPLATELET;FIRST-LINE TREATMENT;HEPATITIS DELTA;HUMAN PAPILLOMAVIRUS;INTRAEPITHELIAL NEOPLASIA;ITALIAN SURVEY;LIFE OBSERVATIONAL;MASTER-B COHORT;MULTICENTER ITALIAN;MULTIPLE MYELOMA;MYELOMA CELLS;NON-SMALL CELL;PAPILLOMAVIRUS INFECTION;SISTEMIC SCLEROSIS","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CRP LEVELS;HIV RNA;MONTHS CI;CANCER PTS;EGFR TKI;LATE BOOKING;LIPOPROTEIN CHOLESTEROL;LOW-FREQUENCY CODING;OBSERVATIONAL STUDY;RS CCT;RS CGA;SECOND-LINE THERAPY;SEQUENCE VARIANTS;SURGICAL RESECTION;TICAGRELOR CLOPIDOGREL;ACTN CTGTC;ACUTE CORONARY;ATRIAL FIBRILLATION;CLINICAL TRIALS;CODING VARIANTS;COMPLEX DISEASES;CORONARY HEART;CTGTC PMETTHR;CTNNB-MUTATED HCC;DEFINITIVE SURGERY;EXOME ARRAY;HEART DISEASE;HIV DIAGNOSIS;LINE TREATMENT;MEDIAN AGE","8;7;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",20,0.26,11.09,7.25,1,2.5,0,3.75,5,0,1.75,8.25,0,0,7,1,1,2.25,2.75,3.25,3.5,0,0,87.5,87.5,1,0,0,2,0,0,0,0,0,0,0,0,2,0,0,4,3,3.24,2,0,2,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BARONI MARIA CRISTINA;CABASSI CLOTILDE SILVIA;ROMANI ANTONELLO","2;2;2","AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA;UNIV PARMA","2;2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES","2;2;1;1","INFECTIOUS DISEASES;ANTIMICROBIAL RESISTANCE;EMERGING INFECTIOUS DISEASES;PATIENT SAFETY","2;1;1;1","5.1 PHARMACEUTICALS","1","A61K38/04;A61K38/16;C07K14/00;C07K7/08;C07K7/50","2;1;1;1;1","A61K38/00;A61K38/04;A61K38/10;A61K38/16;C07K14/00;C07K7/08;C07K7/50;Y02A50/30","2;2;2;2;2;2;2;2",34,8.07,1115.41,30.09,16,0.47,177.21,0,1,13,0,10,0,0,10,0,24,5,0,0,0,0,0,0,31,2,1,29,5,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;United Kingdom","16;5;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3215 REPRODUCTIVE MEDICINE;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4204 MIDWIFERY;4205 NURSING;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","32;20;17;6;5;4;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;HEMATOLOGY;GENETICS;LUNG;ORPHAN DRUG;AUTOIMMUNE DISEASE;CARDIOVASCULAR;CHRONIC PAIN;INFLAMMATORY BOWEL DISEASE;LUNG CANCER;PAIN RESEARCH;PEDIATRIC;PREVENTION;BIOMEDICAL IMAGING;BREAST CANCER","30;20;18;15;9;7;5;4;4;4;3;3;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;BLOOD;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","20;2;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.4 SURGERY;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;7.2 END OF LIFE CARE","23;5;4;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;BRAIN TUMOR;BREAST CANCER;GASTROINTESTINAL TRACT;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;LARYNGEAL CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PANCREATIC CANCER;PROSTATE CANCER;STOMACH CANCER;THYROID CANCER","5;5;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.6 END-OF-LIFE CARE","15;2;2;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,"PUBLIC LIBRARY OF SCIENCE","24","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4202 EPIDEMIOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;4207 SPORTS SCIENCE AND EXERCISE;50 PHILOSOPHY AND RELIGIOUS STUDIES;5003 PHILOSOPHY","30;10;7;5;4;4;3;3;2;2;2;1;1;1;1","PREVENTION;INFECTIOUS DISEASES;CLINICAL RESEARCH;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;ANTIMICROBIAL RESISTANCE;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;AUTOIMMUNE DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BIODEFENSE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;OSTEOPOROSIS;VACCINE RELATED","7;6;4;4;3;3;3;3;2;2;2;1;1;1;1","INFECTION","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.4 SURGERY;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","3;2;1;1;1","CLINICAL;BIOMEDICAL","6;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","14;1","NOT SITE-SPECIFIC CANCER","2",NA,NA
"AOU_PARMA",2015,84,12.9761904761905,2.72619047619048,0.333333333333333,0.30952380952381,0.571428571428571,1.40490797546012,1.12,1.36842105263158,1.45454545454545,0.428571428571429,2,52,13,6,9,0.62,0.15,0.07,0.11,25.79,0.691895740521343,7.03389830508476,0.297619047619048,0.892857142857143,0.447,0.372,0.309,0.351,"FRANCO AVERSA;GABRIELE MISSALE;NICOLA GIULIANI;MARINA BOLZONI;GIOVANNA ARTIOLI;VALENTINA MARCHICA;ELENA MARCHESI;S CALZETTI;DIEGO ARDISSINO;BENEDETTA DALLA PALMA;FABRIZIO ACCARDI;LUISA CRAVIOTTO;ALFONSO SOLLAMI;MATTEO GOLDONI;MARCELLO TISEO;GIUSEPPE LIPPI;ANNA NEGROTTI;CRISTINA MANCINI;EUGENIA MARTELLA;CARMELA PINNETTI","9;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3","FRANCO AVERSA;ALESSANDRA MARTELLI;ALFONSO SOLLAMI;ELENA MARCHESI;S CALZETTI;ANNA NEGROTTI;GIUSEPPE LIPPI;MATTEO GOLDONI;GIOVANNA ARTIOLI;ROSALIA ALOE;EDOARDO RAPOSIO;DIEGO ARDISSINO;LUCA CARICATI;TIZIANA MANCINI;FILIPPO PIGAZZANI;ALBERTO MENOZZI;GABRIELE MISSALE;NICOLA GIULIANI;MARINA BOLZONI;MARIA LETIZIA URBAN","1.52;1;0.86;0.81;0.81;0.81;0.78;0.75;0.63;0.58;0.5;0.48;0.44;0.44;0.39;0.36;0.34;0.34;0.34;0.33","FRANCO AVERSA;GABRIELE MISSALE;NICOLA GIULIANI;GIOVANNA ARTIOLI;ELENA MARCHESI;S CALZETTI;DIEGO ARDISSINO;BENEDETTA DALLA PALMA;FABRIZIO ACCARDI;LUISA CRAVIOTTO;ALFONSO SOLLAMI;MARCELLO TISEO;GIUSEPPE LIPPI;ANNA NEGROTTI;CRISTINA MANCINI;EUGENIA MARTELLA;LIVIA RUFFINI;MASSIMO ALLEGRI;SABRINA BONOMINI;CARLO FERRARI","9;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3","FRANCO AVERSA;ALESSANDRA MARTELLI;ALFONSO SOLLAMI;ELENA MARCHESI;S CALZETTI;ANNA NEGROTTI;GIUSEPPE LIPPI;GIOVANNA ARTIOLI;ROSALIA ALOE;EDOARDO RAPOSIO;DIEGO ARDISSINO;FILIPPO PIGAZZANI;ALBERTO MENOZZI;GABRIELE MISSALE;NICOLA GIULIANI;MARIA LETIZIA URBAN;LUCIO MANENTI;EDOARDO PICETTI;AUGUSTO VAGLIO;ANNACHIARA ALDROVANDI","1.52;1;0.86;0.81;0.81;0.81;0.78;0.63;0.58;0.5;0.48;0.39;0.36;0.34;0.34;0.33;0.33;0.33;0.33;0.33","CESARE GRANDI;AGNÈS LEROUX;ANDERS BILDE;ANNELISE KROGDAHL;AUGUSTO MOREIRA;BENJAMIN GURNEY;CHRISTIAN VON BUCHWALD;CLARE SCHILLING;DAVIDE DONNER;DIDIER DEQUANTER;E. SESENNA;EDWARD ODELL;ELISABETH BLOEMENA;EMMA BRAGANTINI;ENRICO MARIA SILINI;GEORGES LAWSON;GERHARD HUBER;GILLES DOLIVET;GIROLAMO TARTAGLIONE;GÉKE B. FLACH","320;319;319;319;319;319;319;319;319;319;319;319;319;319;319;319;319;319;319;319","E. SESENNA;ENRICO MARIA SILINI;TITO POLI;ALBERTO MENOZZI;DIEGO ARDISSINO;BARBARA AMADEI;SIMONETTA URBANI;STEFANIA FIENI;GIROLAMO CRISI;GABRIELE MISSALE;MASSIMO ALLEGRI;CARLO FERRARI;PAOLA FISICARO;ANDREA VECCHI;ARIANNA ALFIERI;CAROLINA BONI;LAVINIA TALAMONA;MARIA CRISTINA CAVALLO;MARZIA ROSSI;T. GIUBERTI","319;319;319;314;250;160;160;160;123;95;90;84;84;81;81;81;81;81;81;81","FRANCO AVERSA;GABRIELE MISSALE;ALFONSO SOLLAMI;ANNA NEGROTTI;CRISTINA MANCINI;ELENA MARCHESI;EUGENIA MARTELLA;GIUSEPPE LIPPI;MARCELLO TISEO;DIEGO ARDISSINO;NICOLA GIULIANI;ALBERTO MENOZZI;CARLO FERRARI;MASSIMO ALLEGRI;BENEDETTA DALLA PALMA;LIVIA RUFFINI;SABRINA BONOMINI;ANNA DEGLI ANTONI;BARBARA BIZZARRI;CARMINE PINTO","7;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;ECONOMICS;MATHEMATICS;COMPUTER SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;SOCIOLOGY;ENGINEERING;GEOLOGY;HISTORY;MATERIALS SCIENCE","80;26;9;8;6;5;5;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ONCOLOGY;CARDIOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;OPTICS;ANESTHESIA;CANCER RESEARCH;NURSING;PEDIATRICS;RADIOLOGY;ENDOCRINOLOGY;CELL BIOLOGY;ECONOMIC GROWTH;VIROLOGY","63;21;18;16;15;12;11;10;10;9;9;8;8;7;7;7;6;6;5;4;4;4","CANCER;POPULATION;CHEMOTHERAPY;DISEASE;INCIDENCE (GEOMETRY);GENE;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;IMMUNE SYSTEM;MYOCARDIAL INFARCTION;COHORT;MULTIPLE MYELOMA;PREGNANCY;STEM CELL;BONE MARROW;CLINICAL TRIAL;CONFIDENCE INTERVAL;EMERGENCY DEPARTMENT;HEALTH CARE;IN VITRO;PROSPECTIVE COHORT STUDY;VIRUS","11;10;9;9;9;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","CLINICAL ENDPOINT;NEUTROPENIA;PARKINSON'S DISEASE;PERCUTANEOUS CORONARY INTERVENTION;BORTEZOMIB;CD34;CUMULATIVE INCIDENCE;DOPAMINERGIC;HAZARD RATIO;RESTLESS LEGS SYNDROME;ACUTE CORONARY SYNDROME;BREAST CANCER;CANCER INCIDENCE;CANCER REGISTRY;CHEMOKINE;CYCLOPHOSPHAMIDE;FETUS;GENE EXPRESSION;HAEMATOPOIESIS;HEPATITIS B VIRUS;IMMUNITY;MONOCLONAL ANTIBODY;OSTEOBLAST;PACLITAXEL;PLACEBO;PROGENITOR CELL;RAMUCIRUMAB;RESTENOSIS;T CELL;TROPONIN;TROPONIN I;VIABILITY ASSAY;VIRAL LOAD","7;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MACE;TICAGRELOR;CD38;DRUG-ELUTING STENT;MONOCLONAL;P2Y12;TIMI;ALPHA (FINANCE);ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;ANTIRETROVIRAL THERAPY;BASIC LIFE SUPPORT;BETA CELL;BODY CONTOURING;CARBOPLATIN;CASPOFUNGIN;CELL COUNTING;CHEMOIMMUNOTHERAPY;CHEMOKINE RECEPTOR;CROHN DISEASE;CXCR4;CYP2C19;DARATUMUMAB;DASATINIB;DIFFUSING CAPACITY;DNA METHYLATION;DNA OXIDATION;FLUDARABINE;GENOTYPING;HBSAG;HEME OXYGENASE;HYPERALGESIA;IMMUNOGLOBULIN A;IN UTERO;INTERLEUKIN 12;INTERLEUKIN 21;KLEBSIELLA PNEUMONIAE;KRAS;LAMIVUDINE;LENTIVIRUS;LYMPHOPLASMACYTIC LYMPHOMA;MILAN CRITERIA;NATURAL KILLER CELL;NILOTINIB;NKG2D;OFATUMUMAB;OSTEOCYTE;POSACONAZOLE;PRASUGREL;RETURN OF SPONTANEOUS CIRCULATION;SENTINEL NODE;TARGET LESION;TRANSITIONAL CELL CARCINOMA;UBIQUITIN LIGASE;VINCRISTINE","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;AGED;ADULT;CARCINOMA, HEPATOCELLULAR;CORONARY ARTERY DISEASE;HIV INFECTIONS;LIVER NEOPLASMS;PREGNANCY COMPLICATIONS, INFECTIOUS;TREATMENT OUTCOME;ACUTE CORONARY SYNDROME;AGED, 80 AND OVER;ADENOSINE;ANESTHETICS, LOCAL;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION","47;37;36;33;24;23;22;19;11;11;11;11;11;11;9;9;8;8;8;8","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;INTERPROFESSIONAL COLLABORATION IN HEALTHCARE TEAMS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HEALTH SURVEYS IN GERMANY AND PUBLIC HEALTH RESEARCH;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;NATURAL KILLER CELLS IN IMMUNITY;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BODY CONTOURING TECHNIQUES AND PROCEDURES;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CLINICAL ENDPOINT;MACE;TREATMENT;BONE MARROW MICROENVIRONMENT;CANCER INCIDENCE;CUMULATIVE INCIDENCE;INTERPROFESSIONAL EDUCATION;PERIODIC LIMB MOVEMENTS;RESTLESS LEGS SYNDROME;ASSOCIATION (PSYCHOLOGY);BETA (PROGRAMMING LANGUAGE);CANCER TREATMENT EXPENSES;CONCORDANCE;DOPAMINERGIC THERAPY;DRUG-ELUTING STENTS;EPIDURAL ANALGESIA;HEPATOCELLULAR CARCINOMA;HIV;HIV INFECTION;INTERNATIONAL MYELOMA WORKING GROUP","7;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CHRONIC DOPAMINERGIC;COHORT STUDY;CUMULATIVE INCIDENCE;DE NOVO;DOPAMINERGIC THERAPY;HEPATOCELLULAR CARCINOMA;LUNG CANCER;PROSPECTIVE STUDY;BONE MARROW;CANCER INCIDENCE;CHRONIC HEPATITIS;KILLER CELL;MULTICENTER STUDY;MULTIPLE MYELOMA;MYELOMA CELLS;MYELOMA PATIENTS;MYOCARDIAL INFARCTION;NATURAL KILLER;NOVO PD;OBSERVATIONAL STUDY;PARKINSONS DISEASE;PD PATIENTS;PLACEBO PL;PRELIMINARY RESULTS;RAMUCIRUMAB RAM;SUBGROUP ANALYSIS;ACUTE CARE;ACUTE HEPATITIS;ACUTE MYOCARDIAL;ADENOCARCINOMA RAINBOW","3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","THYMIC CARCINOMAS;CARE UNIT;COO NPS;CORPUS CALLOSUM;EPIDURAL INFUSION;RAM DOC;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;THYMIC EPITHELIAL;DMN CONNECTIVITY;HIPPOCAMPAL COMMISSURE;IMMUNE SYSTEM;PRIMARY ENDPOINT;QUANTIFIABLE HIV-RNA;RAM MGKG;SEMANTIC MEMORY;ADVERSE EVENTS;CANCER PATIENTS;CARCINOMAS TYPE;CELL SIGNALING;CHLORINATING ACTIVITY;GASTRIC CANCER;GRADE ADVERSE;HISTOLOGIC SIGNS;INTERPROFESSIONAL COLLABORATION;KRAS PDGFR-ALPHAAND;MEDIAN AGE;MOLECULAR ANALYSIS;NKCELL PHENOTYPE;PYLORI INFECTION;RAINBOW PTS","8;7;7;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",24,0.29,7.62,6,1.75,2,0,1,1,0,1.75,6.25,1,1,4.5,0,0,1,2,3,1,0,0,73.25,73.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,7.8,1801.45,14.57,15,0.68,328.59,0,0,3,2,9,0,1,6,1,15,5,0,0,0,0,0,0,22,0,0,19,2,1,0,0,0,0,0,0,0,"United States;Germany;Italy;Japan","12;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","19;11;9;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;BREAST CANCER;HEMATOLOGY;LUNG;LUNG CANCER;PATIENT SAFETY;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;NEUROSCIENCES;CARDIOVASCULAR;DIGESTIVE DISEASES;GENETICS;HEART DISEASE;LYMPHOMA;ORPHAN DRUG;PREVENTION;ACQUIRED COGNITIVE IMPAIRMENT","18;12;12;7;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;1","CANCER;CARDIOVASCULAR;INFECTION;MENTAL HEALTH;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","10;3;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","15;4;1;1;1;1;1;1","BREAST CANCER;LUNG CANCER;BLOOD CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MELANOMA;MYELOMA;NON-HODGKIN'S LYMPHOMA","4;4;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","9;3;2;1;1;1",1,5593049,559304.9,5,10,7,1,15,199094.820147619,0.421909519985091,"ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;CAPITAL REGION OF DENMARK;DIAGRAM (NETHERLANDS);ISALA;OSPEDALE DI PARMA;RADBOUD UNIVERSITY NIJMEGEN;SAPIENZA UNIVERSITY OF ROME;SERVICIO GALLEGO DE SALUD;STIFTUNG INSTITUT FÜR HERZINFARKTFORSCHUNG;UNIVERSITY OF BERN","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","AGING;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;PHYSICAL REHABILITATION;REHABILITATION","1;1;1;1;1;1","CARDIOVASCULAR","1","7.1 INDIVIDUAL CARE NEEDS","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,22,"PUBLIC LIBRARY OF SCIENCE","22","32 BIOMEDICAL AND CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3213 PAEDIATRICS;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;4202 EPIDEMIOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY","37;7;5;4;4;4;3;2;2;2;1;1;1;1","PEDIATRIC;GENETICS;INFANT MORTALITY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;PREVENTION;CANCER;CONTRACEPTION/REPRODUCTION;NUTRITION;OBESITY;CARDIOVASCULAR;CLINICAL RESEARCH;DIABETES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HUMAN GENOME;LUNG;LUNG CANCER;AGING;ATHEROSCLEROSIS","7;6;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;1;1","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;METABOLIC AND ENDOCRINE;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE","3;3;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","4;1;1","BIOMEDICAL;CLINICAL","4;4","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","8;5","LUNG CANCER","2",NA,NA
"AOU_PARMA",2016,107,16.2897196261682,2.35514018691589,0.299065420560748,0.242990654205607,0.448598130841121,1.56521739130435,1.23076923076923,1.36842105263158,1.41176470588235,0.429906542056075,0,64,19,8,13,0.6,0.18,0.07,0.12,29.09,0.895651536964036,5.93536121673004,0.383177570093458,0.934579439252336,0.4,0.401,0.463,0.388,"MARCELLO TISEO;ALBERTO MENOZZI;FRANCO AVERSA;NICOLA GIULIANI;FABRIZIO ACCARDI;GREGORY C. FANELLI;FRANCESCO GIUSEPPE FOSCHI;GIUSEPPE TARANTINI;VALENTINA MARCHICA;MASSIMO ALLEGRI;HARVEY D. WHITE;MARIO SILVA;ALARICO ARIANI;PHILIPPE GABRÍEL STEG;DEEPAK L. BHATT;EDOARDO PICETTI;ALAIDE CHIEFFO;ANTONIO COLOMBO;NICOLA SVERZELLATI;DIEGO ARDISSINO","11;10;8;8;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","MARCELLO TISEO;ALBERTO MENOZZI;FRANCO AVERSA;NICOLA GIULIANI;MASSIMO ALLEGRI;MARIO SILVA;LUCA CARICATI;SILVIA IULIANO;ALFONSO SOLLAMI;MARCO MANFREDI;FABRIZIO ACCARDI;C. GHETTI;ALARICO ARIANI;GREGORY C. FANELLI;PAOLA BORDI;EDOARDO PICETTI;MARZIA DEL RE;LETIZIA GNETTI;ROMANO DANESI;BENEDETTA DALLA PALMA","1.04;0.64;0.59;0.57;0.56;0.55;0.5;0.5;0.5;0.5;0.47;0.45;0.45;0.43;0.42;0.39;0.38;0.38;0.38;0.37","MARCELLO TISEO;ALBERTO MENOZZI;FRANCO AVERSA;NICOLA GIULIANI;FABRIZIO ACCARDI;GREGORY C. FANELLI;FRANCESCO GIUSEPPE FOSCHI;VALENTINA MARCHICA;MASSIMO ALLEGRI;MARIO SILVA;ALARICO ARIANI;EDOARDO PICETTI;DIEGO ARDISSINO;BENEDETTA DALLA PALMA;ELISABETTA BIASINI;RICCARDO C. BONADONNA;FEDERICA LUMETTI;CATERINA CAMINITI;PAOLA BORDI;MANUELA DE GREGORI","11;10;8;8;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3","MARCELLO TISEO;ALBERTO MENOZZI;FRANCO AVERSA;NICOLA GIULIANI;MASSIMO ALLEGRI;MARIO SILVA;LUCA CARICATI;SILVIA IULIANO;ALFONSO SOLLAMI;MARCO MANFREDI;FABRIZIO ACCARDI;C. GHETTI;ALARICO ARIANI;GREGORY C. FANELLI;PAOLA BORDI;EDOARDO PICETTI;LETIZIA GNETTI;BENEDETTA DALLA PALMA;CARMELINDA MANNA;VALENTINA MARCHICA","1.04;0.64;0.59;0.57;0.56;0.55;0.5;0.5;0.5;0.5;0.47;0.45;0.45;0.43;0.42;0.39;0.38;0.37;0.35;0.33","FRANCO SERVADEI;A. DAVID MENDELOW;ANDREAS UNTERBERG;ANGELOS G. KOLIAS;ANTONIO BELLI;C. ANDREW EYNON;DAVID MENON;DIEDERIK BULTERS;ELIZABETH A. CORTEEN;GILES CRITCHLEY;GORDON MURRAY;GRAHAM M. TEASDALE;IAN ANDERSON;IVAN TIMOFEEV;JAKE TIMOTHY;JOHN D. PICKARD;JOHN WADLEY;JUAN SAHUQUILLO;MAREK CZOSNYKA;MARK H. WILSON","1003;995;995;995;995;995;995;995;995;995;995;995;995;995;995;995;995;995;995;995","FRANCO SERVADEI;FRANCO AVERSA;GABRIELE MISSALE;NICOLA GIULIANI;ELISABETTA BIASINI;MARCELLO TISEO;CRISTINA MANCINI;EUGENIA MARTELLA;FABRIZIO ACCARDI;MASSIMO ALLEGRI;A. CAVALLI;PAOLA STORTI;VALENTINA MARCHICA;GREGORY C. FANELLI;RICCARDO C. BONADONNA;DARIO BUGADA;ALBERTO MENOZZI;L. DELAJ;EDOARDO PICETTI;DIEGO ARDISSINO","1003;289;252;247;217;160;157;157;146;145;142;142;142;140;131;105;102;102;86;82","MARCELLO TISEO;ALBERTO MENOZZI;FRANCO AVERSA;NICOLA GIULIANI;FABRIZIO ACCARDI;GREGORY C. FANELLI;MASSIMO ALLEGRI;ALARICO ARIANI;EDOARDO PICETTI;DIEGO ARDISSINO;CARLO FERRARI;ELISABETTA BIASINI;FEDERICA LUMETTI;CATERINA CAMINITI;FRANCESCA RE;GABRIELE MISSALE;RICCARDO C. BONADONNA;BENEDETTA DALLA PALMA;BEATRICE SBRISCIA-FIORETTI;CHIARA SCHIFANO","11;10;7;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;CHEMISTRY;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;ART;SOCIOLOGY;BUSINESS;GEOGRAPHY","100;26;11;6;6;5;5;5;4;4;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;GENETICS;RADIOLOGY;IMMUNOLOGY;CANCER RESEARCH;PSYCHIATRY;ANESTHESIA;BIOCHEMISTRY;FAMILY MEDICINE;NUCLEAR MEDICINE;PEDIATRICS;INTENSIVE CARE MEDICINE;LAW;MICROBIOLOGY;NEUROSCIENCE;NURSING;OPTICS;PHYSICAL THERAPY","77;27;23;23;16;14;12;11;11;10;8;8;7;7;7;6;6;5;5;5;5;5;5;5","POPULATION;MYOCARDIAL INFARCTION;CANCER;GENE;COHORT;RANDOMIZED CONTROLLED TRIAL;DISEASE;LUNG CANCER;CONFIDENCE INTERVAL;CHEMOTHERAPY;CLINICAL TRIAL;LUNG;MULTIPLE MYELOMA;ASPIRIN;ADVERSE EFFECT;BONE MARROW;HEPATOCELLULAR CARCINOMA;PROSPECTIVE COHORT STUDY;RECEPTOR;REGIMEN;STENT;STROKE (ENGINE);VIRUS","17;12;11;11;10;10;9;9;8;7;6;6;6;5;4;4;4;4;4;4;4;4;4","CLINICAL ENDPOINT;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;PHASES OF CLINICAL RESEARCH;COLORECTAL CANCER;CONVENTIONAL PCI;CLOPIDOGREL;GENOTYPE;HAZARD RATIO;IMMUNOTHERAPY;INTERSTITIAL LUNG DISEASE;MALIGNANT PLEURAL EFFUSION;PROGRESSION-FREE SURVIVAL;A549 CELL;ALLELE;ANTIBIOTIC PROPHYLAXIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;BORTEZOMIB;BRAIN–COMPUTER INTERFACE;CARCINOGENESIS;CARDIAC MAGNETIC RESONANCE IMAGING;CISPLATIN;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CYTOTOXIC T CELL;DEMENTIA;DOCETAXEL;ETOPOSIDE;GENETIC VARIATION;HEPATITIS C VIRUS;INFERIOR FRONTAL GYRUS;KIDNEY TRANSPLANTATION;LENALIDOMIDE;LIVER CANCER;PHENOTYPE;PREMOTOR CORTEX;QUARTILE;REVASCULARIZATION;RITUXIMAB;SORAFENIB;SUPPLEMENTARY MOTOR AREA","8;8;6;6;5;5;4;4;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CRIZOTINIB;ANAPLASTIC LYMPHOMA KINASE;DRUG-ELUTING STENT;KRAS;NIVOLUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;TIMI;CARBOPLATIN;MACE;MICROSATELLITE;MOTOR IMAGERY;NON-SMALL CELL LUNG CANCER (NSCLC);P2Y12;PRASUGREL;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;ALTERNATIVE COMPLEMENT PATHWAY;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;CATECHOL-O-METHYL TRANSFERASE;CD40;CENTRAL VENOUS PRESSURE;CHROMOPHOBE CELL;CXCR4;CYTOREDUCTIVE SURGERY;DIFFUSING CAPACITY;ELLAGITANNIN;ENOS;FICOLIN;FRONTOTEMPORAL DEMENTIA;GENETIC HETEROGENEITY;GENOTYPING;GLUTAMINASE;GLUTAMINE SYNTHETASE;HAPLOTYPE;IBRUTINIB;INFERIOR TEMPORAL GYRUS;INSULIN RECEPTOR;INTERLEUKIN 21;INTRAPERITONEAL CHEMOTHERAPY;KLEBSIELLA PNEUMONIAE;LENTIVIRUS;LEPTOSPIRA INTERROGANS;LOSS OF HETEROZYGOSITY;MEASLES VIRUS;MODIFIED RANKIN SCALE;MONOCLONAL;NATURAL KILLER CELL;NEONATAL RESPIRATORY DISTRESS SYNDROME;ORAL ALLERGY SYNDROME;OSTEOPROTEGERIN;PAZOPANIB;PERITONEAL CARCINOMATOSIS;PHARMACOGENETICS;PLEURAL DISEASE;POMALIDOMIDE;PREMATURE RUPTURE OF MEMBRANES;PROBAND;QUANTITATIVE COMPUTED TOMOGRAPHY;REPRESSOR;REVERSE TRANSCRIPTASE;RIVAROXABAN;RUPTURE OF MEMBRANES;STROKE VOLUME;TICAGRELOR;TICLOPIDINE;TLR2;TOLL-LIKE RECEPTOR;TUMOR SUPPRESSOR GENE;VIROTHERAPY;VOICE PROSTHESIS","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ITALY;ADULT;TREATMENT OUTCOME;PLATELET AGGREGATION INHIBITORS;MYOCARDIAL INFARCTION;TICLOPIDINE;AGED, 80 AND OVER;MULTIPLE MYELOMA;CHRONIC PAIN;RETROSPECTIVE STUDIES;RISK FACTORS;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;LUNG NEOPLASMS","60;48;48;46;37;36;28;21;18;17;16;14;13;12;10;10;10;9;9;9","ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF OTITIS MEDIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;MANAGEMENT OF VALVULAR HEART DISEASE;SMALL CELL LUNG CANCER;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH","7;6;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","TREATMENT;CLINICAL ENDPOINT;CERITINIB;REGIMEN;STROKE (ENGINE);HEPATOCELLULAR CARCINOMA;LIVER CANCER;POSTOPERATIVE PAIN;PROGRESSION-FREE SURVIVAL;REFRACTORY (PLANETARY SCIENCE);TIMI;ALK INHIBITOR;ALK INHIBITORS;ANTICOAGULANT THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BONE MARROW MICROENVIRONMENT;CANGRELOR;CARBOPLATIN;CARDIAC IMAGING;CELL MIGRATION","9;8;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","LUNG CANCER;MULTIPLE MYELOMA;CELL LUNG;DUAL ANTIPLATELET;PATIENTS PTS;PHASE III;ANTIPLATELET THERAPY;BONE MARROW;DRUG-ELUTING STENT;FIRST-LINE TREATMENT;HEPATOCELLULAR CARCINOMA;MYOCARDIAL INFARCTION;NEWLY DIAGNOSED;QUANTITATIVE CT;AB QUANTITATIVE;ACCESS PROGRAMME;ACUTE CORONARY;ANTIBIOTIC PROPHYLAXIS;ARTERY DISEASE;AUTOLOGOUS STEM;BALLOON-EXPANDABLE VALVE;BRIGATINIB BRG;CANCER NSCLC;CANCER SCLC;CELL TRANSPLANTATION;CIRCULATING TUMOR;COGNITIVE IMPAIRMENT;CONSENSUS DOCUMENT;CONTROL STRATEGIES;CORONARY ARTERY","7;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ITALY HEMATOLOGY;HEMATOLOGY UNIT;HR CI;SPONTANEOUS MI;HR CI-;ITALY OSPEDALE;MYOCARDIAL INFARCTION;ROME ITALY;ACUTE CORONARY;ADVERSE EVENTS;CARDIOVASCULAR RISK;DISEASE CONTROL;ITALICA SCORE;ITALY DEPARTMENT;MEDIAN AGE;PATIENTS UNDERGOING;STATISTICALLY SIGNIFICANT;ALK NSCLC;CLINICAL PRACTICE;CLINICAL TRIALS;IV SQ-NSCLC;MEDIAN OS;MGM IV;MORPHINE CONSUMPTION;PATIENTS TREATED;STAGE IV;SURVIVAL OS;BASELINE CHARACTERISTICS;CORONARY INTERVENTION;CORONARY SYNDROME","20;17;10;10;8;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4",35,0.33,11.75,6.5,1.5,3,3,4,2.5,0,2.5,6.5,1,1,7,1,0,1,6,4.75,2,0,0,79.5,79.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5.75,665.82,11.18,14,0.82,275.24,0,1,5,1,8,0,0,2,0,16,1,0,0,0,0,0,0,17,0,0,17,0,0,0,0,0,0,0,0,0,"United States;Japan;Germany;Italy","8;3;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","17;12;6;3;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;ORPHAN DRUG;LUNG;LUNG CANCER;PATIENT SAFETY;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;INFECTIOUS DISEASES;PREVENTION;AGING;BRAIN DISORDERS;CERVICAL CANCER;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS","17;16;13;7;5;4;4;4;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INFECTION","12;1","6.1 PHARMACEUTICALS","15","LUNG CANCER;BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;EAR CANCER;LEUKEMIA / LEUKAEMIA;NASAL CAVITY AND PARANASAL SINUS CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","4;2;2;2;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","9;2;2;1;1;1;1;1",1,4845000,440454.55,4,11,5,1,39,309208.456511256,0.346044869559074,"AMSTERDAM UMC LOCATION VUMC;ATHENS TECHNOLOGY CENTER (GREECE);FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;FRAUNHOFER SOCIETY;HEINRICH HEINE UNIVERSITY DÜSSELDORF;MAASTRO CLINIC;OSPEDALE DI PARMA;POLITECNICO DI MILANO;TECHNICAL UNIVERSITY OF MADRID;UNIVERSITY OF PARMA;VRIJE UNIVERSITEIT AMSTERDAM","1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2015-SINGLE-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES","1;1;1","CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);RARE DISEASES","1;1;1;1","CANCER","1","7.3 MANAGEMENT AND DECISION MAKING","1","HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","1;1;1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1","3 GOOD HEALTH AND WELL BEING","1",16,"PUBLIC LIBRARY OF SCIENCE","16","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4207 SPORTS SCIENCE AND EXERCISE;4613 THEORY OF COMPUTATION;49 MATHEMATICAL SCIENCES;4905 STATISTICS;50 PHILOSOPHY AND RELIGIOUS STUDIES;5003 PHILOSOPHY;5202 BIOLOGICAL PSYCHOLOGY","15;5;5;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LIVER DISEASE;RARE DISEASES;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEPATITIS;HEPATITIS - C;HIV/AIDS;IMMUNIZATION;LIVER CANCER;NEUROSCIENCES;VACCINE RELATED","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1;1","BIOMEDICAL;POPULATION & SOCIETY","1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE;HEALTH SERVICES RESEARCH","2;2;1;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1",NA,NA
"AOU_PARMA",2017,101,17.3762376237624,2.5049504950495,0.207920792079208,0.287128712871287,0.326732673267327,1.45402298850575,1,1.16,1.26923076923077,0.534653465346535,0,61,10,9,13,0.6,0.1,0.09,0.13,24.75,0.839777862265183,6.21908127208481,0.346534653465347,0.900990099009901,0.411,0.31,0.397,0.399,"RICCARDO C. BONADONNA;GIUSEPPE PROCOPIO;UGO DE GIORGI;FRANCO AVERSA;ALESSANDRA DEI;SEBASTIANO BUTI;IVANA ZAVARONI;ALBERTO MENOZZI;VALENTINA SPIGONI;VALENTINA MARCHICA;FABRIZIO ACCARDI;ENRICA TAMBURRINI;CARLO FERRARI;M. RAVIZZA;MARCO VITALE;NICOLA GIULIANI;FEDERICA COSTA;CECILIA CARUBBI;MARCO FLORIDIA;ELEONORA DERLINDATI","8;8;8;7;7;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4","GIOVANNI PAVESI;RICCARDO C. BONADONNA;ALESSANDRA DEI;FRANCO AVERSA;ALFONSO SOLLAMI;IVANA ZAVARONI;CECILIA CARUBBI;VALENTINA SPIGONI;LIBORIO PARRINO;DANIELA GALLI;MARCO VITALE;GIUSEPPE PROCOPIO;UGO DE GIORGI;ELEONORA DERLINDATI;LUIGI CORCIONE;PRISCO MIRANDOLA;FILIPPO DI LELLA;ALBERTO MENOZZI;VALENTINA MARCHICA;FABRIZIO ACCARDI","0.75;0.72;0.65;0.55;0.53;0.53;0.52;0.52;0.5;0.47;0.46;0.44;0.42;0.39;0.39;0.38;0.38;0.37;0.36;0.36","RICCARDO C. BONADONNA;FRANCO AVERSA;ALESSANDRA DEI;SEBASTIANO BUTI;IVANA ZAVARONI;ALBERTO MENOZZI;VALENTINA MARCHICA;FABRIZIO ACCARDI;CARLO FERRARI;MARCO VITALE;NICOLA GIULIANI;CECILIA CARUBBI;FRANCESCA RE;LAURA NOTARFRANCHI;GABRIELE MISSALE;DANIELA GALLI;PRISCO MIRANDOLA;ENRICO MARIA SILINI;GIULIANA GOBBI;ANGELICA BARONE","8;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3","GIOVANNI PAVESI;RICCARDO C. BONADONNA;ALESSANDRA DEI;FRANCO AVERSA;ALFONSO SOLLAMI;IVANA ZAVARONI;CECILIA CARUBBI;LIBORIO PARRINO;DANIELA GALLI;MARCO VITALE;LUIGI CORCIONE;PRISCO MIRANDOLA;FILIPPO DI LELLA;ALBERTO MENOZZI;VALENTINA MARCHICA;FABRIZIO ACCARDI;NICOLA GIULIANI;ARENS TAGA;FULVIO LAURETANI;MARCELLO MAGGIO","0.75;0.72;0.65;0.55;0.53;0.53;0.52;0.5;0.47;0.46;0.39;0.38;0.38;0.37;0.36;0.36;0.36;0.36;0.35;0.35","CARLO FERRARI;BRUCE D. GIVEN;CHING‐LUNG LAI;CHRISTINE I. WOODDELL;DAVID L. LEWIS;DEBORAH CHAVEZ;HENRY LIK‐YUEN CHAN;JAMES HAMILTON;JOHNSON Y.N. LAU;MAN‐FUNG YUEN;ROBERT E. LANFORD;ROBERT G. GISH;STEPHEN LOCARNINI;STEVEN B. KANNER;THOMAS SCHLUEP;ZHAO XU;CAROLINA BONI;MARCO MASSARI;BARBARA MONTANINI;GABRIELE MISSALE","744;387;387;387;387;387;387;387;387;387;387;387;387;387;387;387;329;307;300;280","CARLO FERRARI;CAROLINA BONI;GABRIELE MISSALE;T. GIUBERTI;GRETA ACERBI;MARIA CRISTINA CAVALLO;PAOLA FISICARO;VALERIA BARILI;RICCARDO C. BONADONNA;MARCELLO MAGGIO;TIZIANA MESCHI;DIEGO ARDISSINO;IVANA ZAVARONI;ALESSANDRA DEI;ANTONINO MUSOLINO;NICOLA SVERZELLATI;FRANCO AVERSA;MARIA LUISA CASPANI;FABRIZIO ACCARDI;NICOLA GIULIANI","464;329;280;280;279;279;279;279;213;169;169;145;139;130;116;96;93;85;83;83","RICCARDO C. BONADONNA;SEBASTIANO BUTI;ALBERTO MENOZZI;ALESSANDRA DEI;IVANA ZAVARONI;FRANCO AVERSA;CARLO FERRARI;ANNA MARIA DEGLI ANTONI;ANTONELLA VEZZANI;LUIGI VIGNALI;MARCO VITALE;MARIA BARBAGALLO;MARIA LUISA CASPANI;ANGELICA BARONE;FABIO FACCHINETTI;GABRIELE MISSALE;MARCELLO TISEO;ALESSANDRA COSTA;ALFONSO SOLLAMI;ANTONINO MUSOLINO","7;6;6;6;6;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;ENGINEERING;PHYSICS;BUSINESS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;GEOGRAPHY;PHILOSOPHY","95;27;8;7;6;4;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;NURSING;PSYCHIATRY;CELL BIOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;ANESTHESIA;CANCER RESEARCH;RADIOLOGY;VIROLOGY","76;24;22;19;19;18;17;13;12;9;8;7;7;6;6;6;5;5;5;5","POPULATION;CANCER;GENE;ADVERSE EFFECT;CONFIDENCE INTERVAL;DIABETES MELLITUS;DISEASE;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;IMMUNE SYSTEM;ANTIBODY;BONE MARROW;LUNG;LYMPHOMA;MYOCARDIAL INFARCTION;PROPORTIONAL HAZARDS MODEL;REGIMEN;ALTERNATIVE MEDICINE;CLINICAL TRIAL;COHORT;CORONARY ARTERY DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);MULTIPLE MYELOMA;OBESITY;PREGNANCY;RADIATION THERAPY;RENAL CELL CARCINOMA;RENAL FUNCTION;STEM CELL","17;15;10;9;8;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","HAZARD RATIO;CD8;CLINICAL ENDPOINT;IMMUNOTHERAPY;PLACEBO;VIRAL LOAD;BREAST CANCER;COLORECTAL CANCER;CYTOTOXIC T CELL;INSULIN RESISTANCE;PERCUTANEOUS CORONARY INTERVENTION;RITUXIMAB;T CELL;TYPE 2 DIABETES;VENTILATOR-ASSOCIATED PNEUMONIA;BONE MINERAL;CHROMOSOME;CHRONIC HEPATITIS;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CONVENTIONAL PCI;DOCETAXEL;DYSLIPIDEMIA;FOXP3;GENE EXPRESSION;HEPATITIS B VIRUS;IDIOPATHIC PULMONARY FIBROSIS;INTERIM ANALYSIS;LUNG FUNCTION;MONOCLONAL ANTIBODY;OVERWEIGHT;PHASES OF CLINICAL RESEARCH;PLASMA CELL;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;QUALITY-ADJUSTED LIFE YEAR;SEROLOGY;SUNITINIB;UNIVARIATE ANALYSIS;WEIGHT LOSS","5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;NIVOLUMAB;BENDAMUSTINE;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;CAPECITABINE;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;METASTATIC BREAST CANCER;MONOCLONAL;PAZOPANIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ACUTE CHEST SYNDROME;ADIPONECTIN;ANAPHASE;AROMATASE;BONE HEALTH;CD38;CENTROSOME;CETUXIMAB;CHEMOIMMUNOTHERAPY;CHEMOKINE RECEPTOR;CHILDLESSNESS;CRIZOTINIB;DARATUMUMAB;DNA METHYLATION;DRUG-ELUTING STENT;ENDOTHELIAL PROGENITOR CELL;EPTIFIBATIDE;EXCESS WEIGHT;FLUORESCENCE IN SITU HYBRIDIZATION;GENE EXPRESSION PROFILING;GENE SIGNATURE;GRANZYME B;HBSAG;IBRUTINIB;INCREMENTAL COST-EFFECTIVENESS RATIO;INSULIN GLARGINE;INSULIN RECEPTOR;LAMIVUDINE;LDL RECEPTOR;LEFT ATRIAL APPENDAGE OCCLUSION;LIPOTOXICITY;LIRAGLUTIDE;MACE;MARGINAL ZONE;MEGAKARYOCYTE;METAPHASE;MICROARRAY ANALYSIS TECHNIQUES;MYELOPROLIFERATIVE NEOPLASM;OSTEOPENIA;OSTEOPROTEGERIN;OXALIPLATIN;P2Y12;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PERFORIN;PLK1;POLO-LIKE KINASE;PREDIABETES;PROPHASE;RIBAVIRIN;RNA INTERFERENCE;SEROPREVALENCE;SEX HORMONE-BINDING GLOBULIN;SLEEPWALKING;SPINDLE APPARATUS;SPLENIC MARGINAL ZONE LYMPHOMA;TICLOPIDINE;TIROFIBAN;TRANSCRIPTOME;VENETOCLAX;VILDAGLIPTIN;VINORELBINE","4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ITALY;ADULT;MIDDLE AGED;AGED;HIV INFECTIONS;AGED, 80 AND OVER;DIABETES MELLITUS, TYPE 2;HEPATITIS B, CHRONIC;YOUNG ADULT;BREAST NEOPLASMS;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;ANTI-HIV AGENTS;HYPOGLYCEMIC AGENTS;LIVER;RETROSPECTIVE STUDIES","56;45;43;38;30;27;27;25;17;11;11;11;10;9;9;9;8;8;8;8","HEPATITIS B INFECTION AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;RENAL CELL CARCINOMA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MANAGEMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN ICU PATIENTS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;AUTISM SPECTRUM DISORDERS;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT;CANCER OF UNKNOWN PRIMARY SITE;CARDIOTOXICITY OF CANCER TREATMENTS;CHALLENGES AND OPPORTUNITIES IN TRANSLATIONAL RESEARCH","5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","TREATMENT;REGIMEN;CLINICAL ENDPOINT;BENDAMUSTINE;BIOMARKERS FOR IMMUNOTHERAPY;CROSS-SECTIONAL STUDY;EVEROLIMUS;HEPATITIS B;HIV;RITUXIMAB;VENTILATOR-ASSOCIATED PNEUMONIA;ABIRATERONE ACETATE;ANTIRETROVIRAL THERAPY;ANTIRETROVIRAL TREATMENT;BONE MARROW MICROENVIRONMENT;CABAZITAXEL;CANCER THERAPY;CARDIOVASCULAR RISK ASSESSMENT;DYSLIPIDEMIA;ENZALUTAMIDE","6;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CELL CARCINOMA;METASTATIC RENAL;RENAL CELL;CARCINOMA MRCC;MULTIPLE MYELOMA;PATIENTS PTS;ACCESS PROGRAM;BODY POSITION;BREAST CANCER;CANCER PATIENTS;CROSS-SECTIONAL STUDY;EXPANDED ACCESS;MULTICENTER ITALIAN;PATIENTS TREATED;PROGRAM EAP;SEMIRECUMBENT BODY;ADVANCED BREAST;ADVANCED NSCLC;BONE MARROW;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;CHRONIC HEPATITIS;CLAIMS PROPOSED;CLINICAL OUTCOME;CLINICAL PRACTICE;CLINICAL TRIALS;CONSENSUS DOCUMENT;CORE-URO- STUDY;EMILIA ROMAGNA;EMPHYSEMA EXTENT","5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EFFECTOR CD;MEDIAN AGE;ADVERSE EVENTS;DISEASE CONTROL;NITRIC OXIDE;PTS TREATED;CORONARY HEART;HEART DISEASE;ANTIRETROVIRAL TREATMENT;CD CD;CELL-DERIVED IL-;CHRONIC PAIN;CLINICAL PRACTICE;CONTROL RATE;LIVER DISEASE;OXIDE SIGNALING;TYPE DIABETES;ADVISORY BOARD;BRISTOL-MYERS SQUIB;ENTITY RESPONSIBLE;LEGAL ENTITY;MONTHS CI;PERIPHERAL BLOOD;RENAL FUNCTION;WEIGHT LOSS;ABC PTS;ALK PATIENTS;BREAST CANCER;CONFIDENCE INTERVAL;HR CI","11;11;9;9;9;9;8;8;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5",44,0.44,5.88,7.25,2,1,1,2.25,1,0,1,8,1,1,7.5,0,1,1,4,6.5,3,0,0,89.25,90.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,6.35,727.46,16.67,15,0.56,140,0,0,8,2,8,0,1,8,0,20,6,0,0,0,0,0,0,23,1,3,24,1,0,2,0,0,0,0,0,0,"United States;Italy;Denmark;Germany;Japan;Turkey","13;6;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3209 NEUROSCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","26;15;13;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;LUNG;BIOENGINEERING;COMPARATIVE EFFECTIVENESS RESEARCH;LUNG CANCER;ASSISTIVE TECHNOLOGY;AGING;BREAST CANCER;GENETICS;NEUROSCIENCES;PROSTATE CANCER;UROLOGIC DISEASES;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CARDIOVASCULAR","25;15;15;11;8;7;5;5;5;4;3;3;3;3;3;3;2;2;2;2","CANCER;CARDIOVASCULAR;EYE;MENTAL HEALTH;METABOLIC AND ENDOCRINE;RESPIRATORY","14;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.3 MEDICAL DEVICES","14;2;2;2;2;1","LUNG CANCER;BREAST CANCER;PROSTATE CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA","6;3;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","13;2;2;2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,"PUBLIC LIBRARY OF SCIENCE","21","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4006 COMMUNICATIONS ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;44 HUMAN SOCIETY;4403 DEMOGRAPHY;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3103 ECOLOGY;3105 GENETICS;3204 IMMUNOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4601 APPLIED COMPUTING","19;5;5;5;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;AGING;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIABETES;GENETICS;IMMUNIZATION;KIDNEY DISEASE;NUTRITION;PREVENTION;RARE DISEASES;REHABILITATION","2;2;1;1;1;1;1;1;1;1;1;1;1","METABOLIC AND ENDOCRINE;CANCER;INFLAMMATORY AND IMMUNE SYSTEM","3;2;1","6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;2;1;1;1","CLINICAL;BIOMEDICAL","3;2","CLINICAL MEDICINE AND SCIENCE","10","KIDNEY CANCER","1",NA,NA
"AOU_PARMA",2018,114,16.859649122807,2.51754385964912,0.245614035087719,0.245614035087719,0.447368421052632,1.57692307692308,1.12,1.33333333333333,1.75862068965517,0.62280701754386,1,68,20,6,12,0.6,0.18,0.05,0.11,22.91,0.751019068284607,5.98148148148148,0.368421052631579,0.956140350877193,0.463,0.399,0.365,0.442,"FRANCO AVERSA;MONICA CRUGNOLA;RICCARDO C. BONADONNA;MASSIMILIANO BONIFACIO;ALESSANDRA IURLO;GIUSEPPE A. PALUMBO;ELISABETTA ABRUZZESE;ANTONIO CUNEO;NICOLA SGHERZA;GIANNI BINOTTO;MICAELA BERGAMASCHI;MASSIMO BRECCIA;FRANCESCA PALANDRI;ROBERTO LATAGLIATA;NICOLA POLVERELLI;ALESSIA TIEGHI;COSTANZA BOSI;NICOLA VIANELLI;ALESSANDRO ISIDORI;MICHÈLE CAVO","15;11;9;9;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7","ALARICO ARIANI;GABRIELE MISSALE;RICCARDO C. BONADONNA;FRANCO AVERSA;SILVANO FILICE;ELISABETTA CARIANI;CHIARA DE PANFILIS;ARENS TAGA;MARCO VITALE;FEDERICO MARCHESI;IRENE FLORINDO;MONICA CRUGNOLA;PIETRO MANOTTI;MASSIMO FABI;ANTONIO BALESTRINO;ANTONIO FERRARI;TIZIANA MESCHI;ANDREA TICINESI;NICOLA SVERZELLATI;EMANUELE PRETI","1.38;0.87;0.82;0.81;0.78;0.74;0.71;0.67;0.59;0.5;0.5;0.45;0.45;0.45;0.45;0.45;0.39;0.39;0.38;0.37","FRANCO AVERSA;MONICA CRUGNOLA;RICCARDO C. BONADONNA;ALARICO ARIANI;SEBASTIANO BUTI;DIEGO ARDISSINO;GABRIELE MISSALE;TIZIANA MESCHI;NICOLA SVERZELLATI;BENEDETTA DALLA PALMA;FABRIZIO ACCARDI;FRANCESCA RE;ANDREA TICINESI;UMBERTO MAGGIORE;ALESSANDRA DEI;IVANA ZAVARONI;NICOLA GIULIANI;MARIO SILVA;CHIARA DE PANFILIS;ANTONIO NOUVENNE","15;11;9;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3","ALARICO ARIANI;GABRIELE MISSALE;RICCARDO C. BONADONNA;FRANCO AVERSA;SILVANO FILICE;CHIARA DE PANFILIS;ARENS TAGA;FEDERICO MARCHESI;IRENE FLORINDO;MONICA CRUGNOLA;PIETRO MANOTTI;MASSIMO FABI;ANTONIO BALESTRINO;ANTONIO FERRARI;TIZIANA MESCHI;ANDREA TICINESI;NICOLA SVERZELLATI;CARLO FERRARI;DIEGO ARDISSINO;UMBERTO SCODITTI","1.38;0.87;0.82;0.81;0.78;0.71;0.67;0.5;0.5;0.45;0.45;0.45;0.45;0.45;0.39;0.39;0.38;0.36;0.36;0.33","ANDREA TICINESI;TIZIANA MESCHI;DIEGO ARDISSINO;ANTONIO NOUVENNE;FULVIO LAURETANI;FRANCO AVERSA;ACHIM RITTMEYER;AUGUSTO VILLEGAS;CHRISTINA S. BAIK;CHRISTOPH MEYENBERG;DARIUSZ M. KOWALSKI;DOLORES ISLA;JAVIER DE CASTRO;LISA H. LAM;LUKAS BUBENDORF;MARCELLO TISEO;MICHAEL W. LU;PHILIP BONOMI;PILAR GARRIDO;ROLF A. STAHEL","332;332;302;297;297;210;192;192;192;192;192;192;192;192;192;192;192;192;192;192","DIEGO ARDISSINO;MARCELLO TISEO;GUIDANTONIO MALAGOLI TAGLIAZUCCHI;TIZIANA MESCHI;FRANCO AVERSA;CATERINA CAMINITI;ELISA NICOSIA;GIORGIA DE PAOLI;ANGELA GUIDOROSSI;ANTONIO CROCAMO;FILIPPO PIGAZZANI;FRANCESCA M. NOTARANGELO;GIUSEPPE MAGLIETTA;P BEVILACQUA;BEATRICE PRATI;CLAUDIO TANA;ANGELA GUERRA;ANTONIO NOUVENNE;FRANCA ALLEGRI;FULVIO LAURETANI","302;192;188;186;184;174;174;174;169;169;169;169;169;169;158;158;151;151;151;151","FRANCO AVERSA;MONICA CRUGNOLA;RICCARDO C. BONADONNA;ALARICO ARIANI;DIEGO ARDISSINO;GABRIELE MISSALE;SEBASTIANO BUTI;ALESSANDRA DEI;BENEDETTA DALLA PALMA;FABRIZIO ACCARDI;FRANCESCA RE;NICOLA GIULIANI;CHIARA DE PANFILIS;ANDREA OLIVANI;ANTONINO MUSOLINO;CATERINA CAMINITI;IVANA ZAVARONI;SILVANO FILICE;UMBERTO MAGGIORE;TIZIANA MESCHI","14;10;9;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ECONOMICS;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;GEOGRAPHY;SOCIOLOGY","104;30;13;12;10;8;8;7;6;5;4;4;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;RADIOLOGY;PATHOLOGY;ENDOCRINOLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;NUCLEAR MEDICINE;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CANCER RESEARCH;CARDIOLOGY;OPTICS;PALEONTOLOGY;PHYSICAL THERAPY;INTENSIVE CARE MEDICINE;FOOD SCIENCE;MECHANICAL ENGINEERING;PSYCHIATRY","82;23;20;17;12;11;11;11;10;10;9;9;8;8;8;8;8;7;6;6;6","CANCER;BONE MARROW;GENE;COHORT;DIABETES MELLITUS;DISEASE;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);LUNG;POPULATION;ADVERSE EFFECT;ANTIBODY;CHEMOTHERAPY;CLINICAL TRIAL;HEPATOCELLULAR CARCINOMA;IN VITRO;LYMPHOMA;MAGNETIC RESONANCE IMAGING;HEMATOLOGY;IMMUNE SYSTEM;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;RENAL CELL CARCINOMA;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);STROKE (ENGINE)","18;13;13;9;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","IMMUNOTHERAPY;MYELOFIBROSIS;TYPE 2 DIABETES;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;GENOTYPE;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;GENE EXPRESSION;INTERSTITIAL LUNG DISEASE;MONOCLONAL ANTIBODY;MYELODYSPLASTIC SYNDROMES;NEUTROPENIA;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;RITUXIMAB;WEIGHT LOSS;ACUTE CORONARY SYNDROME;ALLELE;CD8;FOLLICULAR LYMPHOMA;HAZARD RATIO;HEPATITIS B VIRUS;IMATINIB;KIDNEY TRANSPLANTATION;LENALIDOMIDE;MULTICENTER STUDY;MUTATION;PERCUTANEOUS CORONARY INTERVENTION","8;8;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","RUXOLITINIB;NIVOLUMAB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;CD3;DASATINIB;DNA METHYLATION;EXOME SEQUENCING;MONOCLONAL;SINGLE-NUCLEOTIDE POLYMORPHISM;ALTERNATIVE COMPLEMENT PATHWAY;ANAL VERGE;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;AROMATASE;ASYMPTOMATIC BACTERIURIA;BENDAMUSTINE;CD38;CETUXIMAB;CHEMOIMMUNOTHERAPY;COLONOSCOPY;CYP2C19;DARATUMUMAB;DIFFUSING CAPACITY;DNA EXTRACTION;ERLOTINIB;FEBRILE NEUTROPENIA;FICOLIN;FRAMESHIFT MUTATION;GASTRIC BYPASS;GEFITINIB;GENETIC VARIANTS;GENOME EVOLUTION;GENOTYPING;GERIATRIC DEPRESSION SCALE;GERMLINE MUTATION;GLUTAMINASE;GLUTAMINE SYNTHETASE;GRANZYME B;HUMAN GENOME;IMATINIB MESYLATE;INCRETIN;INSULIN GLARGINE;INTERNATIONAL PROGNOSTIC INDEX;INTRAOPERATIVE MRI;KRAS;LAMIVUDINE;LEFT ATRIAL APPENDAGE OCCLUSION;LOSS FUNCTION;LYSO-;MEK INHIBITOR;MICROSATELLITE;MORBIDLY OBESE;MULTICENTER TRIAL;MYCOBACTERIUM KANSASII;NATURAL KILLER CELL;NILOTINIB;PAZOPANIB;PERFORIN;PRASUGREL;PREDIABETES;QUANTITATIVE COMPUTED TOMOGRAPHY;RIGHT RENAL ARTERY;SPLENIC MARGINAL ZONE LYMPHOMA;STEREOTACTIC RADIOTHERAPY;TICAGRELOR;TOLL-LIKE RECEPTOR;TRANSPOSABLE ELEMENT;TRIPLE-NEGATIVE BREAST CANCER;TUMOR IMMUNOLOGY;TUMOR-INFILTRATING LYMPHOCYTES;UNDERWEIGHT","7;5;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;DIABETES MELLITUS, TYPE 2;AGED, 80 AND OVER;ITALY;RETROSPECTIVE STUDIES;BRAIN NEOPLASMS;PRIMARY MYELOFIBROSIS;YOUNG ADULT;ADOLESCENT;TREATMENT OUTCOME;BONE NEOPLASMS;CARCINOMA, RENAL CELL;KIDNEY CALCULI;KIDNEY NEOPLASMS","58;56;40;37;28;28;25;21;13;12;12;11;11;10;9;8;7;7;7;7","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CANCER IMMUNOTHERAPY;LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATOCELLULAR CARCINOMA;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC STUDIES AND ASSOCIATION ANALYSES;GLIOMAS;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;SUICIDAL BEHAVIOR AND PREVENTION STRATEGIES","8;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MYELOFIBROSIS;RUXOLITINIB;RUXOLITINIB THERAPY;CLINICAL ENDPOINT;HEMATOLOGY;STROKE (ENGINE);CARDIAC IMAGING;CARDIOVASCULAR MRI;COLLATION;DISCONTINUATION;EMOTION REGULATION;EXPANDED ACCESS;HEALTH CLAIMS;INTENSITY-MODULATED RADIOTHERAPY;INTERSTITIAL LUNG DISEASE;NUTRITION LABELING;TREATMENT;TYPE 2 DIABETES;BIOMARKERS FOR IMMUNOTHERAPY;BONE MARROW MICROENVIRONMENT","7;7;7;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2","TYPE DIABETES;CELL CARCINOMA;CLAIMED EFFECTS;EFFECTS OUTCOME;HEALTH CLAIMS;HEPATOCELLULAR CARCINOMA;METASTATIC RENAL;OUTCOME VARIABLES;PATIENTS TREATED;RENAL CELL;BREAST CANCER;ELDERLY PATIENTS;INTERSTITIAL LUNG;MULTICENTER STUDY;MULTIPLE MYELOMA;MYELOFIBROSIS TREATED;MYELOMA PATIENTS;REJECTION SENSITIVITY;ACCESS PROGRAM;ACUTE CORONARY;ADVERSE EVENTS;ATRIAL APPENDAGE;BARIATRIC SURGERY;BLACK AFRICAN;CANCER PATIENTS;CARCINOMA MRCC;CLINICAL OUTCOME;DISEASE RELATED;EXPANDED ACCESS;FONDAZIONE ITALIANA","6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;RESEARCH FUNDING;ADVISORY BOARD;BOARD SPEAKERS;CD CELLS;MM PATIENTS;RUX START;COMMITTEES RESEARCH;FUNDING SPEAKERS;HR CI;TYPE DIABETES;COMMITTEES SPEAKERS;HEALTH CLAIMS;HONORARIA SPEAKERS;POST-ET MF;BONE MARROW;BREAST CANCER;BUREAU GILEAD;BUREAU JANSSEN;CONFIDENCE INTERVAL;OVERT PMF;ASYMPTOMATIC BACTERIURIA;BONE DISEASE;CELGENE HONORARIA;COMPUTED TOMOGRAPHY;ENTITY RESPONSIBLE;GILEAD HONORARIA","74;74;62;43;29;19;16;16;12;12;11;10;10;10;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7",51,0.45,13.39,13,2,1,0,2.25,1,0,1,14,1,1,14,1,1.75,2.5,7,8,8.25,0,0,93.5,93.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,5.44,828.74,16.09,19,0.68,210.57,0,0,10,0,10,0,2,6,0,23,5,0,0,0,0,0,0,25,1,2,27,0,0,0,1,0,0,0,0,0,"United States;Italy;Japan;United Kingdom;Germany;Switzerland","12;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","28;18;17;5;3;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;LUNG;BREAST CANCER;LUNG CANCER;PEDIATRIC;PREVENTION;BRAIN DISORDERS;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;ORPHAN DRUG;AGING;BIOMEDICAL IMAGING;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE","27;22;19;9;8;6;4;4;4;4;3;3;3;3;3;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","15;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","20;2;1;1;1;1;1;1","BREAST CANCER;LUNG CANCER;LEUKEMIA / LEUKAEMIA;KIDNEY CANCER;PROSTATE CANCER;ANAL CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER","4;4;3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","12;2;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS","14;12;1","31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;44 HUMAN SOCIETY;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;4206 PUBLIC HEALTH;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4301 ARCHAEOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;37 EARTH SCIENCES;3705 GEOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;4401 ANTHROPOLOGY;4403 DEMOGRAPHY","15;11;11;8;7;4;4;3;3;3;2;1;1;1;1;1;1;1;1;1","KIDNEY DISEASE;GENETICS;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOTECHNOLOGY;CLINICAL RESEARCH;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HUMAN GENOME;LIVER CANCER;LIVER DISEASE;ORGAN TRANSPLANTATION;PREVENTION;RARE DISEASES;REHABILITATION;STROKE;TRANSPLANTATION","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;RENAL AND UROGENITAL;STROKE","1;1;1","7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;6.7 PHYSICAL","3;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","5;1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","7;4","NOT SITE-SPECIFIC CANCER;LIVER CANCER","4;1",NA,NA
"AOU_PARMA",2019,147,19.312925170068,2,0.210884353741497,0.163265306122449,0.238095238095238,1.58918918918919,1.03333333333333,1.2,1.06060606060606,0.571428571428571,1,77,27,8,16,0.52,0.18,0.05,0.11,20.14,0.82834850243383,5.62371888726208,0.394557823129252,0.91156462585034,0.461,0.415,0.344,0.389,"FRANCESCA RE;MONICA CRUGNOLA;MARCELLO TISEO;MASSIMILIANO BONIFACIO;ALESSANDRA IURLO;GIANNI BINOTTO;IAN W. FLINN;ROBERTO LATAGLIATA;MARIO TIRIBELLI;ANTONIO PINTO;MICHÈLE CAVO;MASSIMO BRECCIA;ROSALIA ALOE;STACEY KALAMBAKAS;PHILLIP SCHEINBERG;KOJI IZUTSU;JOHN P. LEONARD;NATHAN FOWLER;PIERRE FUSTIER;ELISABETTA ABRUZZESE","15;14;13;11;10;9;8;8;8;8;8;8;7;7;7;7;7;7;7;7","WALTER SERRA;MARCELLO TISEO;PAOLO CRAVEDI;CHIARA CANTARELLI;FRANCESCA RE;ROSALIA ALOE;TIZIANA MESCHI;ANDREA TICINESI;CARLO CAFFARELLI;CARLA MASTRORILLI;ANGELICA SANTORO;ENRICO FIACCADORI;ANTONIO NOUVENNE;FULVIO LAURETANI;CRISTINA MANCINI;MONICA CRUGNOLA;CLAUDIO TANA;GIROLAMO CRISI;IAN W. FLINN;UMBERTO MAGGIORE","1;1;0.93;0.93;0.75;0.71;0.65;0.65;0.57;0.57;0.53;0.49;0.49;0.49;0.48;0.47;0.42;0.41;0.4;0.38","FRANCESCA RE;MONICA CRUGNOLA;MARCELLO TISEO;ROSALIA ALOE;NICOLA SVERZELLATI;TIZIANA MESCHI;ANDREA TICINESI;CHIARA CANTARELLI;ENRICO FIACCADORI;ANTONIO NOUVENNE;RICCARDO C. BONADONNA;UMBERTO MAGGIORE;LUCA AMPOLLINI;FULVIO LAURETANI;NICOLA GIULIANI;CRISTINA MANCINI;ALARICO ARIANI;DANIELE SANTILLI;CARLO CAFFARELLI;SEBASTIANO BUTI","15;14;13;7;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3","WALTER SERRA;MARCELLO TISEO;CHIARA CANTARELLI;FRANCESCA RE;ROSALIA ALOE;TIZIANA MESCHI;ANDREA TICINESI;CARLO CAFFARELLI;CARLA MASTRORILLI;ANGELICA SANTORO;ENRICO FIACCADORI;ANTONIO NOUVENNE;FULVIO LAURETANI;CRISTINA MANCINI;MONICA CRUGNOLA;CLAUDIO TANA;GIROLAMO CRISI;UMBERTO MAGGIORE;NICOLA SVERZELLATI;SILVANO FILICE","1;1;0.93;0.75;0.71;0.65;0.65;0.57;0.57;0.53;0.49;0.49;0.49;0.48;0.47;0.42;0.41;0.38;0.37;0.37","FRANCESCA RE;FEDERICO CAPPUZZO;DIANA GIANNARELLI;IAN W. FLINN;LAURA FOGLIATTO;ADRIANA SCHELIGA;ANTONIO PINTO;CHENGQING WU;FRITZ OFFNER;GRZEGORZ S. NOWAKOWSKI;JOHN P. LEONARD;KOJI IZUTSU;MAREK TRNĚNÝ;NATHAN FOWLER;PHILLIP SCHEINBERG;PIERRE FUSTIER;STACEY KALAMBAKAS;JOHN G. GRIBBEN;CLÁUDIA MOREIRA;DAVID LIU","428;354;342;332;332;331;331;331;331;331;331;331;331;331;331;331;331;320;317;317","FRANCESCA RE;MARCELLO TISEO;ANDREA TICINESI;ANTONIO NOUVENNE;TIZIANA MESCHI;RICCARDO C. BONADONNA;GIOVANNI MARIA ROSSI;ROSALIA ALOE;DIEGO ARDISSINO;SEBASTIANO BUTI;ERMINIA RIDOLO;ANDREA VECCHI;ARIANNA ALFIERI;CARLO FERRARI;CAROLINA BONI;DILETTA LACCABUE;FEDERICA BRILLO;GRETA ACERBI;MARZIA ROSSI;PAOLA FISICARO","428;258;201;184;184;180;174;134;121;120;119;114;114;114;114;114;114;114;114;114","FRANCESCA RE;MONICA CRUGNOLA;MARCELLO TISEO;ROSALIA ALOE;CHIARA CANTARELLI;ANDREA TICINESI;ANTONIO NOUVENNE;TIZIANA MESCHI;RICCARDO C. BONADONNA;GIROLAMO CRISI;MARTINA DI PIETRO;ALARICO ARIANI;ANGELICA BARONE;CRISTINA MANCINI;DANIELE SANTILLI;FLAVIO MOZZANI;FULVIO LAURETANI;MARIELLA DIPALO;SIMONA PUPO;UMBERTO MAGGIORE","15;14;9;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATHEMATICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;GEOLOGY;PHILOSOPHY","142;39;13;10;9;7;6;5;4;4;4;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;ENDOCRINOLOGY;CANCER RESEARCH;PALEONTOLOGY;PSYCHIATRY;CARDIOLOGY;PEDIATRICS;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;STATISTICS;ASTROBIOLOGY;FAMILY MEDICINE;MECHANICAL ENGINEERING;NURSING;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;UROLOGY","119;46;35;34;25;25;17;17;15;12;12;10;10;10;9;9;8;6;6;5;5;5;5;5;5;5","CANCER;CHEMOTHERAPY;POPULATION;LYMPHOMA;CLINICAL TRIAL;DISEASE;GENE;ANTIBODY;CONFIDENCE INTERVAL;ALTERNATIVE MEDICINE;BONE MARROW;COHORT;TRANSPLANTATION;IMMUNE SYSTEM;LUNG CANCER;MULTIPLE MYELOMA;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL","28;20;15;13;12;12;12;11;11;10;10;10;10;9;9;9;9;9;9;9","CLINICAL ENDPOINT;RITUXIMAB;HAZARD RATIO;IMATINIB;PLACEBO;LENALIDOMIDE;NEUTROPENIA;ADENOCARCINOMA;BREAST CANCER;IMMUNOTHERAPY;MYELOFIBROSIS;FOLLICULAR LYMPHOMA;MALIGNANT PLEURAL EFFUSION;PHENOTYPE;RANDOMIZATION;TROPONIN I;COLORECTAL CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;GEMCITABINE;GESTATION;HEAD AND NECK CANCER;IMMUNOGLOBULIN E;INTERSTITIAL LUNG DISEASE;KIDNEY TRANSPLANTATION;MONOCLONAL ANTIBODY;MUTATION;PROSTATE CANCER;TYPE 2 DIABETES;UNIVARIATE ANALYSIS","15;10;8;7;7;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CRIZOTINIB;IMATINIB MESYLATE;NIVOLUMAB;DASATINIB;MONOCLONAL;NILOTINIB;ROS1;RUXOLITINIB;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN RECEPTOR;ANTHRACYCLINE;CHEMOIMMUNOTHERAPY;CLINICAL PHENOTYPE;ENDOVASCULAR ANEURYSM REPAIR;OXALIPLATIN;RIBAVIRIN;ACE INHIBITOR;ADJUVANT CHEMOTHERAPY;ALLERGEN IMMUNOTHERAPY;ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;CAREGIVER BURDEN;CD38;CHEMOKINE RECEPTOR;CLAUDICATION;DNA METHYLATION;DONOR SPECIFIC ANTIBODIES;EARLY PREGNANCY LOSS;FAS LIGAND;FAS RECEPTOR;GENE EXPRESSION PROFILING;GENOTYPE-PHENOTYPE DISTINCTION;GERIATRIC DEPRESSION SCALE;GESTATIONAL DIABETES;GLUTAMINASE;GLUTAMINOLYSIS;HBSAG;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HISTONE DEACETYLASE;IMMUNOGLOBULIN D;INSULIN SENSITIVITY;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;KIDNEY DONATION;KRAS;LEFT ATRIAL APPENDAGE OCCLUSION;LYMPHOBLASTIC LYMPHOMA;MARGINAL ZONE;MEAN ARTERIAL PRESSURE;MEGAKARYOCYTE;MEPOLIZUMAB;MILK ALLERGY;MODIFIED RANKIN SCALE;MOTOR SYMPTOMS;MYELOPROLIFERATIVE NEOPLASM;NAB-PACLITAXEL;NUCLEOTIDE EXCISION REPAIR;OMALIZUMAB;PEMBROLIZUMAB;PEMETREXED;PNEUMOCOCCAL INFECTIONS;PNEUMOCOCCAL VACCINE;PROTEIN KINASE DOMAIN;QUANTITATIVE COMPUTED TOMOGRAPHY;RAR-RELATED ORPHAN RECEPTOR GAMMA;RELATIVE SURVIVAL;RIGHT CORONARY ARTERY;SERINE PROTEASE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAXANE;TICAGRELOR;TIMI;UROTHELIAL CANCER;UROTHELIAL CARCINOMA;VINCRISTINE;VITAMIN K ANTAGONIST;WEIGHT CHANGE","4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;AGED, 80 AND OVER;ITALY;LUNG NEOPLASMS;YOUNG ADULT;CARCINOMA, NON-SMALL-CELL LUNG;ADOLESCENT;NEOPLASM RECURRENCE, LOCAL;RETROSPECTIVE STUDIES;PROGNOSIS;STROKE;POSTOPERATIVE COMPLICATIONS;DIABETES MELLITUS, TYPE 2;TROPONIN I","78;68;59;58;43;39;30;28;25;18;17;15;14;13;13;12;12;11;10;10","LYMPHOID NEOPLASMS;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;SCHIZOPHRENIA RESEARCH AND TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLIOMAS","10;7;6;5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;DISCONTINUATION;BIOMARKER ANALYSIS;REFRACTORY (PLANETARY SCIENCE);RITUXIMAB;STROKE (ENGINE);TREATMENT;TREATMENT OUTCOMES;GOLD STANDARD (TEST);IMATINIB MESYLATE;MANTLE CELL LYMPHOMA;TREATMENT DISCONTINUATION;ANTICOAGULANT THERAPY;CANCER IMAGING;CARDIOVASCULAR EVALUATION;FOLLICULAR LYMPHOMA;HEMATOLOGY;MOLECULAR RESPONSE;MYELOFIBROSIS;RUXOLITINIB","14;9;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","PHASE II;CHRONIC MYELOID;LUNG CANCER;MYELOID LEUKEMIA;CELL LUNG;MULTIPLE MYELOMA;PATIENTS TREATED;RANDOMIZED TRIAL;ACUTE KIDNEY;CANCER PATIENTS;CML PATIENTS;FONDAZIONE ITALIANA;II RANDOMIZED;INDOLENT NHL;ITALIANA LINFOMI;KIDNEY INJURY;LENALIDOMIDERITUXIMAB RSUPSUP;LEUKEMIA PATIENTS;LUNG DISEASE;MARGINAL ZONE;MULTICENTER STUDY;NECK CANCER;OBSERVATIONAL STUDY;PHASE III;ACCESS PROGRAM;ADVANCED NON-SMALL;ALECTINIB VERSUS;ANAPLASTIC LYMPHOMA;ATRIAL FIBRILLATION;AUGMENT PHASE","8;7;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;CONSULTANCY HONORARIA;RESEARCH FUNDING;HONORARIA INCYTE;NOVARTIS HONORARIA;INCYTE HONORARIA;HONORARIA NOVARTIS;COMMITTEES SPEAKERS;PFIZER HONORARIA;HONORARIA PFIZER;BMS HONORARIA;NOVARTIS CONSULTANCY;ACCOMMODATION EXPENSES;ADVISORY CONSULTANCY;INCYTE CONSULTANCY;TRAVEL ACCOMMODATION;MG OAD;HONORARIA BMS;COMMITTEES RESEARCH;HR CI;PFIZER CONSULTANCY;MEDIAN AGE;CELGENE HONORARIA;FUNDING SPEAKERS;BUREAU EXPERT;CONSULTANCY NOVARTIS;CONSULTANCY SPEAKERS","140;140;97;67;62;47;45;41;40;38;33;30;29;23;21;20;20;20;20;19;18;17;15;15;14;13;13;12;12;12",60,0.41,10.15,10,1,1,0,7,3.5,1,1.5,11,1,0,8.75,0,0,1.75,6,7,8.25,0,0,56,56,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,5.81,850.33,24,32,0.76,259.62,1,1,10,3,17,0,2,8,0,37,5,0,0,0,0,0,0,38,3,1,42,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;France;Switzerland","31;11;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","42;30;21;11;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;LUNG;LUNG CANCER;PATIENT SAFETY;ORPHAN DRUG;BREAST CANCER;DIGESTIVE DISEASES;GENETICS;NEUROSCIENCES;HEMATOLOGY;BRAIN DISORDERS;COLO-RECTAL CANCER;HUMAN GENOME;LYMPHOMA;PREVENTION;BIOMEDICAL IMAGING;ESTROGEN","42;34;32;15;12;10;10;8;7;7;7;6;5;3;3;3;3;3;2;2","CANCER;ORAL AND GASTROINTESTINAL;RESPIRATORY;CARDIOVASCULAR;NEUROLOGICAL;RENAL AND UROGENITAL","28;2;2;1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.7 PHYSICAL","32;5;4;4;3;2;1;1;1;1;1;1","LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;PHARYNGEAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;STOMACH CANCER","11;7;3;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","23;7;4;3;2;2;1",1,0,0,6,4,2,1,13,221974.616363636,0.662237882908135,"ISTITUTO NAZIONALE GENETICA MOLECOLARE;NEWCASTLE UNIVERSITY;OSPEDALE DI PARMA;UNITELMA SAPIENZA UNIVERSITY","1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;LIVER CANCER;LIVER DISEASE;RARE DISEASES","1;1;1;1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","LIVER CANCER","1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1","A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",21,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS;MENDELEY DATA;SAGE JOURNALS;TAYLOR & FRANCIS GROUP","9;4;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3213 PAEDIATRICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4207 SPORTS SCIENCE AND EXERCISE;5202 BIOLOGICAL PSYCHOLOGY;3107 MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS;51 PHYSICAL SCIENCES;5203 CLINICAL AND HEALTH PSYCHOLOGY","29;8;8;5;5;4;2;2;2;2;1;1;1;1;1;1;1","CANCER;LUNG;LUNG CANCER;CLINICAL RESEARCH;RARE DISEASES;BRAIN DISORDERS;CEREBRAL PALSY;MENTAL HEALTH;NEUROSCIENCES;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PHYSICAL REHABILITATION;REHABILITATION;BIOTECHNOLOGY;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;GENETICS","5;5;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL;RESPIRATORY;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","8;2;2;2;1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","3;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","3;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","14;3","LUNG CANCER;EAR CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;NOT SITE-SPECIFIC CANCER;NON-HODGKIN'S LYMPHOMA","6;4;4;4;4;4;4;4;2;1",NA,NA
"AOU_PARMA",2020,171,19.8830409356725,2.74269005847953,0.245614035087719,0.286549707602339,0.280701754385965,2.09375,1.27272727272727,1.88461538461538,1.37142857142857,0.567251461988304,0,90,43,10,13,0.53,0.25,0.06,0.08,24.67,0.979123736224159,6.33761232349165,0.245614035087719,0.947368421052632,0.503,0.338,0.39,0.354,"ENRICO FIACCADORI;MONICA CRUGNOLA;LORENZO PELIZZA;SIMONA PUPO;ILARIA SCAZZA;MICHELE POLETTI;ANDREA RABALLO;LUIGI ROCCO CHIRI;NICOLA GIULIANI;SILVIA AZZALI;ANTONIO NOUVENNE;FEDERICA PATERLINI;MASSIMILIANO BONIFACIO;MICHÈLE CAVO;SARA GARLASSI;ELISABETTA PARENTI;VALENTINA MARCHICA;ANDREA TICINESI;GIUSEPPE REGOLISTI;GIOVANNI CAOCCI","16;12;10;10;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7","ENRICO FIACCADORI;LORENZO PELIZZA;SIMONA PUPO;ILARIA SCAZZA;MICHELE POLETTI;ANDREA RABALLO;LUIGI ROCCO CHIRI;SILVIA AZZALI;ELISABETTA PARENTI;FEDERICA PATERLINI;SARA GARLASSI;GIOVANNI MARIA ROSSI;ANTONIO NOUVENNE;GIUSEPPE REGOLISTI;GIOVANNI PEPE;ANDREA TICINESI;ISABELLA PISANI;NICOLA GIULIANI;LIVIA RUFFINI;FRANCESCA DI MARIO","1.63;1.47;1.47;0.97;0.97;0.97;0.97;0.97;0.88;0.86;0.86;0.79;0.77;0.77;0.77;0.73;0.73;0.69;0.68;0.66","ENRICO FIACCADORI;MONICA CRUGNOLA;SIMONA PUPO;NICOLA GIULIANI;ANTONIO NOUVENNE;ELISABETTA PARENTI;ANDREA TICINESI;GIUSEPPE REGOLISTI;TOMMASO DI MOTTA;ISABELLA PISANI;TIZIANA MESCHI;FRANCESCA DI MARIO;BENEDETTA DALLA PALMA;GIOVANNI MARIA ROSSI;CHIARA CANTARELLI;PAOLO GRECO;GABRIELE MISSALE;R. MENOZZI;RICCARDO C. BONADONNA;LUCIO MANENTI","16;12;10;9;8;8;7;7;6;6;6;6;6;6;6;6;6;6;5;5","ENRICO FIACCADORI;SIMONA PUPO;ELISABETTA PARENTI;GIOVANNI MARIA ROSSI;ANTONIO NOUVENNE;GIUSEPPE REGOLISTI;GIOVANNI PEPE;ANDREA TICINESI;ISABELLA PISANI;NICOLA GIULIANI;LIVIA RUFFINI;FRANCESCA DI MARIO;PAOLO GRECO;FRANCESCO PEYRONEL;LUCIO MANENTI;TOMMASO DI MOTTA;GUIDANTONIO MALAGOLI TAGLIAZUCCHI;NICOLA SVERZELLATI;GIORGIO BALDARI;SILVIA MIGLIARI","1.63;1.47;0.88;0.79;0.77;0.77;0.77;0.73;0.73;0.69;0.68;0.66;0.66;0.65;0.63;0.61;0.58;0.58;0.58;0.58","SANDRA ROSSI;DAVIDE CHIUMELLO;LUCIANO GATTINONI;JOAQUÍN MANRIQUE;PAOLO CRAVEDI;GIANLUIGI ZAZA;ANTONIO NOUVENNE;BARBARA MURPHY;MEREDITH HAVERLY;UMBERTO MAGGIORE;LEONARDO V. RIELLA;ANDREA TICINESI;TIZIANA MESCHI;AILEEN X. WANG;ANDREA RANGHINO;DOLORES REDONDO‐PACHÓN;ENVER AKALIN;HET PATEL;ILARIA GANDOLFINI;LAURA GOLDFARB CYRINO","748;678;643;609;609;470;452;413;413;401;394;387;385;352;352;352;352;352;352;352","SANDRA ROSSI;ANTONIO NOUVENNE;UMBERTO MAGGIORE;ANDREA TICINESI;ILARIA GANDOLFINI;TIZIANA MESCHI;CHIARA CANTARELLI;ALBERTO PARISE;DIEGO ARDISSINO;CLAUDIO FELICIANI;ENRICO FIACCADORI;FULVIO LAURETANI;MARCELLO MAGGIO;GABRIELE MISSALE;NICOLA SVERZELLATI;SIMONA PUPO;BEATRICE PRATI;ELENA BIGNAMI;MARCO BACIARELLO;ELENA SACCANI","678;452;401;387;352;283;268;243;221;214;210;193;191;170;156;147;141;141;141;125","ENRICO FIACCADORI;MONICA CRUGNOLA;SIMONA PUPO;NICOLA GIULIANI;ANTONIO NOUVENNE;ELISABETTA PARENTI;ANDREA TICINESI;GIUSEPPE REGOLISTI;GIOVANNI MARIA ROSSI;TOMMASO DI MOTTA;ISABELLA PISANI;CHIARA CANTARELLI;FRANCESCA DI MARIO;PAOLO GRECO;CATERINA MACCARI;DIEGO ARDISSINO;FRANCESCO PEYRONEL;LUCIO MANENTI;MARCELLO TISEO;RICCARDO C. BONADONNA","16;12;10;9;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;SOCIOLOGY;BUSINESS;MATERIALS SCIENCE;MATHEMATICS;GEOGRAPHY;HISTORY","162;38;16;10;9;9;8;5;4;4;4;3;3;3;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;GENETICS;ENDOCRINOLOGY;GASTROENTEROLOGY;RADIOLOGY;CANCER RESEARCH;PSYCHIATRY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;CARDIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;VIROLOGY;CLINICAL PSYCHOLOGY;NUCLEAR MEDICINE;OPTICS;PALEONTOLOGY","125;38;35;32;31;19;18;18;18;14;14;13;13;12;12;12;11;9;9;8;8","DISEASE;CANCER;GENE;BONE MARROW;IMMUNE SYSTEM;ANTIBODY;CLINICAL TRIAL;COHORT;POPULATION;DIABETES MELLITUS;KIDNEY;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;MULTIPLE MYELOMA;CONFIDENCE INTERVAL;DIALYSIS;INCIDENCE (GEOMETRY);LYMPHOMA;PSYCHOSIS;CHEMOTHERAPY;HEMODIALYSIS;PNEUMONIA;RANDOMIZED CONTROLLED TRIAL;STROKE (ENGINE)","30;21;15;14;14;12;12;12;12;11;11;10;9;9;8;8;8;8;8;7;7;7;7;7","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;CD8;2019-20 CORONAVIRUS OUTBREAK;IMMUNOTHERAPY;MONOCLONAL ANTIBODY;GLOMERULONEPHRITIS;MUTATION;MYELODYSPLASTIC SYNDROMES;MYELOFIBROSIS;PRODROME;AUTOANTIBODY;BREAST CANCER;CD14;HAZARD RATIO;INTERSTITIAL LUNG DISEASE;NEPHROPATHY;NEUTROPENIA;OSTEOARTHRITIS;PHASES OF CLINICAL RESEARCH;POLYCYSTIC KIDNEY DISEASE;PROGRESSION-FREE SURVIVAL;PROTEINURIA;TYPE 2 DIABETES","13;10;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);MONOCLONAL;EXOME SEQUENCING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;RUXOLITINIB;BONE MARROW FAILURE;IMMUNE CHECKPOINT;METHYLTRANSFERASE;NIVOLUMAB;PHILADELPHIA CHROMOSOME;TUMOR-INFILTRATING LYMPHOCYTES;ABCIXIMAB;ALTERNATIVE COMPLEMENT PATHWAY;ANCA-ASSOCIATED VASCULITIS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTHRACYCLINE;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIRETROVIRAL THERAPY;ANTISENSE RNA;AORTIC VALVULOPLASTY;ATRIAL APPENDAGE;ATRIAL TACHYCARDIA;ATYPICAL HEMOLYTIC UREMIC SYNDROME;AXITINIB;BONE METASTASIS;BRENTUXIMAB VEDOTIN;BRUTON'S TYROSINE KINASE;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CD3;CD38;CHEMOKINE RECEPTOR;CHROMOPHOBE CELL;COPY-NUMBER VARIATION;CRIZOTINIB;CROSSOVER STUDY;CRYSTALLURIA;CXCR4;DAPAGLIFLOZIN;DARATUMUMAB;DASATINIB;DECLARATION OF HELSINKI;DIFFUSING CAPACITY;DNA METHYLATION;DOPAMINE AGONIST;ECULIZUMAB;EMPAGLIFLOZIN;FOLINIC ACID;FOOD ALLERGENS;FREE THYROXINE;GENOMICS;GERMLINE MUTATION;GLOMERULOPATHY;GLOMERULOSCLEROSIS;GLUCOSE TOLERANCE TEST;GLUTAMINE SYNTHETASE;HELSINKI DECLARATION;IBRUTINIB;IMATINIB MESYLATE;IMPAIRED GLUCOSE TOLERANCE;INSULIN GLARGINE;INSULIN RESPONSE;INSULIN SENSITIVITY;IRINOTECAN;KARYOTYPE;LEFT ATRIAL APPENDAGE OCCLUSION;LIPOTOXICITY;LITHIUM CARBONATE;LONG NON-CODING RNA;LOSS OF HETEROZYGOSITY;LYMPHOBLASTIC LYMPHOMA;LYMPHOPLASMACYTIC LYMPHOMA;MAMMOGRAPHY;MEDULLARY CARCINOMA;MEMBRANOUS NEPHROPATHY;METASTATIC BREAST CANCER;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MICROSCOPIC POLYANGIITIS;MISSENSE MUTATION;MODIFIED RANKIN SCALE;NONTUBERCULOUS MYCOBACTERIA;ONCOMIR;OXALIPLATIN;P22PHOX;PEMBROLIZUMAB;PEMPHIGUS FOLIACEUS;PERCUTANEOUS ETHANOL INJECTION;PKD1;PODOCYTE;PROTEINASE 3;RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS;RECTAL EXAMINATION;RENAL ONCOCYTOMA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;RNA INTERFERENCE;ROS1;ROSEBURIA;SHOTGUN PROTEOMICS;SOMATROPIN;SUICIDAL IDEATION;SUICIDE ATTEMPT;TAXANE;TIROFIBAN;TRABECTEDIN;TRANSCRIPTOME;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;VIROTHERAPY;VO2 MAX;WHOLE GENOME SEQUENCING","13;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;ITALY;MIDDLE AGED;AGED;ADULT;PNEUMONIA, VIRAL;CORONAVIRUS INFECTIONS;PSYCHOTIC DISORDERS;RETROSPECTIVE STUDIES;ATRIAL FIBRILLATION;AGED, 80 AND OVER;TREATMENT OUTCOME;ADOLESCENT;FOLLOW-UP STUDIES;YOUNG ADULT;COVID-19;STROKE","86;85;54;50;38;36;31;28;21;20;18;18;17;16;16;14;14;13;11;11","CORONAVIRUS DISEASE 2019;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SCHIZOPHRENIA RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;ATRIAL FIBRILLATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;NATURAL KILLER CELLS IN IMMUNITY;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;CANCER IMMUNOTHERAPY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT","5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2","CLINICAL ENDPOINT;PANDEMIC;TREATMENT;INFARCTION TREATMENT;STROKE (ENGINE);2019-20 CORONAVIRUS OUTBREAK;CARDIAC ULTRASOUND;INTERQUARTILE RANGE;NK CELL ACTIVATION;PRODROME;RENAL REPLACEMENT THERAPY;RUXOLITINIB THERAPY;DIABETES;DIALYSIS;EXTRACORPOREAL;HEMATOLOGY;HEMODIALYSIS;LUNG ULTRASOUND;NEPHROLOGY;NK CELL RECOGNITION","10;8;8;7;7;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3","MULTIPLE MYELOMA;CELL CARCINOMA;BONE MARROW;CRITICALLY ILL;EPISODE PSYCHOSIS;HEPATOCELLULAR CARCINOMA;PHASE II;RETROSPECTIVE STUDY;ATRIAL FIBRILLATION;CHRONIC MYELOID;CITRATE ANTICOAGULATION;COVID- OUTBREAK;COVID- PNEUMONIA;ILL PATIENTS;LEUKEMIA PATIENTS;LONGITUDINAL STUDY;LOW-EFFICIENCY DIALYSIS;LUNG CANCER;METASTATIC RENAL;MULTICENTER STUDY;MYELODYSPLASTIC SYNDROMES;MYELOID LEUKEMIA;PATIENTS PTS;REGIONAL CITRATE;RENAL CELL;SUSTAINED LOW-EFFICIENCY;SYSTEMIC SCLEROSIS;ULTRA-HIGH RISK;ABERRANT SALIENCE;ACADEMIC HOSPITAL","6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;GN PATIENTS;COMMITTEES SPEAKERS;AZIENDA OSPEDALIERO-UNIVERSITARIA;DI PARMA;OSPEDALIERO-UNIVERSITARIA DI;ACUTE KIDNEY;KIDNEY INJURY;MDS PATIENTS;CORONAVIRUS DISEASE;DEPARTMENT AZIENDA;PARMA ITALYSEARCH;PARMA PARMA;RISK FACTORS;BONE MARROW;KIDNEY DISEASE;COVID- PNEUMONIA;GLUCOSE TOLERANCE;HR CI;MEDIAN AGE;TRAVEL EXPENSES;GA VERSUS;HONORARIA NOVARTIS;KIDNEY TRANSPLANT;PATIENTS TREATED","68;68;44;33;31;30;29;24;20;20;20;19;19;18;17;16;16;16;16;15;14;13;13;13;13;12;11;11;11;11",86,0.5,5.24,7.75,1,1.5,0,2,1.5,1,1.5,8,1,1,7,1,1,2,2,4,3,0,0,52.5,52.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,3.71,705.28,19.81,28,0.67,120.55,1,0,10,3,17,0,3,8,0,34,7,0,0,0,0,0,0,42,0,0,39,1,0,2,0,0,0,0,0,0,"United States;Germany;Italy;Japan;Switzerland;United Kingdom","14;4;3;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING;50 PHILOSOPHY AND RELIGIOUS STUDIES","41;30;22;7;4;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;LUNG;LUNG CANCER;PREVENTION;DIGESTIVE DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;ORPHAN DRUG;GENETICS;LYMPHOMA;NEURODEGENERATIVE;NEUROSCIENCES;PNEUMONIA;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY","39;30;21;15;14;13;9;8;6;6;5;5;4;3;3;3;3;2;2;2","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;SKIN","20;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","33;4;4;3;2;2;1;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;BLADDER CANCER;BREAST CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;SALIVARY GLAND CANCER","9;3;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","11;2;1;1;1;1;1;1",4,7002328.33,505521.32,4.5,8.75,4.5,0.75,9,313283.961666667,0.545830686927866,"OSPEDALE DI PARMA;ARTTIC (FRANCE);AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BARTS HEALTH NHS TRUST;CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX;DÉLÉGATION PARIS 11;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;GILEAD SCIENCES (UNITED STATES);HANNOVER MEDICAL SCHOOL;HELMHOLTZ CENTRE FOR INFECTION RESEARCH;HELMHOLTZ ZENTRUM MÜNCHEN;HOSPICES CIVILS DE LYON;HOSPITAL CLÍNIC DE BARCELONA;INSERM TRANSFERT;INSTITUT NÉEL;INSTITUT PASTEUR;KAROLINSKA INSTITUTET;LEIPZIG UNIVERSITY;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH;SWISS NATIONAL SCIENCE FOUNDATION","2;1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","3;2;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);NATIONAL RESEARCH PROGRAMMES (NRPS) (FUNDING INSTRUMENT HIERARCHY);NRP 78 COVID-19 (FUNDING INSTRUMENT);PROGRAMMES (FUNDING INSTRUMENT HIERARCHY)","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","4;2;2;1;1","CLINICAL RESEARCH;BIODEFENSE;BIOTECHNOLOGY;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - B;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;LUNG;PREVENTION;VACCINE RELATED;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;GENETICS;HIV/AIDS;LUNG CANCER","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","INFECTION;CANCER","2;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","2;2;1;1;1;1","LIVER CANCER;LUNG CANCER","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.4 VACCINES;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2;1;1","A01 CLINICAL MEDICINE","4","3 GOOD HEALTH AND WELL BEING","3",28,"SPRINGER NATURE;PUBLIC LIBRARY OF SCIENCE;ZENODO;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS","12;9;4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;4207 SPORTS SCIENCE AND EXERCISE;46 INFORMATION AND COMPUTING SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS;5203 CLINICAL AND HEALTH PSYCHOLOGY","35;12;9;7;6;2;2;2;2;1;1;1;1;1;1","CANCER;AGING;BRAIN DISORDERS;NEUROSCIENCES;PATIENT SAFETY;PROSTATE CANCER;UROLOGIC DISEASES;BREAST CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETICS;PREVENTION;RARE DISEASES","6;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;RESPIRATORY","5;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","3;1;1","BIOMEDICAL;CLINICAL","4;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","8;7;1","BRAIN TUMOR;BREAST CANCER;PROSTATE CANCER;LIVER CANCER","12;2;2;1",NA,NA
"AOU_PARMA",2021,192,22.640625,2.359375,0.213541666666667,0.234375,0.34375,1.97816593886463,1.13888888888889,1.55172413793103,1.22222222222222,0.661458333333333,0,88,54,14,12,0.46,0.28,0.07,0.06,9.57,0.620783074112817,6.43468715697037,0.359375,0.916666666666667,0.486,0.391,0.464,0.391,"FRANCESCA RE;GIOVANNI RAIMONDO;ALARICO ARIANI;FRANCESCO AZZAROLI;EDOARDO G. GIANNINI;GIANLUCA SVEGLIATI‐BARONI;FRANCO TREVISANI;ALBERTO MASOTTO;ANDREA MEGA;GIANPAOLO VIDILI;GERARDO NARDONE;GERARDO MUSURACA;EUGENIO CATURELLI;FABIO FARINATI;FRANCESCO GIUSEPPE FOSCHI;MARCO ZOLI;GIUSEPPE CABIBBO;RODOLFO SACCO;ENRICO FIACCADORI;FABIO MARRA","13;13;12;12;12;12;12;12;12;12;12;12;12;11;11;11;11;11;11;10","ALARICO ARIANI;ENRICO FIACCADORI;LORENZO PELIZZA;SIMONA PUPO;RICCARDO C. BONADONNA;NICOLA GIULIANI;TIZIANA MESCHI;PAOLO CRAVEDI;ANTONIO NOUVENNE;DENISE TOSCANI;LIVIA RUFFINI;GIUSEPPE REGOLISTI;CHIARA CANTARELLI;SILVIA MIGLIARI;FRANCESCA DI MARIO;ELEONORA DI DONATO;ANDREA BECCIOLINI;FLAVIO MOZZANI;ILARIA SCAZZA;MICHELE POLETTI","1.23;1.14;1.07;0.94;0.88;0.82;0.78;0.76;0.75;0.68;0.67;0.66;0.62;0.62;0.62;0.6;0.6;0.6;0.57;0.57","FRANCESCA RE;ALARICO ARIANI;ENRICO FIACCADORI;RICCARDO C. BONADONNA;MONICA CRUGNOLA;GABRIELE MISSALE;LIVIA RUFFINI;TIZIANA MESCHI;FLAVIO MOZZANI;NICOLA GIULIANI;ANTONIO NOUVENNE;ELISABETTA BIASINI;SILVIA MIGLIARI;CHIARA CANTARELLI;GIUSEPPE REGOLISTI;MARCO DELSANTE;ELEONORA DI DONATO;FRANCESCA DI MARIO;GIULIA MAZZASCHI;ANDREA TICINESI","13;12;11;9;9;9;8;8;8;8;7;6;6;6;6;5;5;5;5;5","ALARICO ARIANI;ENRICO FIACCADORI;SIMONA PUPO;RICCARDO C. BONADONNA;NICOLA GIULIANI;TIZIANA MESCHI;ANTONIO NOUVENNE;LIVIA RUFFINI;GIUSEPPE REGOLISTI;CHIARA CANTARELLI;SILVIA MIGLIARI;FRANCESCA DI MARIO;ELEONORA DI DONATO;ANDREA BECCIOLINI;FLAVIO MOZZANI;MARCO ZARDINI;GIULIA MAZZASCHI;ANTONINO SAMMARTANO;DONATELLO GASPARRO;UMBERTO MAESTRONI","1.23;1.14;0.94;0.88;0.82;0.78;0.75;0.67;0.66;0.62;0.62;0.62;0.6;0.6;0.6;0.55;0.55;0.54;0.52;0.52","GABRIELE MISSALE;GERARDO NARDONE;GIOVANNI RAIMONDO;ALBERTO MASOTTO;ANDREA MEGA;ANTONIO GASBARRINI;EDOARDO G. GIANNINI;EUGENIO CATURELLI;FRANCESCO AZZAROLI;FRANCESCO GIUSEPPE FOSCHI;FRANCO TREVISANI;GIANLUCA SVEGLIATI‐BARONI;GIANPAOLO VIDILI;MARCO ZOLI;FILOMENA MORISCO;FABIO FARINATI;FABIO MARRA;GIUSEPPE CABIBBO;RODOLFO SACCO;FILIPPO OLIVERI","221;205;196;194;194;194;194;194;194;194;194;194;194;194;190;186;186;182;173;152","GABRIELE MISSALE;FRANCESCA RE;CARLO FERRARI;NICOLA GIULIANI;UMBERTO MAGGIORE;ENRICO FIACCADORI;ANTONIO NOUVENNE;TIZIANA MESCHI;ANDREA TICINESI;BEATRICE PRATI;NICOLETTA CERUNDOLO;GIUSEPPE REGOLISTI;DIEGO ARDISSINO;CHIARA CANTARELLI;ALARICO ARIANI;ELISABETTA BIASINI;SANDRA ROSSI;MARCO DELSANTE;IVAN COMELLI;SIMONA BUI","209;123;107;102;98;94;92;92;80;80;80;78;76;74;66;66;63;62;56;54","FRANCESCA RE;ALARICO ARIANI;RICCARDO C. BONADONNA;ENRICO FIACCADORI;MONICA CRUGNOLA;ANTONIO NOUVENNE;GABRIELE MISSALE;LIVIA RUFFINI;TIZIANA MESCHI;FLAVIO MOZZANI;GIUSEPPE REGOLISTI;ELISABETTA BIASINI;NICOLA GIULIANI;CHIARA CANTARELLI;ANDREA TICINESI;BEATRICE PRATI;FRANCESCA DI MARIO;MARCO DELSANTE;NICOLETTA CERUNDOLO;SILVIA MIGLIARI","13;12;9;9;9;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;CHEMISTRY;ENGINEERING;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE","187;38;18;11;10;10;10;8;7;7;7;3;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;RADIOLOGY;PEDIATRICS;CARDIOLOGY;GENETICS;INTENSIVE CARE MEDICINE;OPTICS;NUCLEAR MEDICINE;CANCER RESEARCH;BIOCHEMISTRY;NURSING;PHYSICAL THERAPY;ENDOCRINOLOGY","163;46;40;40;35;22;21;21;20;16;15;15;15;15;14;13;11;11;11;10","DISEASE;CANCER;COHORT;POPULATION;CONFIDENCE INTERVAL;PROPORTIONAL HAZARDS MODEL;GENE;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);LYMPHOMA;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;TRANSPLANTATION;ALTERNATIVE MEDICINE;BONE MARROW;DIABETES MELLITUS;HEALTH CARE;LUNG;MYOCARDIAL INFARCTION;VIRUS","32;29;26;21;20;15;14;14;14;14;12;11;11;11;10;10;9;9;9;8;8;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;CLINICAL ENDPOINT;RITUXIMAB;BREAST CANCER;HEPATITIS C VIRUS;IMMUNOTHERAPY;TYPE 2 DIABETES;2019-20 CORONAVIRUS OUTBREAK;COLORECTAL CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;FOLLICULAR LYMPHOMA;IMATINIB;LIVER CANCER;METASTASIS;PRODROME;TYPE 2 DIABETES MELLITUS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;GENOTYPE;GERIATRIC ONCOLOGY;GLOMERULONEPHRITIS;HEAD AND NECK CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INSULIN RESISTANCE;INTERSTITIAL LUNG DISEASE;PARKINSON'S DISEASE;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSION-FREE SURVIVAL;T CELL;TYROSINE-KINASE INHIBITOR;UNIVARIATE ANALYSIS","17;11;9;8;6;6;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);NILOTINIB;CARFILZOMIB;DASATINIB;INSULIN GLARGINE;ANTHRACYCLINE;CRYOGLOBULINEMIA;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;HISTONE DEACETYLASE;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC INDEX;MODIFIED RANKIN SCALE;NIVOLUMAB;QUANTITATIVE COMPUTED TOMOGRAPHY;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;UNDERWEIGHT;VINCRISTINE;ABSCOPAL EFFECT;ACE INHIBITOR;AGGRESSIVE LYMPHOMA;ANTERIOR CEREBRAL ARTERY;APOBEC;APREMILAST;ARTERY DISSECTION;ATYPICAL HEMOLYTIC UREMIC SYNDROME;AXIAL SPONDYLOARTHRITIS;BENDAMUSTINE;BONE METASTASIS;BRADYCARDIA;CCL18;CD3;CHLORAMBUCIL;COMPLEMENTATION;CONNECTIVE TISSUE DISEASE;CROSSOVER STUDY;DABIGATRAN;DEMENTIA WITH LEWY BODIES;DEPERSONALIZATION;DIFFUSING CAPACITY;DISEASE MANAGEMENT;DISTANT METASTASIS;DNA METHYLATION;DYNACTIN;ENDOVASCULAR COILING;ENTHESITIS;FAILED BACK SURGERY;FEBRILE NEUTROPENIA;FIBROMUSCULAR DYSPLASIA;FIRST TRIMESTER;FLUORESCENCE IN SITU HYBRIDIZATION;GERMLINE MUTATION;GLUCOSE HOMEOSTASIS;GLUCOSE TOLERANCE TEST;GLUTAMATE CARBOXYPEPTIDASE II;HBSAG;HERPESVIRIDAE;IBRUTINIB;IMMUNE CHECKPOINT;IMPAIRED GLUCOSE TOLERANCE;INFLAMMATORY BOWEL DISEASES;INTERLEUKIN 12;INTERLEUKIN 21;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IPILIMUMAB;KRAS;LEFT ATRIAL APPENDAGE OCCLUSION;LYMPH NODE METASTASIS;LYMPHOCYTE SUBSETS;LYMPHOPLASMACYTIC LYMPHOMA;LYMPHOVASCULAR INVASION;MACE;MANAGEMENT OF OBESITY;MASS CYTOMETRY;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;MEMBRANOUS NEPHROPATHY;MICROSATELLITE;MONOCLONAL;NATURAL KILLER CELL;NKG2D;OSTEOCYTE;PANCREATIC HORMONE;PAPILLARY THYROID CANCER;PARVOVIRIDAE;PATIENT HEALTH QUESTIONNAIRE;PEMBROLIZUMAB;PERIPHERAL T-CELL LYMPHOMA;PLASMA RENIN ACTIVITY;PNEUMOCYSTIS PNEUMONIA;PODOCYTE;POSACONAZOLE;PRENATAL DIAGNOSIS;PRIMARY ANGIOPLASTY;RAD51;RADIAL HEAD FRACTURE;RENAL ARTERY STENOSIS;REVERSE TRANSCRIPTASE;RIBAVIRIN;RNA EDITING;SANGER SEQUENCING;SPINAL CORD STIMULATOR;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION;THYMOGLOBULIN;TILT TABLE TEST;TRASTUZUMAB;VENTRICULOMEGALY","17;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;COVID-19;ITALY;AGED;RETROSPECTIVE STUDIES;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;ADULT;PROSPECTIVE STUDIES;TREATMENT OUTCOME;RISK FACTORS;CROSS-SECTIONAL STUDIES;SARS-COV-2;AGED, 80 AND OVER;PROGNOSIS;HEPATITIS C","101;90;46;41;33;28;27;22;20;18;18;15;15;14;12;11;11;10;10;9","HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;RENAL CELL CARCINOMA;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CORONAVIRUS DISEASE 2019;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;SCHIZOPHRENIA RESEARCH AND TREATMENT;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;CANCER IMMUNOTHERAPY;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GLIOMAS;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS","11;9;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","CLINICAL ENDPOINT;HEPATOCELLULAR CARCINOMA;PANDEMIC;CROSS-SECTIONAL STUDY;DIABETES;FIBROMYALGIA;HEPATITIS C;INTERQUARTILE RANGE;LIVER CANCER;REGIMEN;TYPE 2 DIABETES;CANCER IMAGING;CYSTIC FIBROSIS;DISCONTINUATION;FOLLICULAR LYMPHOMA;GUIDELINE;LYMPHOMA;MANTLE CELL LYMPHOMA;PRODROME;RENAL CELL CARCINOMA","10;9;7;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","HEPATOCELLULAR CARCINOMA;FONDAZIONE ITALIANA;ITALIANA LINFOMI;CELL CARCINOMA;ITALIAN SOCIETY;PHASE II;RENAL CELL;LINFOMI FIL;PATIENTS TREATED;CANCER PATIENTS;CROSS-SECTIONAL STUDY;CYSTIC FIBROSIS;OBSERVATIONAL STUDY;CHRONIC MYELOID;MULTIPLE MYELOMA;MYELOID LEUKEMIA;PROSPECTIVE STUDY;TYPE DIABETES;B-CELL LYMPHOMA;CARCINOMA PATIENTS;CLINICAL PRACTICE;COMPUTED TOMOGRAPHY;COVID- PATIENTS;COVID- PNEUMONIA;ELDERLY PATIENTS;ELDERLY PROJECT;EUROPEAN POOLED;FIBROMYALGIA SEVERITY;FOLL TRIAL;FOLLICULAR LYMPHOMA","13;8;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;RESEARCH FUNDING;PUBMED SCOPUS;HONORARIA MEMBERSHIP;HR CI;ACCOMODATIONS EXPENSES;CROSSREF PUBMED;TRAVEL ACCOMODATIONS;MEDIAN AGE;HD PATIENTS;ACTHAR GEL;ADVISORY ROLE;COMMITTEES SPEAKERS;CONSULTANCY MEMBERSHIP;BRISTOL MYERS;CLINICAL OUTCOMES;INCREASED RISK;PB- PB-;GILEAD SCIENCES;JANSSEN CONSULTANCY;NOVARTIS HONORARIA;SOC NEPHROL;CLINICAL PRACTICE;HONORARIA SPEAKERS;LOGISTIC REGRESSION;MM PATIENTS;PFIZER HONORARIA","132;132;77;55;54;31;28;26;23;23;23;22;19;16;16;16;16;15;15;15;15;14;14;14;14;13;13;13;13;13",83,0.43,11.3,14,1,1,0,2,1,1,1,17,0,0,14,0,0,1,5,10.25,4,0,0,37,37,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,4.52,1077.06,14.55,20,0.65,94.71,0,1,8,2,9,0,0,11,0,22,9,0,0,0,0,0,0,28,0,3,31,0,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Japan;Netherlands;Denmark;France","10;8;4;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","30;18;15;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;PATIENT SAFETY;LUNG CANCER;PREVENTION;RARE DISEASES;AGING;BRAIN DISORDERS;NEUROSCIENCES;BIOENGINEERING;BREAST CANCER;CARDIOVASCULAR;GENETICS;PROSTATE CANCER;UROLOGIC DISEASES;DIGESTIVE DISEASES;HEART DISEASE;IMMUNIZATION","29;22;16;9;7;6;6;6;4;4;4;3;3;3;3;3;3;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY;EYE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;STROKE","14;3;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","21;4;3;2;2;1;1;1;1;1","LUNG CANCER;BREAST CANCER;PROSTATE CANCER;BLADDER CANCER;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;LIVER CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER","7;3;3;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;KARGER PUBLISHERS;FUTURE SCIENCE GROUP","11;6;4;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;3105 GENETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4202 EPIDEMIOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY;4403 DEMOGRAPHY;49 MATHEMATICAL SCIENCES;5203 CLINICAL AND HEALTH PSYCHOLOGY","34;9;8;8;7;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CANCER;DIGESTIVE DISEASES;LIVER DISEASE;PREVENTION;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NUTRITION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;FIBROMYALGIA;GENETICS;HEMATOLOGY;HUMAN GENOME;KIDNEY DISEASE;LIVER CANCER;OBESITY;PAIN RESEARCH","11;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CONGENITAL;CARDIOVASCULAR;INFECTION;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","2;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.4 SURGERY;2.4 SURVEILLANCE AND DISTRIBUTION;3.3 NUTRITION AND CHEMOPREVENTION","5;4;3;2;1;1","CLINICAL;BIOMEDICAL","11;1","CLINICAL MEDICINE AND SCIENCE","16","LIVER CANCER;NOT SITE-SPECIFIC CANCER;MYELOMA;COLON AND RECTAL CANCER;KIDNEY CANCER","4;4;2;1;1","2 ZERO HUNGER;4 QUALITY EDUCATION","1;1"
"AOU_PARMA",2022,151,21.4304635761589,3.03973509933775,0.264900662251656,0.245033112582781,0.278145695364238,1.73207547169811,1.17647058823529,1.48,1.23529411764706,0.728476821192053,1,64,34,13,6,0.42,0.23,0.09,0.04,5.46,0.611299510190527,5.6676891615542,0.291390728476821,0.920529801324503,0.505,0.357,0.376,0.352,"MONICA CRUGNOLA;LUIGI VIGNALI;ALESSANDRA IURLO;GIAMPAOLO NICCOLI;GIORGIO BENATTI;DIEGO ARDISSINO;RICCARDO C. BONADONNA;EMILIA SOLINAS;ELISABETTA ABRUZZESE;MASSIMILIANO BONIFACIO;MONICA BOCCHIA;MARIA ALBERTA CATTABIANI;MARIO TIRIBELLI;TIZIANA MESCHI;FRANCESCA RE;MICHÈLE CAVO;IACOPO TADONIO;GIANNI BINOTTO;LIVIA RUFFINI;ANGELICA BARONE","9;9;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;5;5","PAOLA FISICARO;RICCARDO C. BONADONNA;TIZIANA MESCHI;LIVIA RUFFINI;LUIGI VIGNALI;GIAMPAOLO NICCOLI;VALENTINA SPIGONI;GLORIA CINQUEGRANI;ALESSANDRA DEI;ANDREA TICINESI;MARIA ALBERTA CATTABIANI;GIORGIO BENATTI;ANTONIO NOUVENNE;DIEGO ARDISSINO;IACOPO TADONIO;DAVIDE CAMPOBASSO;LORENZO PELIZZA;SIMONA PUPO;ENRICO FIACCADORI;EMILIA SOLINAS","1.08;0.96;0.75;0.72;0.72;0.68;0.62;0.62;0.62;0.61;0.55;0.53;0.52;0.5;0.48;0.47;0.47;0.47;0.45;0.43","MONICA CRUGNOLA;LUIGI VIGNALI;GIAMPAOLO NICCOLI;GIORGIO BENATTI;DIEGO ARDISSINO;RICCARDO C. BONADONNA;EMILIA SOLINAS;MARIA ALBERTA CATTABIANI;TIZIANA MESCHI;FRANCESCA RE;IACOPO TADONIO;LIVIA RUFFINI;ANGELICA BARONE;DAVIDE CAMPOBASSO;ANDREA TICINESI;UMBERTO MAGGIORE;ENRICO FIACCADORI;GIOVANNI ROTI;FEDERICO BAROCELLI;FILIPPO LUCA GURGOGLIONE","9;9;8;8;8;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5","PAOLA FISICARO;RICCARDO C. BONADONNA;TIZIANA MESCHI;LIVIA RUFFINI;LUIGI VIGNALI;GIAMPAOLO NICCOLI;ALESSANDRA DEI;ANDREA TICINESI;MARIA ALBERTA CATTABIANI;GIORGIO BENATTI;ANTONIO NOUVENNE;DIEGO ARDISSINO;IACOPO TADONIO;DAVIDE CAMPOBASSO;SIMONA PUPO;ENRICO FIACCADORI;EMILIA SOLINAS;ALBERTO PARISE;BEATRICE PRATI;GIORGIO BALDARI","1.08;0.96;0.75;0.72;0.72;0.68;0.62;0.61;0.55;0.53;0.52;0.5;0.48;0.47;0.47;0.45;0.43;0.43;0.43;0.42","MICHÈLE CAVO;CIHAT ŞEN;FRANCESCA RE;NICOLA GIULIANI;RICCARDO C. BONADONNA;PAOLO CRAVEDI;ANDREA MEGA;ANTONIO GASBARRINI;CIRO CELSA;CLAUDIA CAMPANI;DIEGO ARDISSINO;FILIPPO PELIZZARO;FRANCESCO GIUSEPPE FOSCHI;FRANCO TREVISANI;GIAN LUDOVICO RAPACCINI;GIANLUCA SVEGLIATI‐BARONI;GIOVANNI RAIMONDO;RODOLFO SACCO;ANDRÉS J.M. FERRERI;DAVIDE CAMPOBASSO","60;59;59;56;50;47;45;45;45;45;45;45;45;45;45;45;45;45;44;42","FRANCESCA RE;NICOLA GIULIANI;DIEGO ARDISSINO;DAVIDE CAMPOBASSO;UMBERTO MAGGIORE;CHIARA CANTARELLI;ELISABETTA BIASINI;EMILIA SOLINAS;FEDERICO BAROCELLI;GIORGIO BENATTI;N. VOLPE;SIMONA PUPO;DOMENICO TUTTOLOMONDO;GIAMPAOLO NICCOLI;RICCARDO C. BONADONNA;ANTONIO CROCAMO;GIORGIA DE PAOLI;MARIA FRANCESCA NOTARANGELO;ANDREA BIAGI;ANDREA BOTTI","59;56;45;42;42;41;38;38;38;38;37;37;35;32;31;30;30;30;29;29","MONICA CRUGNOLA;LUIGI VIGNALI;GIORGIO BENATTI;EMILIA SOLINAS;DIEGO ARDISSINO;FRANCESCA RE;IACOPO TADONIO;MARIA ALBERTA CATTABIANI;GIAMPAOLO NICCOLI;FEDERICO BAROCELLI;ANGELICA BARONE;NICOLA GIULIANI;TIZIANA MESCHI;UMBERTO MAGGIORE;DAVIDE CAMPOBASSO;RICCARDO C. BONADONNA;ANTONIO CROCAMO;GIORGIA DE PAOLI;ANDREA TICINESI;ANTONIO NOUVENNE","9;9;8;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;HISTORY;GEOGRAPHY;MATERIALS SCIENCE","140;43;17;12;10;8;7;6;6;6;4;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;OPTICS;PEDIATRICS;CANCER RESEARCH;ENDOCRINOLOGY;MECHANICAL ENGINEERING;CLINICAL PSYCHOLOGY;EMERGENCY MEDICINE;BIOCHEMISTRY","109;35;25;24;23;19;17;17;17;16;14;13;12;12;11;10;10;9;9;8","COHORT;CANCER;GENE;POPULATION;DISEASE;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;CLINICAL TRIAL;OBSERVATIONAL STUDY;STROKE (ENGINE);MULTIPLE MYELOMA;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;BONE MARROW;CHEMOTHERAPY;CORONARY ARTERY DISEASE;IMMUNE SYSTEM;KIDNEY DISEASE;LYMPHOMA","20;16;15;14;12;11;11;10;9;9;9;8;8;8;8;7;7;7;7;7;7;7","CLINICAL ENDPOINT;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;IMMUNOTHERAPY;MYELOFIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;FETUS;IMATINIB;INSULIN RESISTANCE;NEURORADIOLOGY;PERINATAL MEDICINE;PHASES OF CLINICAL RESEARCH;SCAD;T CELL;WARFARIN;ACUTE CORONARY SYNDROME;ADENOCARCINOMA;ALBUMINURIA;AORTIC VALVE REPLACEMENT;AT RISK MENTAL STATE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BEVACIZUMAB;BIOENERGETICS;CARDIAC MAGNETIC RESONANCE;CATHETER ABLATION;CONVENTIONAL PCI;CORONARY ANGIOGRAPHY;CUMULATIVE INCIDENCE;DEEP VEIN;DEPRESSIVE SYMPTOMS;ETOPOSIDE;GENE EXPRESSION;GENOTYPE;GESTATIONAL AGE;GLYCOLYSIS;HISTONE;INTRACEREBRAL HEMORRHAGE;ISLET;KIDNEY TRANSPLANTATION;LENALIDOMIDE;LIVER CANCER;MACROGLOBULINEMIA;MALIGNANT PLEURAL EFFUSION;METASTATIC MELANOMA;MYELODYSPLASTIC SYNDROMES;MYOCARDIAL FIBROSIS;PHENOTYPE;POLYMERASE CHAIN REACTION;POSITIVE AND NEGATIVE SYNDROME SCALE;PRODROME;PROGRESSION-FREE SURVIVAL;PROSTATE;PSORIATIC ARTHRITIS;RANDOMIZATION;RELIABILITY (SEMICONDUCTOR);SINUS RHYTHM;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;WALDENSTROM MACROGLOBULINEMIA","11;9;7;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);RUXOLITINIB;NILOTINIB;NIVOLUMAB;ARTERY DISSECTION;BETA CELL;CRIZOTINIB;DASATINIB;DNA METHYLATION;HISTONE DEACETYLASE;IMATINIB MESYLATE;LEFT ATRIAL APPENDAGE OCCLUSION;LOWER URINARY TRACT SYMPTOMS;MACE;ANAEROBIC GLYCOLYSIS;ANAPLASTIC LYMPHOMA KINASE;ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA;ANGIOTENSIN RECEPTOR BLOCKERS;ANTERIOR CEREBRAL ARTERY;ANTIMICROBIAL STEWARDSHIP;ANTIVIRAL THERAPY;AQUAPORIN 2;ATAXIA-TELANGIECTASIA;ATRIAL TACHYCARDIA;BAFILOMYCIN;BASDAI;BRADYCARDIA;BREAST SURGERY;CARBOPLATIN;CAROTID STENTING;CATH LAB;CD38;CONCURRENT VALIDITY;CONGENITAL NEUTROPENIA;CRITICAL LIMB ISCHEMIA;DECAY-ACCELERATING FACTOR;DIGITAL POLYMERASE CHAIN REACTION;DNA EXTRACTION;EMPAGLIFLOZIN;ENTHESITIS;FETAL HEAD;FIRST TRIMESTER;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GLOMERULOSCLEROSIS;GLUCOSE HOMEOSTASIS;GLUCOSE TOLERANCE TEST;GLYCATED HEMOGLOBIN;GROUND-GLASS OPACITY;HORMONAL THERAPY;IDH1;IL-2 RECEPTOR;INSULIN SENSITIVITY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRAVENTRICULAR HEMORRHAGE;IVACAFTOR;JURKAT CELLS;KARYOTYPE;LIPOTOXICITY;LYMPHOPLASMACYTIC LYMPHOMA;MAMMOGRAPHY;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;PARADOXICAL EMBOLISM;PENTOSE PHOSPHATE PATHWAY;PHENOTYPIC SCREENING;PKD1;POLY ADP RIBOSE POLYMERASE;PRIMARY TUMOR;PROTEIN PHOSPHORYLATION;RETROGRADE EJACULATION;RIBAVIRIN;ROS1;SHOTGUN SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;SYNTHETIC LETHALITY;TARGET LESION;TAXANE;THIOTEPA;TRICARBOXYLIC ACID;UNDERWEIGHT;VENETOCLAX;ZIDOVUDINE","9;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;COVID-19;MALE;FEMALE;PSYCHOTIC DISORDERS;STROKE;AGED;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;ATRIAL FIBRILLATION;FIBROMYALGIA;CORONARY ARTERY DISEASE;PROSTATIC HYPERPLASIA;RENAL DIALYSIS;SURVEYS AND QUESTIONNAIRES;ADULT;BRAIN ISCHEMIA","81;68;17;15;13;13;12;11;11;9;9;9;7;7;6;6;6;6;5;5","CORONAVIRUS DISEASE 2019 RESEARCH;ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF FIBROMYALGIA SYNDROME;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;PREVALENCE AND MANAGEMENT OF KIDNEY STONES;SCHIZOPHRENIA RESEARCH AND TREATMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ACUTE MYELOID LEUKEMIA;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS","5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","CLINICAL ENDPOINT;STROKE (ENGINE);DISCONTINUATION;ECHOCARDIOGRAPHY;GUIDELINE;HEPATOCELLULAR CARCINOMA;PRENATAL DIAGNOSIS;RUXOLITINIB;RUXOLITINIB THERAPY;TREATMENT;ANTICOAGULANT THERAPY;CARDIAC IMAGING;FETAL MRI;FIBROMYALGIA;FOUNDATION (EVIDENCE);MAGNETIC RESONANCE IMAGING;NEURORADIOLOGY;PANDEMIC;PERINATAL MEDICINE;REGIMEN","11;9;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","OBSERVATIONAL STUDY;NEWLY DIAGNOSED;CLINICAL PRACTICE;CORONARY ARTERY;FONDAZIONE ITALIANA;ITALIANA LINFOMI;DIAGNOSED TYPE;HEPATOCELLULAR CARCINOMA;MULTIPLE MYELOMA;PERINATAL MEDICINE;PHASE II;TYPE DIABETES;APPENDAGE OCCLUSION;CML PATIENTS;INTENSIVE CARE;ISCHEMIC STROKE;LUNG CANCER;MEDICINE FOUNDATION;MYELOID LEUKEMIA;MYELOMA PATIENTS;PATIENTS TREATED;PRACTICE GUIDELINE;PROGNOSTIC ROLE;PROSPECTIVE OBSERVATIONAL;RETROSPECTIVE STUDY;SPONTANEOUS CORONARY;TYROSINE KINASE;ABERRANT SALIENCE;ACUTE ISCHEMIC;ACUTE KIDNEY","7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","MEDIAN AGE;VIEW LARGEDOWNLOAD;GLOBAL HEART;CML PATIENTS;NEWLY DIAGNOSED;CELL LINES;ECV VALUES;PRIMARY ENDPOINT;CARDIAC ARREST;FRONTLINE TKI;MEDIAN FOLLOW-UP;MM PATIENTS;PATIENTS TREATED;HEART FAILURE;HR CI;STAGE III;STATISTICALLY SIGNIFICANT;ANAEROBIC GLYCOLYSIS;BONE MARROW;CARDIAC DEATH;CLINICAL PRACTICE;CLOSE MODAL;FIGURE VIEW;III NSCLC;LARGEDOWNLOAD PPT;LARGEDOWNLOAD PPTFIGURE;PPT CLOSE;PPTFIGURE VIEW;RISK FACTORS;SUDDEN CARDIAC","18;18;17;16;15;13;13;13;12;12;12;11;11;10;10;10;10;9;9;9;9;9;9;9;9;9;9;9;9;9",64,0.42,10.06,10,1,1,0,2,0,1,0,10.25,0,1,10,1,0,2,3.5,7,4,0,0,16,16,1,0,0,2,0,0,0,0,0,0,0,0,1,0,1,1,16,6.97,4,0,2,2,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ARENA UMBERTO;BARILI VALERIA;BUSLETTA CHIARA;CALIGIURI ALESSANDRA;CAPPON ANDREA;FERRARI CARLO;FISICARO PAOLA;GENTILINI ALESSANDRA;LEVRERO MASSIMO;MARRA FABIO","2;2;2;2;2;2;2;2;2;2","AZIENDA OSPEDALIERO UNIV DI PARMA;UNIV DEGLI STUDI DI FIRENZE;UNIV DEGLI STUDI DI PARMA;UNIV DI ROMA LA SAPIENZA","2;2;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES","3;2;1","DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;LIVER DISEASE","1;1;1;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2;1","A61K;A61K31/4406;A61K31/455;A61K31/706;A61K31/7084;A61P31/12","1;1;1;1;1;1","A61K31/4406;A61K31/455;A61K31/706;A61K31/7084;A61P31/12","2;2;2;2;2",21,4.14,1101.05,8.71,12,0.57,131.67,0,0,3,2,8,0,0,8,0,15,6,0,0,0,0,0,0,20,1,0,20,0,0,1,0,0,0,0,0,0,"Italy;United States;France;Japan;Spain;United Kingdom","7;7;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES","21;11;10;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;DIGESTIVE DISEASES;PREVENTION;RARE DISEASES;LUNG CANCER;PATIENT SAFETY;CARDIOVASCULAR;HEMATOLOGY;INFECTIOUS DISEASES;PEDIATRIC;AUTOIMMUNE DISEASE;BREAST CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;EMERGING INFECTIOUS DISEASES;ESTROGEN;GENETICS;HEART DISEASE","21;14;11;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;BLOOD;INFECTION;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;CONGENITAL;NEUROLOGICAL;RESPIRATORY","10;3;2;2;2;2;1;1;1","6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","15;2;2;2;1;1","LUNG CANCER;BREAST CANCER;LIVER CANCER;COLON AND RECTAL CANCER;GASTROINTESTINAL TRACT;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;RESPIRATORY SYSTEM","4;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","10;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,"FRONTIERS;ZENODO;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FUTURE SCIENCE GROUP;KARGER PUBLISHERS","19;4;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3204 IMMUNOLOGY;49 MATHEMATICAL SCIENCES;4905 STATISTICS;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;4410 SOCIOLOGY","44;13;11;8;6;4;3;3;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;PATIENT SAFETY;RARE DISEASES;DIGESTIVE DISEASES;AGING;LIVER CANCER;LIVER DISEASE;GENETICS;KIDNEY DISEASE;ORPHAN DRUG;PREVENTION;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEART DISEASE;PEDIATRIC;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD)","18;13;7;7;6;5;5;5;4;4;4;4;3;3;3;3;3;2;2;2","CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL;NEUROLOGICAL;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RESPIRATORY","10;3;3;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;6.4 SURGERY","7;4;4;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","10;6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","22;4;2","LIVER CANCER;COLON AND RECTAL CANCER;BREAST CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","5;3;2;2;2;2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_PARMA",2023,141,22.4255319148936,2.56028368794326,0.177304964539007,0.26241134751773,0.24113475177305,1.94086021505376,1.08695652173913,1.27586206896552,1.13333333333333,0.723404255319149,0,67,25,7,6,0.48,0.18,0.05,0.04,2.96,0.676358320730721,5.23349753694581,0.26241134751773,0.957446808510638,0.436,0.292,0.318,0.348,"MONICA CRUGNOLA;LORENZO PELIZZA;SIMONA PUPO;GIUSEPPINA PAULILLO;PIETRO PELLEGRINI;SILVIA AZZALI;EMANUELA LEUCI;EMANUELA QUATTRONE;ENRICO FIACCADORI;GABRIELE MISSALE;ALESSANDRA IURLO;MARIO TIRIBELLI;ELISABETTA ABRUZZESE;MASSIMILIANO BONIFACIO;CARLO FERRARI;GIANNI BINOTTO;FRANCESCA PALANDRI;MONICA BOCCHIA;NICOLA POLVERELLI;ROBERTO M. LEMOLI","10;10;10;9;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6","LORENZO PELIZZA;SIMONA PUPO;GIUSEPPINA PAULILLO;PIETRO PELLEGRINI;SILVIA AZZALI;EMANUELA LEUCI;EMANUELA QUATTRONE;ENRICO FIACCADORI;CARLO CAFFARELLI;MARCO MENCHETTI;PIERPACIFICO GISMONDI;MARCO MANFREDI;UMBERTO MAGGIORE;CATERINA CAMINITI;LUCA DE FIORE;BERTRAND TCHANA;MICHELE ANTONELLI;DAVIDE DONELLI;LIVIA RUFFINI;GIORGIO BALDARI","1.19;1.19;1.09;1.09;1.09;0.99;0.99;0.87;0.74;0.7;0.58;0.58;0.57;0.5;0.5;0.5;0.49;0.49;0.47;0.45","MONICA CRUGNOLA;SIMONA PUPO;GIUSEPPINA PAULILLO;ENRICO FIACCADORI;GABRIELE MISSALE;CARLO FERRARI;FRANCESCA RE;PAOLA FISICARO;CAROLINA BONI;ANDREA VECCHI;VALENTINA REVERBERI;LIVIA RUFFINI;BENEDETTA DALLA PALMA;ILARIA MONTALI;DAVIDE DONELLI;ANTONIO NOUVENNE;SUSANNA ESPOSITO;GIORGIO BALDARI;AMALIA PENNA;NICOLA SVERZELLATI","10;10;9;8;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4","SIMONA PUPO;GIUSEPPINA PAULILLO;ENRICO FIACCADORI;CARLO CAFFARELLI;PIERPACIFICO GISMONDI;UMBERTO MAGGIORE;CATERINA CAMINITI;DAVIDE DONELLI;LIVIA RUFFINI;GIORGIO BALDARI;MAURA SCARLATTEI;LUIGI VIGNALI;DAVIDE CAMPOBASSO;GIUSEPPE REGOLISTI;SILVIA MIGLIARI;SUSANNA ESPOSITO;R. MENOZZI;BENEDETTA DALLA PALMA;MARCO DELSANTE;MARIA ALBERTA CATTABIANI","1.19;1.09;0.87;0.74;0.58;0.57;0.5;0.49;0.47;0.45;0.45;0.44;0.43;0.43;0.43;0.42;0.38;0.37;0.37;0.37","LORENZO PELIZZA;SIMONA PUPO;SILVIA AZZALI;GABRIELE MISSALE;MONICA CRUGNOLA;GIUSEPPINA PAULILLO;PIETRO PELLEGRINI;CARLO FERRARI;EMANUELA LEUCI;EMANUELA QUATTRONE;ALESSANDRA IURLO;ELISABETTA ABRUZZESE;MONICA BOCCHIA;DAVIDE DONELLI;MICHELE ANTONELLI;MARCO MASSARI;PIETRO LAMPERTICO;FAUSTO CATENA;DILETTA LACCABUE;MARCO MENCHETTI","50;50;49;42;41;38;38;37;37;37;36;36;36;34;34;33;33;32;30;30","SIMONA PUPO;MONICA CRUGNOLA;GABRIELE MISSALE;ANDREA VECCHI;CAROLINA BONI;PAOLA FISICARO;AMALIA PENNA;DAVIDE DONELLI;CARLO FERRARI;ARIANNA ALFIERI;ENRICO FIACCADORI;EDOARDO PICETTI;ANTONIO NOUVENNE;DIEGO ARDISSINO;FEDERICA BRILLO;ALESSANDRA DEI;GIAMPAOLO NICCOLI;LIVIA RUFFINI;VALENTINA REVERBERI;FRANCESCO LEONARDI","50;41;32;27;27;27;26;25;24;23;23;17;16;16;15;14;14;14;14;13","MONICA CRUGNOLA;SIMONA PUPO;ENRICO FIACCADORI;ANDREA VECCHI;CAROLINA BONI;GABRIELE MISSALE;PAOLA FISICARO;FRANCESCA RE;CARLO FERRARI;LIVIA RUFFINI;VALENTINA REVERBERI;ANTONIO NOUVENNE;DAVIDE CAMPOBASSO;DAVIDE DONELLI;DIEGO ARDISSINO;GIORGIO BALDARI;LUIGI VIGNALI;MARCELLO TISEO;MAURA SCARLATTEI;R. MENOZZI","10;10;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;ENVIRONMENTAL SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE","135;35;16;10;10;9;6;5;4;3;3;3;3;2;2;1","INTERNAL MEDICINE;IMMUNOLOGY;ONCOLOGY;SURGERY;GASTROENTEROLOGY;PSYCHIATRY;PATHOLOGY;GENETICS;PEDIATRICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;CANCER RESEARCH;CLINICAL PSYCHOLOGY;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;DERMATOLOGY;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;NURSING;VIROLOGY","100;33;25;24;22;21;18;17;17;15;14;13;12;12;11;10;10;7;7;6;6;6","CANCER;DISEASE;COHORT;IMMUNE SYSTEM;GENE;POPULATION;ANTIBODY;CHEMOTHERAPY;DISCONTINUATION;RANDOMIZED CONTROLLED TRIAL;BONE MARROW;PSYCHOSIS;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);CLINICAL TRIAL;DIABETES MELLITUS;LYMPHOMA;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;STROKE (ENGINE);TRANSPLANTATION","17;16;15;15;13;13;12;10;10;10;9;9;9;8;8;8;8;7;7;7;7;7","CD8;POSITIVE AND NEGATIVE SYNDROME SCALE;CLINICAL ENDPOINT;GLOBAL ASSESSMENT OF FUNCTIONING;MYELOFIBROSIS;COMPLEMENT SYSTEM;INFECTIOUS DISEASE (MEDICAL SPECIALTY);THROMBOLYSIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CYTARABINE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;IMMUNITY;IMMUNOTHERAPY;MICROANGIOPATHY;MULTICENTER STUDY;NEURORADIOLOGY;PHASES OF CLINICAL RESEARCH;PHENOTYPE;RITUXIMAB;T CELL;THROMBOTIC MICROANGIOPATHY;TOLERABILITY","7;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","RUXOLITINIB;CORONAVIRUS DISEASE 2019 (COVID-19);APREMILAST;CARBOPLATIN;COMPLEMENTATION;ECULIZUMAB;ENTHESITIS;HBSAG;MODIFIED RANKIN SCALE;NIVOLUMAB;PARADOXICAL EMBOLISM;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TUMOR-INFILTRATING LYMPHOCYTES;ACUTE LYMPHOCYTIC LEUKEMIA;AL AMYLOIDOSIS;ALCOHOLIC HEPATITIS;ALTERNATIVE COMPLEMENT PATHWAY;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BRCA MUTATION;CAPECITABINE;CARFILZOMIB;CEFTAZIDIME;CHEMOKINE RECEPTOR;DABIGATRAN;DARATUMUMAB;DASATINIB;DECAY-ACCELERATING FACTOR;DIFFUSING CAPACITY;DIRECTED EVOLUTION;DNA METHYLATION;DUP;ERLOTINIB;EVANS SYNDROME;EXHALED NITRIC OXIDE;FACTOR H;FEBRILE NEUTROPENIA;FETAL GROWTH;FETAL HEAD;FETAL HEART;FIRST TRIMESTER;FLUORESCENCE IN SITU HYBRIDIZATION;FOLLICLE-STIMULATING HORMONE;FORAMEN OVALE (HEART);GLUTAMATE CARBOXYPEPTIDASE II;GRANZYME B;HISTONE DEACETYLASE;HUMAN MICROBIOME PROJECT;IMATINIB MESYLATE;INSULIN GLARGINE;INTERNATIONAL PROGNOSTIC INDEX;IVACAFTOR;KIDNEY TRANSPLANT;LACTOBACILLUS PLANTARUM;LACTOBACILLUS RHAMNOSUS;LEFT ATRIAL APPENDAGE OCCLUSION;LOWER RESPIRATORY TRACT INFECTION;LYMPHOPLASMACYTIC LYMPHOMA;MARGINAL ZONE;MEMBRANOUS NEPHROPATHY;MEROPENEM;METASTATIC BREAST CANCER;MICROSCOPIC POLYANGIITIS;MONOCLONAL;MONTREAL COGNITIVE ASSESSMENT;NILOTINIB;NON-SMALL CELL LUNG CANCER (NSCLC);OBINUTUZUMAB;PEMBROLIZUMAB;PERFORIN;PERIPHERAL BLOOD STEM CELLS;POLY ADP RIBOSE POLYMERASE;POMALIDOMIDE;SINGLE-NUCLEOTIDE POLYMORPHISM;SPLENIC MARGINAL ZONE LYMPHOMA;SUICIDAL IDEATION;THIOTEPA;VENETOCLAX;VINCRISTINE;VIROTHERAPY","5;4;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;STROKE;BRAIN ISCHEMIA;RETROSPECTIVE STUDIES;ACUTE KIDNEY INJURY;ADOLESCENT;ADULT;AGED;TREATMENT OUTCOME;ITALY;PSYCHOTIC DISORDERS;CHILD;COVID-19;MIDDLE AGED;THROMBECTOMY;HEPATITIS B, CHRONIC;KIDNEY","75;65;15;13;13;12;12;10;10;10;10;10;9;9;8;7;7;7;6;6","SCHIZOPHRENIA RESEARCH AND TREATMENT;LYMPHOID NEOPLASMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;CORONAVIRUS DISEASE 2019 RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS B INFECTION AND TREATMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;IMPACT OF URBAN GREEN SPACE ON PUBLIC HEALTH;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;PATENT FORAMEN OVALE AND CEREBROVASCULAR EVENTS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE","7;5;5;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","DISCONTINUATION;STROKE (ENGINE);CLINICAL ENDPOINT;TREATMENT DISCONTINUATION;RUXOLITINIB;RUXOLITINIB THERAPY;INTERNATIONAL MYELOMA WORKING GROUP;MYELOFIBROSIS;TOLERABILITY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;DIABETES;DISENGAGEMENT THEORY;ETIOLOGY;HEPATITIS B;INFARCTION TREATMENT;METASTATIC PROSTATE CANCER;MICROANGIOPATHY;MINIMAL RESIDUAL DISEASE;NEURORADIOLOGY;PATHOGENESIS","10;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HEPATOCELLULAR CARCINOMA;IV THROMBOLYSIS;MULTIPLE MYELOMA;MYELOID LEUKEMIA;CHRONIC HEPATITIS;CRITICALLY ILL;DIABETES MELLITUS;EPISODE PSYCHOSIS;FOLLOW-UP STUDY;FONDAZIONE ITALIANA;ILL PATIENTS;ITALIANA LINFOMI;OBSERVATIONAL STUDY;PROSTATE CANCER;PSYCHOSIS RESULTS;TYPE DIABETES;ACUTE KIDNEY;ACUTE MYELOID;ALCOHOL-RELATED HEPATOCELLULAR;BREAST CANCER;CEREBRAL ISCHEMIA;CHRONIC MYELOID;CLINICAL IMPACT;CLINICAL OUTCOMES;CLINICAL SETTING;COHORT STUDY;EMERGENCY DEPARTMENTS;FINAL RESULTS;FORAMEN OVALE;HBV-SPECIFIC CD","5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MM PATIENTS;HR CI;DISEASE SEVERITY;MEDIAN AGE;MEDIAN FOLLOW-UP;RESPONSE RATE;CLINICAL PRACTICE;FEMALE SURGEONS;PRIMARY ENDPOINT;TRANSPLANT SURGEONS;ACUTE KIDNEY;AL AMYLOIDOSIS;CELL LINES;FOREST THERAPY;KIDNEY INJURY;MOLECULAR RESPONSE;PATIENTS PTS;STATISTICALLY SIGNIFICANT;SURVIVAL OS;SURVIVAL PFS;TKI DISCONTINUATION;ADVISORY ROLE;CONFIDENCE INTERVAL;COVID- INFECTION;LYMPH NODE;MULTIVARIATE ANALYSIS;NEWLY DIAGNOSED;PFO CLOSURE;RATE ORR;RETROSPECTIVE STUDY","15;13;10;10;10;10;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7",53,0.38,6.65,7,1,1,0,5.75,0,1,0,11,0,0,7,1,0,1,2,6.5,3,0,0,9,9,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,3,0.83,2,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BARILI VALERIA;MISSALE GABRIELE;ZECCA ALESSANDRA","1;1;1","AZIENDA OSPEDALIERO UNIV DI PARMA;UNIVERSITA’ DEGLI STUDI DI PARMA","1;1","31 BIOLOGICAL SCIENCES;3103 ECOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1",NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61K","1","A61K31/4439;A61K31/5377;A61P35/00","1;1;1",8,3.12,1362,4.62,4,0.5,120.88,0,0,2,0,3,0,0,3,0,6,2,0,0,0,0,0,0,8,0,0,8,0,0,0,0,0,0,0,0,0,"United States;Denmark","5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","7;6;4;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;HEART DISEASE;LUNG;LUNG CANCER;PATIENT SAFETY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BREAST CANCER;ESTROGEN;GENETICS;HEART DISEASE - CORONARY HEART DISEASE;MENTAL HEALTH;NEUROSCIENCES;PSORIASIS","8;6;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;SKIN","4;2;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","6;1","LUNG CANCER;BREAST CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",1,1446254,289250.8,4,5,4,1,0,385596.661666667,0.365667066178828,"EUROPEAN RESEARCH SERVICES;OSPEDALE DI PARMA;UNIVERSITY OF MÜNSTER;UNIVERSITY OF SALZBURG;UPPSALA UNIVERSITY","1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CITIZENS, EQUALITY, RIGHTS AND VALUES PROGRAMME (CERV) (PROGRAMME)","1","44 HUMAN SOCIETY;48 LAW AND LEGAL STUDIES;4805 LEGAL SYSTEMS","1;1;1","CLINICAL RESEARCH","1",NA,NA,"7.3 MANAGEMENT AND DECISION MAKING","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1","16 PEACE, JUSTICE AND STRONG INSTITUTIONS","1",25,"FRONTIERS;ZENODO;PUBLIC LIBRARY OF SCIENCE;FUTURE SCIENCE GROUP;TAYLOR & FRANCIS GROUP","13;6;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;44 HUMAN SOCIETY;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;4202 EPIDEMIOLOGY;4608 HUMAN-CENTRED COMPUTING;49 MATHEMATICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","41;14;8;4;4;3;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;HEART DISEASE;CANCER;KIDNEY DISEASE;AUTOIMMUNE DISEASE;LUNG;LUPUS;PATIENT SAFETY;PREVENTION;RARE DISEASES;BIOMEDICAL IMAGING;DIGESTIVE DISEASES;GENETICS;HEART DISEASE - CORONARY HEART DISEASE;HUMAN GENOME;AGING;ATHEROSCLEROSIS;BRAIN DISORDERS;COLO-RECTAL CANCER","12;6;6;5;4;3;3;3;3;3;3;2;2;2;2;2;1;1;1;1","CARDIOVASCULAR;CANCER;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;NEUROLOGICAL","6;5;4;3;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.4 SURVEILLANCE AND DISTRIBUTION","7;4;3;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","10;5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","15;5;1","NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;LUNG CANCER;KIDNEY CANCER","4;2;2;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_PARMA",2024,126,20.1507936507937,2.6984126984127,0.26984126984127,0.253968253968254,0.277777777777778,1.44255319148936,1.0625,1.18518518518519,1.12903225806452,0.595238095238095,1,56,28,17,8,0.44,0.22,0.13,0.06,0.86,0.896870141789513,4.12551867219917,0.30952380952381,0.936507936507937,0.478,0.346,0.317,0.321,"EMANUELA LEUCI;PIETRO PELLEGRINI;EMANUELA QUATTRONE;SIMONA PUPO;MARCO MENCHETTI;LORENZO PELIZZA;GIUSEPPINA PAULILLO;SILVIA AZZALI;ANDREA TICINESI;RICCARDO C. BONADONNA;DOMENICO TUTTOLOMONDO;NICOLA GAIBAZZI;ANTONIO NOUVENNE;TIZIANA MESCHI;GIOVANNI ROTI;ALBERTO PARISE;MARCO DELSANTE;ROSARIO PASCARELLA;GIAMPAOLO NICCOLI;A. DALL’ASTA","11;11;11;11;10;9;8;8;7;6;6;6;5;5;5;4;4;4;4;4","EMANUELA LEUCI;PIETRO PELLEGRINI;EMANUELA QUATTRONE;SIMONA PUPO;NICOLA GAIBAZZI;MARCO MENCHETTI;DOMENICO TUTTOLOMONDO;MELISSA BERSANELLI;LORENZO PELIZZA;GIUSEPPINA PAULILLO;SILVIA AZZALI;ANDREA TICINESI;DAVIDE DONELLI;MICHELE ANTONELLI;ANTONIO NOUVENNE;TIZIANA MESCHI;S CALZETTI;ANNA NEGROTTI;ALBERTO PARISE;NICOLETTA CERUNDOLO","1.22;1.22;1.22;1.22;1.17;1.11;1.03;1;1;0.87;0.87;0.86;0.69;0.57;0.56;0.56;0.5;0.5;0.47;0.47","SIMONA PUPO;GIUSEPPINA PAULILLO;ANDREA TICINESI;RICCARDO C. BONADONNA;DOMENICO TUTTOLOMONDO;NICOLA GAIBAZZI;ANTONIO NOUVENNE;TIZIANA MESCHI;GIOVANNI ROTI;ALBERTO PARISE;MARCO DELSANTE;ROSARIO PASCARELLA;GIAMPAOLO NICCOLI;A. DALL’ASTA;MARIALUISA ZEDDE;DAVIDE CAMPOBASSO;VALERIA PERGOLA;NICOLETTA CERUNDOLO;T. GHI;ALESSANDRO PEZZINI","11;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","SIMONA PUPO;NICOLA GAIBAZZI;DOMENICO TUTTOLOMONDO;MELISSA BERSANELLI;GIUSEPPINA PAULILLO;ANDREA TICINESI;DAVIDE DONELLI;ANTONIO NOUVENNE;TIZIANA MESCHI;S CALZETTI;ANNA NEGROTTI;ALBERTO PARISE;NICOLETTA CERUNDOLO;RICCARDO C. BONADONNA;T. GHI;DAVIDE CAMPOBASSO;A. DALL’ASTA;CHIARA MELITO;RICCARDO BOCCALETTI;CARMINE PIZZI","1.22;1.17;1.03;1;0.87;0.86;0.69;0.56;0.56;0.5;0.5;0.47;0.47;0.46;0.46;0.41;0.4;0.34;0.33;0.33","DOMENICO TUTTOLOMONDO;NICOLA GAIBAZZI;ANGELO SQUERI;CARMINE PIZZI;CRISTINA SPAZIANI;ELISA GHERBESI;EMILIANO GUERRA;FRANCESCO ANGELI;KHRYSTYNA RYABENKO;LUCA BERGAMASCHI;MATTEO ARMILLOTTA;SILVIA GIANSTEFANI;STEFANO CARUGO;ALEXANDRA STRODA;PATRICK MEYBOHM;ALFARO DANIEL VIRGIL;AMBIKA SELVAKUMAR;ARTURO CARTA;BENNETT JEFFREY;BIANCHI MARZOLI STEFANIA","27;27;25;25;25;25;25;25;25;25;25;25;25;12;12;10;10;10;10;10","DOMENICO TUTTOLOMONDO;NICOLA GAIBAZZI;ARTURO CARTA;ANTONIO NOUVENNE;TIZIANA MESCHI;ALBERTO PARISE;ANDREA TICINESI;DAVIDE DONELLI;NICOLETTA CERUNDOLO;GIOVANNI ROTI;ANDREA BECCIOLINI;BERTRAND TCHANA;ELEONORA DI DONATO;ELISABETTA BIASINI;BECCIOLINI ANDREA;DAVIDE CAMPOBASSO;DI DONATO ELEONORA;FUSARO ENRICO;GIUDITTA ADORNI;LUCCHINI GIANLUCA","27;27;10;9;9;7;7;7;7;5;4;4;4;4;3;3;3;3;3;3","SIMONA PUPO;RICCARDO C. BONADONNA;NICOLA GAIBAZZI;ANDREA TICINESI;ANTONIO NOUVENNE;DAVIDE CAMPOBASSO;DOMENICO TUTTOLOMONDO;GIOVANNI ROTI;TIZIANA MESCHI;DAVIDE DONELLI;SUSANNA ESPOSITO;ALBERTO PARISE;ALESSANDRO PEZZINI;MARTINA DI PIETRO;NICOLETTA CERUNDOLO;ALARICO ARIANI;ANDREA BECCIOLINI;ANGELA GUERRA;BERTRAND TCHANA;CARMINE SINISCALCHI","11;6;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATHEMATICS;ECONOMICS;CHEMISTRY;SOCIOLOGY;ART;GEOLOGY;POLITICAL SCIENCE;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY","116;27;17;13;12;11;10;7;6;6;3;3;2;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;PSYCHIATRY;SURGERY;RADIOLOGY;PATHOLOGY;GENETICS;CLINICAL PSYCHOLOGY;ONCOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MATHEMATICAL ECONOMICS;MECHANICAL ENGINEERING;NUCLEAR MEDICINE","80;24;21;20;18;17;13;11;11;10;10;9;7;7;7;7;6;6;6;6;6;6","DISEASE;PSYCHOSIS;MYOCARDIAL INFARCTION;GENE;COHORT;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);CANCER;DIABETES MELLITUS;OBSERVATIONAL STUDY;OUTCOME (GAME THEORY);POPULATION;ANTIBODY;HEART FAILURE;CHEMOTHERAPY;COHORT STUDY;COMPUTED TOMOGRAPHY;INCIDENCE (GEOMETRY);INTERVENTION (COUNSELING);MAGNETIC RESONANCE IMAGING;POSITRON EMISSION TOMOGRAPHY;PSYCHOPATHOLOGY;RECEPTOR;STROKE (ENGINE);TERM (TIME);ULTRASOUND","17;12;10;9;7;7;7;7;6;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4","CORONARY ANGIOGRAPHY;HAZARD RATIO;TYPE 2 DIABETES;EJECTION FRACTION;GLOBAL ASSESSMENT OF FUNCTIONING;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTRACEREBRAL HEMORRHAGE;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;POSITIVE AND NEGATIVE SYNDROME SCALE;ANTIPSYCHOTIC;BORTEZOMIB;CARDIAC MAGNETIC RESONANCE;CLINICAL ENDPOINT;COLORECTAL CANCER;CORONARY ARTERIES;EARLY PSYCHOSIS;GENOTYPE;GLOMERULONEPHRITIS;HEPATITIS B VIRUS;IMMUNE DYSREGULATION;LUPUS NEPHRITIS;MIDDLE CEREBRAL ARTERY;NEURORADIOLOGY;NEUTROPENIA;PROSTATE CANCER;PSORIATIC ARTHRITIS;SCHIZOAFFECTIVE DISORDER;SCHIZOPHRENIA SPECTRUM;STRESS ECHOCARDIOGRAPHY;SYSTEMATIC REVIEW","4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ARTERY DISSECTION;ENTHESITIS;HBSAG;MACE;SCHIZOPHRENIFORM DISORDER;SPECKLE TRACKING ECHOCARDIOGRAPHY;ABSOLUTE NEUTROPHIL COUNT;ADAMTS13;AL AMYLOIDOSIS;ANDROGEN DEPRIVATION THERAPY;ANTERIOR CEREBRAL ARTERY;ATAXIA-TELANGIECTASIA;BETA CELL;CAPECITABINE;COGNITIVE DECLINE;COMPLEMENTATION;CONTINUOUS GLUCOSE MONITORING;CORONARY ARTERY ECTASIA;CORONARY CALCIUM SCORE;DECAY-ACCELERATING FACTOR;DNA METHYLATION;DUP;ELLAGIC ACID;ENDOVASCULAR ANEURYSM REPAIR;EPH RECEPTOR A2;EVANS SYNDROME;EXENATIDE;EXOME SEQUENCING;FIBROMUSCULAR DYSPLASIA;GENOTYPING;GLOMERULOPATHY;GLUCOSE TOLERANCE TEST;HEPATITIS DELTA;HISTONE DEACETYLASE;IMMUNE CHECKPOINT;IMPAIRED GLUCOSE TOLERANCE;INSULIN GLARGINE;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LEVODOPA;LYMPHOCYTIC PLEOCYTOSIS;MARGINAL ZONE;MECHANICAL INDEX;MISSENSE MUTATION;MODIFIED RANKIN SCALE;MONOCLONAL;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;MYOCARDIAL BRIDGING;OMALIZUMAB;OSTEOCALCIN;OSTEOPROTEGERIN;P2Y12;PROSTATE-SPECIFIC ANTIGEN;RANKL;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;SUICIDAL IDEATION;SUICIDE ATTEMPT;SYNTHETIC LETHALITY;TAKOTSUBO SYNDROME;TIMI;TRPC6","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;ADOLESCENT;CHILD;AGED, 80 AND OVER;ANIMALS;RISK FACTORS;YOUNG ADULT;CARCINOMA, HEPATOCELLULAR;CELL PROLIFERATION;CHILD, PRESCHOOL;FOLLOW-UP STUDIES;LIVER NEOPLASMS","79;45;31;30;20;19;13;10;10;7;7;6;5;5;5;4;4;4;4;4","SCHIZOPHRENIA RESEARCH AND TREATMENT;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;ROLE OF PERIVASCULAR ADIPOSE TISSUE IN CARDIOVASCULAR HEALTH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CONGENITAL CORONARY ARTERY ANOMALIES AND THEIR MANAGEMENT;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;HEPATITIS B INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT","7;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ECHOCARDIOGRAPHY;CARDIAC IMAGING;STROKE (ENGINE);LONGITUDINAL STUDY;NEUROPSYCHOLOGICAL PERFORMANCE;PREDICTIVE MODELING;REGIMEN;TREATMENT;ANCA-ASSOCIATED;ARTERY DISSECTION;BORDERLINE PERSONALITY DISORDER;CARDIAC MAGNETIC RESONANCE;CARDIAC SURGERY RISK MODELS;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONTINUOUS GLUCOSE MONITORING;CORONARY ARTERIES;CORONARY ARTERY ANOMALIES","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ARTERY;COMPUTED TOMOGRAPHY;EPISODE PSYCHOSIS;ARTERY DISEASE;CHEST COMPUTED;LONGITUDINAL STUDY;MACHINE LEARNING;OBSERVATIONAL STUDY;AD ALTA;ALTA SENSIBILITÀ;ANAMNESTIC RADIOLOGICAL;ARTERY DISSECTION;BORDERLINE PERSONALITY;BRAIN METASTASES;CELL LUNG;CHECKPOINT INHIBITORS;CHILDHOOD-ONSET LUPUS;CLINICAL CHARACTERISTICS;CLINICAL PRESENTATION;CORONARY INFLAMMATION;DI TROPONINA;DIAGNOSTIC SHIFT;DISSECTION DATA;EMISSION TOMOGRAPHY;ETNIA ETÀ;HEPATOCELLULAR CARCINOMA;HS-CTN SPECIFICI;IMMUNE CHECKPOINT;INTRARENAL SURGERY;ITALIAN SOCIETY","7;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KIDNEY BIOPSY;CORONARY ARTERY;KIDNEY DISEASE;NEGATIVE SYMPTOMS;COMPUTED TOMOGRAPHY;DIAGNOSTIC STABILITY;FOLLOW-UP PERIOD;HR CI;MEDIAN AGE;ADIPOSE TISSUE;GLUCOSE TOLERANCE;LOGISTIC REGRESSION;RETROSPECTIVE STUDY;RISK FACTOR;RISK FACTORS;AL AMYLOIDOSIS;BETA CELL;CLINICAL FEATURES;DIAGNOSTIC CHANGE;MEDIAN FOLLOW-UP;OBSTRUCTIVE CAD;ODDS RATIO;PATIENTS TREATED;PRIMARY ENDPOINT;REGRESSION ANALYSIS;SUICIDAL IDEATION;TISSUE ATTENUATION;ADVERSE EVENTS;ARTERY DISEASE;CKD STAGE","12;9;8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"FRONTIERS","1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES","2;2;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;RARE DISEASES","1;1;1;1;1;1","MUSCULOSKELETAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA
